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ABSTRACT 
 
Overexpression  of  the  epidermal  growth  factor  receptor  (EGFR)  is  associated  with 
resistance to chemotherapy and radiotherapy. EGFR involvement, in repair of radiation-
induced DNA damage, is mediated by association with the catalytic subunit of DNA 
protein kinase (DNAPKcs). This study investigated the role of EGFR nuclear import, 
and  its  association  with  DNAPKcs,  on  DNA  repair  following  treatment  either  with 
cisplatin or ionizing radiation (IR). EGFR- null murine NIH3T3 cells were transfected 
with  wild  type  or  with  mutated  EGFR  (mutations  found  in  human  cancers  L858R, 
EGFRvIII  and  mutations  in  the  EGFR  nuclear  localization  signal  (NLS)  sequence 
NLS123,  LNLS123).  Comet  assay  analysis,  which  measures  unhooking  of  cisplatin 
crosslinks  and  repair  of  IR  induced  strand  breaks,  demonstrated  that  wtEGFR  and 
EGFRvIII  completely  repair  cisplatin  and  IR  induced  DNA  damage. 
Immunoprecipitation  studies  show that repair is  associated with  the binding of both 
wtEGFR and EGFRvIII to DNAPKcs, which increases by 2- fold 18 hours following 
cisplatin treatment. Confocal analysis and proximity ligation assay indicated that this 
association takes place both in the cytoplasm and in the nucleus resulting in a significant 
increase of DNA-PK kinase activity.  Intermediate levels of repair as shown by the 
L858R  construct  with  impaired  nuclear  localization  demonstrated  that  EGFR  kinase 
activity is partially involved in repair but is not sufficient to determine EGFR nuclear 
expression.  EGFR-NLS  mutants  showed  impaired  nuclear  localization  and  impaired 
DNAPKcs  association  resulting  in  significant  inhibition  of  DNA  repair  and  down-
regulation of DNA-PK kinase activity.  
Our  data  suggest  that  EGFR  nuclear  localization  is  required  for  the  modulation  of 
cisplatin  and  IR  induced  DNA  damage  repair.  The  EGFR-DNAPKcs  binding  is 
triggered by cisplatin or IR and not by EGFR nuclear translocation per se. 
Understanding mechanisms regulating EGFR subcellular distribution in relation to DNA 
repair  kinetics  will  be  a  critical  determinant  of  improved  molecular  targeting  and 
response to therapy.  
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ABBREVIATIONS 
Abl   Abelson 
AP-2            adaptor protein 2 
APTX          Aprataxin 
ATM           Ataxia Telangiectasia Mutated homolog protein 
ATP  Adenosine TriPhosphate 
ATR  Ataxia Telangiectasia and Rad3 related protein 
Bad   Bcl-2-associated death promoter 
Bax   Bcl-2–associated X protein 
Bcl-2  B-cell CLL/lymphoma 2 
BER  Base Excision Repair 
bp    base pair 
BSA             Bovine serum albumin 
BRCT  BRCA1 Carboxyl Terminus 
cAMP          Cyclic adenosine monophosphate 
cavME          cavoelae mediated endocytosis 
Cbl                Casitas B-lineage lymphoma protein 
CCPs              clathrin coated pits 
Cdc   Cell division cycle 
CDDP  cis-diamminedichloroplatinum(II), cisplatinum or cisplatin 
Cdk   Cyclin-dependent kinases  
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cDNA  complementary DNA  
CHK1/2  Choline Kinase 
COMET  Single-cell gel electrophoresis 
COX-2  CycloOxygenase 2 
CT    Carboxy-terminal  
DMEM  Dulbecco Modified Eagle's Minimal Essential Medium 
DMSO  DiMethyl SulfOxide 
DNA  Deoxyribose Nucleic Acid 
DNA-PK  DNA-dependent Protein Kinase comples 
DNAPKcs      DNA-dependent Protein Kinase catalytic subunit 
DSB                Double strand break 
dNTP  deoxyNucleoside triphosphate 
ECD  Extracellular Domain 
ECL            Enhanced chemoilluminescence 
EDTA  EthyleneDiamine Tetraacetic Acid 
EGF  Epidermal Growth Factor 
EGFR  HER1 or ErbB1, Epidermal Growth Factor Receptor 
EGFRvIII  Epidermal Growth Factor Receptor variant III 
ELISA  Enzyme-Linked ImmunoSorbent Assay 
ER    Endoplasmic Reticulum 
ErbB2  HER2 or ErbB2/neu, Epidermal Growth Factor Receptor 2 
ErbB3         HER3, Epidermal Growth Factor Receptor 3  
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ErbB4        HER4, Epidermal Growth Factor Receptor 4 
ERCC  Excision Repair Cross-Complementing 
ERK1/2  Extracellular signal-Regulated Kinase 
FA    Fanconi Anemia  
FANCA  Fanconi Anemia Complementation group A 
FANCC  Fanconi Anemia Complementation group C 
FANCD  Fanconi Anemia Complementation group D 
FCS    Foetal Calf Serum 
GG-NER  Global Genome Nucleotide Excision Repair 
GIST  GastroIntestinal Stromal Tumors 
Grb2  Growth factor receptor-bound protein 2 
GSK-3  Glycogen Synthase Kinase 3 
Gy               Gray (irradiation unit) 
H2AX  variant of the histone H2A 
HR   Homologous Recombination 
HRP  HorseRadish Peroxidase 
ICL   Interstrand CrossLinks 
IF    ImmunoFluorescence 
IR    Ionizing Radiation 
i-NOS          Inducible nitric oxide synthase 
IP3               Inositol triphosphate 
JAK             Janus kinase  
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JNK            C-jun N-terminal kinase 
kDa            kiloDaltons 
Kb              kilobase 
L                 Leucine 
L858R         EGFR mutant bearing substitution of the Leucine 858 into Arginine 
LNLS123    L858R bearing the NLS123 mutation 
M1           EGFR mutant bearing the mutation of the first cluster of Arginine   into  
Alanine 
    M12          EGFR mutant bearing the mutation of the first and second cluster  of  
basic amino acid residues into Alanine 
MAPK  Mitogen Activated Protein Kinase 
MDM2  Murine Double Minute 2 protein 
MEK1/2  MAPK/ERK kinase 
MRE11  Meiotic Recombination 11 
MRN  MRE11/NBS1/RAD51  
mTOR  mammalian Target Of Rapamycin 
n    degree of freedom 
NBS1  Nijmegen Breakage Syndrome 1 
NER  Nucleotide Excision Repair 
NFkB            nuclear factor kappa-light-chain-enhancer of activated B cells 
NHEJ    Non Homologous End-Joining 
NLS    Nuclear Localisation Signal 
NLS123   EGFR bearing the mutation of all the cluster of Arginine into Alanine  
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NRGs            Neuregulins 
NSCLC  Non Small Cell Lung Cancer 
OD             Optical Density 
OTK  Oncogenic Tyrosine Kinase 
p    level of significance 
PY                  Phospho tyrosine 
P                      proline 
PARP  Poly (ADP-Ribose) Polymerase 
PBS    Phosphate Buffered Saline 
PCNA  Proliferating Cell Nuclear Antigen 
PCR  Polymerase Chain Reaction 
PDGFR  Platelet-derived Growth Factor Receptor 
PDK1/2  Phosphoinositide Dependent Kinase 
PI    Propidium Iodide 
PI3K  PhosphatidylInositol-3 Kinase 
PIKK             Phosphatidylinositol-3 kinase-related kinases 
PIP2    PhosphatidylInositol bisPhosphate 
PIP3    PhosphatidylInositol (3,4,5)-trisPhosphate 
PKB  Protein Kinase B (Akt) 
PLC-γ         Phospholipase C subunit γ 
PKC  Protein Kinase C 
PNK  PolyNucleotide Kinase  
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PTB  Phospho Tyrosine Binding domain 
PTEN  Phosphatase and TENsin homolog 
mRNA  messenger RiboNucleic Acid 
R                  Arginine 
ROS             Reactive oxygen species 
RT                Room temperature 
RTK             Receptor tyrosine kinase 
RPA  Replication Protein A 
RT-PCR  Reverse Transcriptase PCR 
S                  Serine 
S473  Serine 473 
SCID           Severe combined immunodeficient 
SCLC           Small cell lung cancers 
SDS             Sodium dodecylsulphate 
scFv  single chain variable Fragment 
SD    Standard Deviation 
SE    Standard Error 
SH2             Src homology 2 
SOS             Son of sevenless 
SSB              Single strand break 
Src    V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
STAT  Signal Transducer and Activator of Transcription  
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T308  Threonine 308 
TBS             Tris buffered saline 
TBS-T         Tris buffered saline Tween 
TCR  Transcription Coupled Repair 
TGF  Transforming Growth Factor 
TK    Tyrosine Kinase 
TKD            Tyrosine kinase domain 
TKIs            Tyrosine kinase inhibitors 
TOPO2   Topoisomerase II  
TP53           Tumour suppressor p53 
UV   UltraViolet 
VEGF  Vascular Endothelial Growth Factor 
Y                 Turosine 
XPA  Xeroderma Pigmentosum A 
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1.1 CANCER EPIDEMIOLOGY 
According to the world health organization (WHO) more than 11 million people are 
diagnosed with cancer every year. It is the leading cause of death worldwide accounting 
for 7.4 million deaths in 2004 and 7.9 million deaths in 2007 (around 13% of all deaths).  
The  main  types  of  Cancer  leading  to  overall  cancer  mortality  are  lung  (1.3  million 
deaths/year),  stomach  (803000  deaths),  colorectal  (639000),  liver  (610000),  breast 
(519000). It has been estimated that deaths from cancer will rise with an estimated 12 
million deaths in 2030. 
 
1.2 CANCER AETIOLOGY 
1.2.1 The molecular origin of Cancer 
In  contrast  to  genetic  disorders  where  a  single  gene  mutation  is  sufficient  to  cause 
disease, cancer is a multi-step process (Hanahan & Weinberg, 2000). Tumorigenesis 
stems from an acquired abnormal cellular growth and unregulated cellular replication 
(Croce, 2008). Cumulative mutations within oncogenes, tumour suppressor genes and 
stability genes arise from chromosomal translocation, gene amplifications or intragenic 
mutations. These induce gene product over expression or constitutive activation leading 
to  cancer  and  its  progression  (Vogelstein  &  Kinzler,  2004).  Missense  mutations, 
deletions, insertions or epigenetic silencing that reduce tumour suppressor  activation 
and/or expression lead to unregulated cellular replication (Martin, 2003).  
Eukaryotic cells have evolved a complex system to respond to their environment and 
needs. Correct cellular replication is indispensable to maintain integrity of the genome 
within  one  cell  and  throughout  its  progeny  (DePinho,  2000).  Stability  genes  or 
caretakers family of genes comprise DNA repair genes and genes involved in mitotic 
recombination or chromosomal segregation. These genes minimise genetic alteration but 
when inactive, mutations in other genes occur at a higher rate. Every gene can be a 
target  of  increased  mutation  rate,  but  only  mutations  in  oncogenes  and  tumour 
suppressors can confer selective growth advantage over non-mutated cells (Vogelstein 
& Kinzler, 2004). 
Germline mutations of these genes result in hereditary predisposition to cancer (Merlo et 
al, 2006; Shackleton et al, 2009). The mutations of these genes in somatic cells result in 
tumours. The first somatic mutation in an oncogene or tumour suppressor that causes  
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clonal  expansion  initiates  the  neoplastic  process.  Following  mutations  result  in 
additional rounds of clonal expansion and therefore tumour progression (Hanahan & 
Weinberg, 2000) 
 
1.2.2 Cancer Heterogeneity confers resistance to treatments 
According  to  the  clonal  evolution  theory  a  tumour  can  grow,  mutate  and  undergo 
different  selective  pressures  acquiring  a  fundamental  diversity  both  between  cancer 
types and within an individual tumour. This model holds that such secondary or tertiary 
genetic alterations confer a selective advantage that allows individual clones to out-
compete other clones and acquire differences in clinical behaviour, in the response to 
therapy and in their resistance potential (Nowell, 1976). In contrast to this approach the 
cancer stem cell model suggests that some cancers are driven by a small population 
subset  of  cancer  cells  (Dick,  2008).  As  a  normal  stem  cell  differentiates  into 
phenotypically different cells, it has been shown that also cancer cells may undergo a 
series of epigenetic changes that result in a progeny with a limited proliferative potential 
and irreversible loss of tumorigenic capacity. These non-tumorigenic cells compose the 
bulk of a tumour (Shackleton et al, 2009).  While these two models are not mutually 
exclusive in cancers that follow the stem cells model (cancer stem cell will generate a 
progeny  in  a  clonal  evolution  fashion)  (Williams  et  al,  2007),  the  heterogeneity  of 
cancers that do not follow the stem cell model is only due to clonal evolution. The main 
difference between the two models  is  that the heterogeneity proposed  by the clonal 
evolution model suggests that all cells within a cancer have the potential to contribute to 
disease  progression  and  therefore  all  cells  must  be  eliminated  to  cure  the  disease 
(Shackleton et al, 2009).  In contrast the cancer stem cell origin suggests that only a 
specific subset population of cancer stem cells needs  to be eradicated (Dick, 2008). 
Difficulty  of  eliminating  all  the  tumorigenic  cells  before  even  one  reaches  growth 
advantage (clonal evolution model) and the difficulty of reaching cancer stem cells and 
distinguish them from non tumorigenic cells make clinical management difficult. This 
and the clear understanding of which cancers follow which model are central to improve 
successfulness of targeted therapy.  
 
1.3 CANCER TREATMENTS 
Surgery,  radiation  therapy  (RT),  hormonal  therapy  and  chemotherapy  are  the  major 
treatments for cancer.  Radiotherapy is based on the use of ionising radiation (IR) and  
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specifically  targets  a  limited  area  of  a  tumour.  Chemotherapy  is  a  more  systemic 
approach, usually utilized to treat larger or spread tumours. The majority of patients 
affected by cancer will receive some form of RT or chemotherapy as a single therapy or 
in combination as a concomitant therapy, or adjuvant after surgical removal of a tumour. 
It has been reported that the assessment of the contributions of different modalities to 
cure rates, of those cured, 11% are cured by chemotherapy, 40% are cured by RT and 
49% are cured by surgery (Tobias J & Hochhauser D.; 2010). 
 
1.3.1 Radiotherapy 
Standard radiotherapy is applied by the usage of high photons X-rays produced by linear 
accelerators. Following the first observation that IR reduced the viscosity of DNA in 
solution (Dikomey & Franzke, 1986a), IR has been shown to induce single and double 
DNA  strand  breaks  (SSBs,  DSBs)  and  covalent  bonds  leading  to  DNA-protein 
crosslinks (Dikomey & Franzke, 1986b) and DNA-DNA crosslinks (Jackson & Bartek, 
2009; Szumiel, 2008; Ward, 1995). In a mammalian cell 1 Gray (Gy) of IR has been 
estimated to produce 1000 SSBs, 30-40 DSBs and around 3000 base damages (being a 
single  strand  break  the  consequence  of  2.7  base  damages)  (Ward,  1995).  DSBs  are 
known to be the most lethal type of damage and even 1 unresolved DSB could cause 
cell death (Jackson & Bartek, 2009; Jeggo & Lavin, 2009). IR-induced DNA damage is 
not randomly distributed throughout the genome of an exposed cell (Olive & Banath, 
2006). Due to the high local energy deposition via a radiation particle track, the damage 
produced (comprising 1 or more DSBs, associated SSBs, base damages and crosslinks) 
is all clustered within about 10 base pairs (Glei et al, 2009). Because of its complexity, 
this  type  of  clustered  damage  is  less  repairable  than  sparse  damage  throughout  the 
genome.  
 
1.3.1.1 Radiotherapy unspecificty 
Therapeutic usage of X-rays requires high voltage varying from 50kVto 30 MeV. As the 
voltage increases,  X-rays  of shortage wavelength  are  also  produced  (Collins,  2004). 
Although  these  have  a  greater  penetration  within  the  tissues,  the  radiation  energy 
deposited  at  any  depth  of  tissue  falls  off  exponentially  leading  to  irradiation  of  the 
superficial area of the tumour and beyond it (the tumour free tissue surrounding it). This 
represents  the  major  limiting  factor  of  Radiation  therapy  (McArt  et  al,  2009).  The  
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effects of RT depend on two main factors: oxygenation of the tumour tissue and tumour 
repopulation following treatment.  
 
1.3.1.1.1 Oxygenation  
Well  oxygenated  tissues  are  more  radiosensitive  than  those  that  are  anoxic.  This  is 
because RT produces free oxygen radical adding a great deal of DNA damage to what 
IR has already produced per se. Cancer cells often display increased glycolysis and CO2 
production resulting in acidification and production of a hypoxic environment. Hypoxic 
cancer cells require higher doses of radiation compared to anoxic cells because lack of 
oxygen impedes formation of free radicals.  Reduction of tumour bulk via RT results in 
relieve  of  vascular  obstruction  allowing  blood  supply  and  greater  sensitivity  to 
subsequent doses of irradiation due to the oxygenation effect (Azqueta et al, 2009; Fyles 
et al, 1998; Masunaga et al, 2009). 
 
1.3.1.1.2 Repopulation 
Tumour repopulation  during, or at  the  end of, the course of RT can take place via 
regeneration of the radioresistant stem cells. Resistance to RT is usually acquired via: a) 
DNA induced damage, b) the binding of free radicals by glutathione and other sulfryd 
molecules, c) the increased glutathione S transferase and other enzymes that eliminate 
free radicals and inhibit expression of anti apoptotic proteins (Bentzen, 2003; Gao et al, 
2010; Schmidt-Ullrich et al, 1999). 
 
 1.3.2 Chemotherapy 
The majority of current anticancer drugs exert their effects by targeting and reducing   
enhanced  cellular  proliferation  and  division  of  cancer  cells.  Recently,  the  design  of 
drugs that target invasion, metastasis and vascularisation of tumour cells has been also a 
major focus of cancer therapy (Helleday et al, 2008).  Cell cycle and cellular division 
can be targeted in several ways: 
  Targeting DNA directly with DNA damaging drugs 
  Direct  targeting  of  the  cell  division  with  inhibitors  of  the  mitotic  spindles  that 
prevent equal division of DNA to the two daughter cells 
  Targeting the growth signals that promote entry of the cell into the cell cycle via 
hormonal manipulation  
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  Targeting the signalling pathway that control growth, proliferation and division 
The majority of the drugs in use today fall in the first two categories. Highly replicating 
cells, like cancer cells, can undergo increased cellular death by attempting to replicate 
over damaged DNA. The capability of cancer cells to overcome/bypass this obstacle 
suggests  that  DNA  repair  pathways  efficacy  can  modulate  the  effects  of 
chemotherapeutic drugs. In some cancers the inherited inactivation of these pathways is 
one  of  the  contributing  factors  of  carcinogenesis  (Middleton  &  Margison,  2003). 
Paradoxically, tumour progression has been associated in some instances with activation 
and enhancement of the DNA repair pathways and in some other cases their inactivation 
has  also  been  associated  with  chemoresistance.  These  features  make  DNA  repair 
mechanisms and their modulators a promising target for cancer therapy (Darzynkiewicz 
et al, 2009; Fojo, 2001; Helleday et al, 2008). 
Anticancer  drugs  can  be  grouped  according  to  type  of  DNA  damage  induced  as 
described in Fig 1.1. Only the most relevant drugs to this study have been reviewed. 
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Figure 1.1: Summary of the toxic lesions produced by Cancer Treatment and the 
pathways engaged to repair them. The diagram shows the type of treatment together 
with the chemical structure of the most representative molecules (left), the toxic lesion 
correspondent to the treatment and the major DNA repair pathway involved (right). The 
diagram was taken from (Helleday et al, 2008). 
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1.3.2.1 Alkylating Agents 
These drugs induce a type of lesion that interferes with the replication fork progression 
via the production of a chemical modification (adduct) of the DNA bases. Adducts are 
generally created by the covalent binding of the drug alkyl group (R-CH2) to chemical 
moieties  in  DNA  after  being  metabolized  in  the  body  (McCune  &  Slattery,  2002). 
Alkylating agents are categorized in Monofunctional alkylators with one active moiety 
that modifies single bases and Bifuctional alkylating agents that have two reactive sites 
and usually crosslink DNA with protein and/or crosslink two DNA bases within the 
same  DNA  strand  (intrastrand  cross-links)  or  on  opposite  DNA  strands  (interstrand 
cross-links). The cross-link is dependent on the chemical structure of the drug which 
determines 1) the length of DNA that it affects, 2) the type of adduct on the opposite 
strand and 3) the sequence of bases that is most favourable for the binding. Therefore, 
alkylating  agent‟s  damage  is  highly  chemical  selective  explaining  the  different 
responses in different tumours (Lind & Ardiet, 1993). 
Examples of monofunctional alkylators are: Alkysulphonates, Nitrosourea compounds, 
Temozolomide.  Nitrogen  mustards,  Mytomicin  C  and  Cisplatin  are  bifunctional 
alkylators (Chabner & Roberts, 2005). 
 
1.3.2.1.2 Cisplatin 
Cisplatin (cis-Diamine dichloroplatinum (II)) or cis-DPP (Fig 1.2) is one of the most 
used antitumour drugs today. Its anticancer properties were only noticed in the middle 
1960 by Rosenberg and co-workers when they realized that platinum electrodes released 
platinum complexes by redox reactions that provoked complete inhibition of cellular 
division in Escherichia coli (Cepeda et al, 2007). Cisplatin is a neutral, square planar 
molecule of platinum (II) bound to two chloride and two ammonia groups, where the 
chloride  molecules  are  in  the  cis-geometry(Wang  &  Lippard,  2005).  When 
administrated intravenously, quickly diffuses into tissues binding primarily to plasma 
proteins. Due to the strong reactivity of platinum against sulphur and thiol groups of 
amino acids such as cysteine, nearly 90% of platinum in the blood is bound to albumin 
and other proteins leading to the inactivation of the majority of cisplatin. 
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Figure  1.2:  Structure  of  cisplatin.  Cisplatin  (cis-diamminedichloroplatinum(II), 
CDDP) is an inorganic compound with a planar structure. 
 
The loss of chloride groups is required for the binding to genomic DNA (gDNA). In the 
blood, the chloride concentration is high (100mM) whereas upon entering cells, where it 
is lower (30mM), the chloride groups are replaced by water molecules. This cationic 
aquated mono, [Pt(H2O)Cl(NH3)2]
+, and diaquo, [Pt(H2O)2(NH3)2]
+2, species of cisplatin 
are very reactive with nucleophilic sites on macromolecules . The N7 atoms of guanine 
(G)  and  adenine  (A)  located  in  the  major  groove  of  the  double  helix  are  the  most 
accessible  and  reactive  sites  for  platinum  binding  to  DNA  due  to  their  high 
nucleophilicity  and  accessibility  (Cepeda  et  al,  2007;  Wang  &  Lippard,  2005). 
Interestingly only 10% of the covalently bound cell-associated cisplatin is found in the 
gDNA and about 75-85% of the drug binds to proteins, RNA, thiol-containing peptides, 
and  other  cellular  components  rich  in  nucleophilic  sites  such  as  cytoskeletal 
microfilaments (Akaboshi et al, 1992). The formation of the crosslinks inhibits DNA 
replication  and  transcription,  by  stalling  the  replication  machinery  at  the  site  of  the 
crosslink that can bend the double helix towards the major groove or even unwind it 
(Martin  et  al,  2008).  Recognition  of  the  damage,  failure  to  unhook  the  crosslink, 
replication  machinery  stall,  indirect  further  damage  produced  by  the  crosslinks  and 
activation  of  other  signalling  pathways  contribute  towards  cisplatin  cytotoxicity 
(Jakupec et al, 2003; Kartalou & Essigmann, 2001a; Kartalou & Essigmann, 2001b).  
Cisplatin is a widely used chemotherapeutic agent for a large number of cancers it is 
effective in ovarian cancer, bladder cancer, lymphoma and non small-cell carcinoma of 
the bronchis. It is active in osteosarcoma, oesophagogastric cancer, squamos cancer of 
the  head  and  neck.  It  has  been  used  in  combination  with  radiotherapy  and  other 
chemotherapeutic agents in cancer that have shown resistance to treatment (Borst et al, 
2008), (Tobias & Hochhauser 2010), (Savage et al, 2009). 
 
Pt
H3N
Cl H3N
Cl 
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1.3.3 Hormonal therapy 
The drugs utilized for this approach aim at targeting the endocrine function by affecting 
steroid  hormones  and  their  antagonists.  This  leads  to  a  modulation  of  the  tumour 
growth. They are divided into two classes: antagonists or competitive antagonists of the 
estrogen  receptor  (mainly  used  in  breast  cancer)  and  glucorticoids.  The  first  group 
induces a G-S transition arrest resulting in cell death the second group targets protein 
synthesis leading to apoptosis (Prat & Baselga, 2008). 
 
1.4 DNA DAMAGE AND REPAIR 
Exogenous and endogenous damage agents that cause different types of DNA damage 
constantly threaten the human genome (De Bont & van Larebeke, 2004; Shrivastav et al, 
2008). These are:  
Byproducts of normal cellular metabolism: 
  Hydrolysis is a cause of spontaneous DNA depurination, reactive oxygen species 
that cause DNA breaks (Li et al, 2000) 
   Replication  defects  can  cause  mismatches  and  replication  fork  collapses 
resulting in strand breaks (Paques & Haber, 1999).  
Environmental agents: 
  ultraviolet light (UV) (De Bont & van Larebeke, 2004),  
  ionizing radiation (IR) (Azevedo et al) 
  Genotoxic chemicals (Branzei & Foiani, 2008). 
 As  previously  explained  this  constant  induction  of  DNA  damage  and  the  inherited 
mutation within the sequence of key genes can affect the integrity of the genome and 
induce  tumorigenesis.  In  order  to  protect  themselves  from  the  consequences  of  this 
damage, cells have evolved DNA damage repair systems, which recognise the different 
type of damage and activate specific repair pathways that will repair the DNA lesions 
(Zhou & Elledge, 2000). Activation of DNA repair pathways often induces a cell cycle 
arrest to allow sufficient time to completely repair the DNA lesions; however improper 
repair  can  take  place  mostly  due  to  the  large  extent  of  the  damage.  This  causes 
inheritable permanent mutations to the daughter cells and oncogenesis or sometimes 
programmed  cell  death  (Moynahan  &  Jasin,  2010).  For  example,  recognition  of 
unrepaired  DSBs  can  cause  either  activation  of  apoptosis  or  improper  chromosome  
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segregation resulting in chromosome aberrations such as deletions, translocations, and 
ultimately oncogenesis (Lobrich & Jeggo, 2007; Selvanayagam et al, 1995). 
The next section will illustrate the different DNA repair mechanisms, their impact on 
the cell cycle and the mechanism of cellular death triggered by DNA damage.   
Fig 1.3 summarises the cellular response to DNA damage. 
 
Figure 2.3: Cellular response to DNA damage.  Different types of damage are dealt 
by the cell in different ways. The diagram shows the cellular response to DNA damage 
and its consequences. The diagram was taken from (Shiloh, 2003). 
 
1.4.1 Nucleotide excision repair (NER) 
It is the most versatile and most ubiquitous repair mechanism. It recognizes a wide 
variety  of  unrelated  DNA  lesions  such  as  6-4  pyrimidone  photoproducts, 
benzo[a]pyrene  DNA  adducts  induced  by  cigarettes  smoke,  cyclobutane  pyrimidine 
dimers induced by UV and cisplatin adducts (Bessho et al, 1997; De Silva et al, 2000; 
De Silva et al, 2002). There are two subsets of the NER pathway, global genomic repair 
(GGR),  also  called  short  patch,  and  transcription-coupled  repair  (TCR),  long  patch, 
which only  differ in  the recognition  of the damage  (Nojima  et  al,  2005; Tornaletti, 
2009). In its simplest form NER involves four steps: 1) recognition of the damage and 
formation of a pre-incision complex, 2) asymmetric incision at the 5‟ and 3‟ of the 
lesion to produce a short oligo containing the single stranded damaged DNA 3) Repair 
by utilizing the undamaged complementary strand 4) ligation of the newly synthesized  
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strand to complete the repair of DNA (Hoeijmakers, 2001). While in GGR XPC/HR23B 
is the major DNA lesion recognition complex, in TCR the damage is recognized by the 
arrest  of  the  elongating  RNA  polymerase  (RNAP)  at  the  site  of  the  lesion.  The 
recognition of the lesion triggers the recruitment of the transcription factor II H (TFIIH). 
TFIIH is a nine subunit complex two of which, XPB and XPD, are DNA helicases that 
unwind the DNA damaged duplex.  Once the strands are unwound and the damages site 
inaccessible, XPF-ERCC1and XPG are recruited to make the 5‟ and 3‟ excision on each 
site of the lesion creating a 22-30 base oligonucleotide. Using the opposite undamaged 
strand replication factor C (RFC), PCNA, DNA polymerase   or  , DNA ligase I and 
RPA, gap fill the excised strand and ligate the synthesized oligonucleotide to the DNA 
strand (Andressoo et al, 2005; Andressoo et al, 2006; Hoeijmakers, 2001; Hoeijmakers, 
2007; Hoeijmakers, 2009; Mitchell et al, 2003). Fig 1.4 summarise the pathway. 
 
1.4.2 Base excision repair (BER) 
It is mainly involved in the repair of DNA damage cause by cellular metabolism. BER 
recognizes mainly DNA damage occurring during cellular metabolism as a result of 
reactive oxygen species, hydrolysis, methylation and deamination. In addition BER is 
employed by the formation of a SSB following IR (Swartzlander et al; Swartzlander et 
al, 2010). 
Normally glycosilases flip the damaged base out of the helix forming an abasic site 
(hydrolysis per se forms and abasic site). At this stage the endonuclease APE1 makes an 
incision at the damaged strand and DNA pol  removes the 5‟ baseless sugar residue and 
allows the XRCC1 protein to synthesize the damaged base. DNA Ligase 3 seals the 
strand break completing the repair. If the long patch pathway is activated, DNA pol  /  
and  PCNA  produce  an  incision  and  re-synthesize  2-10  bases,  FEN1  endonuclease 
cleaves the displaced DNA fragment and DNA Ligase I seals it to the DNA strand. 
Some BER lesions can cause block of transcription, which will be dealt by the TCR 
(Hoeijmakers, 2007). Usually when BER is utilized for the repair of a SSB, the poly 
ADP ribose polymerase-1 (PARP1) and PNK are recruited to the site of the damage to 
prevent any unwanted recombination event and signal for BER initiation (Griffiths et al, 
2009). Fig 1.5 shows the steps of this pathway.  
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1.4.3 Mismatch repair (MMR) 
It is a highly conserved mechanism, strand specific which is initiated by the recognition 
of  mismatched  or  unmatched  DNA  base  pairs  or  insertion-deletion  of  loops.  
Mammalian  MMR  involves  the  family  members  of  the  E.  coli  MutS  and  MutL. 
Heterodimer formation of the human MutS homolog 2 and homolog 6 (hMSH2/6) also 
called hMutS  recognizes mismatches and single base loops (Zdraveski et al, 2002). 
Insertion or deletion loops are usually recognized by the hMSH2/3 (hMutS ) (Sugawara 
et al, 1997). Formation of other heterodimeric complexes of the hMutL-like proteins 
hMLH1/hPMS2  (hMutL )  and  hMLH1/hPMS1  (hMutL )  interact  with  the  MSH 
complexes and the replication factors either to contact the replication machinery or to 
stabilize the MSH complexes on the lesion. Following recognition of the damage strand 
discrimination of the newly synthesized (containing the mismatch) strand is probably 
based on physical contact with the nearby replication machinery (Martin et al, 2008). 
Excision of a DNA fragment past the mismatch and its degradation are carried out by 
RPA, PCNA, RFC, exonuclease1 and endonuclease FEN1(Hoeijmakers, 2001). Correct 
synthesis is mediated by the activity of pol / . Fig 1.6 shows a diagram of the pathway. 
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Figure 1.4: Nucleotide excision repair. The diagram shows the different steps and the 
molecules involved in this repair pathway (Hoeijmakers, 2001). 
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Figure 1.5: Base excision repair (BER) pathways. (Hoeijmakers, 2001) 
  
38 
 
 
Figure 1.6 Mismatch repair (MMR) pathway. Hoeijmakers J.H., Nature 2001 
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1.4.4 Double strand breaks repair pathways: Nonhomologous end joining 
and Homologous recombination. 
 
1.4.4.1 Double strand breaks causes and consequences 
DSB are naturally generated in the cells when the replication fork encounters a DNA 
nick or blocking lesion. DSBs can be classified in Physiological DSBs and Pathological 
DSBs.  Physiological  DSBs  are  those  that  arise  from  programmed  genome 
rearrangement (yeast mating switch type, V(D)J recombination, antigen receptor gene 
rearrangement and meiosis). Pathological double strand breaks are those produced by 
oxidative free radicals, IR, replication across another lesion, inadvertent nuclear enzyme 
action  at  a  fragile  site,  topoisomerase  failure,  and  physical  stress  imposed  on  the 
chromosome during mitosis (Caldecott, 2008). Normally during oxidative respiration 
mitochondria  convert  from  0.1-1%  of  the  oxygen  to  superoxide  (O2
-).  Superoxide 
dismutase in the mitochondrion (SOD2) and in the cytosol (SOD1) converts this into 
hydroxyl free radicals, which react with DNA causing single strand breaks. Two closely 
spaced SSBs give rise to a DSB. Each hour around 10
22 ROS are produced in the human 
body (10
9 per hour per cell). Environmental IR, such as  -rays and X-rays, is also a 
cause of DSBs. Only at seas level around 300 million IR particles pass through each 
person per hour. These create free radicals that cluster around DNA generating 1 DSB 
for every 25 SSBs (De Bont & van Larebeke, 2004). Despite being the most mutagenic 
form of DNA damage, mammals have evolved a way to exploit the formation of DSBs 
to control biological processes and maintain heterogeneity. In addition to the action of 
topoisomerases II that induce the formation of DSBs to decatenate the DNA strands, 
DSBS occur also to initiate rearrangement during maturation of immunoglobulin genes 
and are central in the recombination events between homologs during meiotic prophase 
I (McKinnon & Caldecott, 2007).  
The failure to repair or missrepair DSBs can result in cellular death or in large-scale 
chromosome  deletions,  translocations,  and  fusions  enhancing  genome  instability  and 
induce carcinogenesis. This is one of the main reasons why chemical agents such as 
Topoisomerase poisons, other chemotherapeutic drugs and IR therapy while inducing 
substantial damage to eradicate cancer cells may induce, at the same time, secondary 
malignancies, by targeting the genome integrity of non cancer cells (Jeggo & Lobrich, 
2007; Khanna & Jackson, 2001). 
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1.4.4.2 Double strand breaks repair pathways 
Two major pathways in diploid cells repair DSBs. The most common form of repair is 
the homology-directed repair or homologous recombination (HR), which requires long 
sequence of homology to repair the damage. The second, but mostly developed in non-
dividing haploid  organisms  and diploid  organism is  the nonhomologous  end joining 
(NHEJ), which does not require the presence of a homologous strand to repair the DSB 
(Shrivastav  et  al,  2008).  Although  still  active  area  of  investigation,  it  s  generally 
accepted that during S phase the physical vicinity of the sister chromatids provides the 
homology required for activation of HR. During S/G2 transition if a homolog is not 
present NHEJ will be used to repair the break and outside of this phase NHEJ is the only 
possible option. The issue of homologue proximity and the possible competition among 
the components of these pathways are yet to be fully understood (Allen et al, 2003). 
Recent  studies  have  suggested  the  DNA  ligase  IV  complex  may  be  responsible  to 
suppress the HR initiation step, leading to NHEJ activation (Shrivastav et al, 2008). 
 
1.4.4.2.1 Non-homologous end joining (NHEJ) 
Accurate and mostly precise on simple breaks such as blunt ends, this pathway rejoins 
the two damaged ends of the DNA break in a sequence independent fashion (van Gent 
&  van  der  Burg,  2007).  Although  described  as  non  homologous  a  small  region  of 
homology (1-6bp) can facilitate the strand break rejoining (van Gent & van der Burg, 
2007). It requires Ku heterodimer (Ku70 and Ku80) which binds to the reciprocal DNA 
ends through is ring shape structure. This complex has mainly the function of a scaffold 
to assemble the other components of the pathways at the DNA termini.  One of the first 
enzymes to be recruited is the DNA dependent kinase catalytic subunit (DNAPKcs). 
This serine-threonine 460kDa protein forms a so-called synaptic complex that holds the 
two ends  of the broken DNA molecule together. Together with  Ku70/80 it forms a 
holeo-enzyme complex called DNAPK (Hammel et al, 2010). Usually in presence of 
DNA  blunt  ends  or  complementary  5‟  phosphate  and  3‟  hydroxyl  group,  the  auto-
phosphorylation of DNAPKcs allows juxtapositioning of the DNA ends that become 
available  for  ligation  by  the  DNA  ligase  IV  complex  containing  XRCC4  and  XLF 
cofactors (Weterings & Chen, 2007). In many cases, ends cannot be precisely rejoined 
because of aberrant 3‟phoshate groups, 5‟ hydroxyl groups damaged backbone sugar 
residues and damaged DNA bases. These ends require processing before ligation takes  
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place.  This process can be mediated by different proteins according to the different type 
of DNA ends fromed at the site of the break. Polynucleotide kinase (PNK) interacts with 
DNA ligase IV in presence of 3‟ phosphate groups and 5‟ hydroxyl groups and recruits 
ancillary components such aprataxin (APTX) and PNK-APTX like factor (PALF) for 
additional  3‟  nuclease  activity  (van  Gent  &  van  der  Burg,  2007).  Artemis  nuclease 
activity  is  involved  in  the  resolution  of  difficult  DSBs.    Following  binding  and 
phosphorylation  by  DNAPKcs,  Artemis  exerts  a  diverse  array  of  nuclease  activity 
including 5‟ and 3‟ endonuclease activity, hairpin opening activity in addition to its own 
5‟ exonulease activity. In presence of aberrant DNA ends DNAPKcs phosphorylates 
Werner  helicase  (WRN)  whose  nuclease  activity  is  required  for  their  processing 
(Stracker et al, 2009). Despite the great flexibility shown by the XFL:XRCC4:DNA 
ligase  IV  to  ligate  across  gaps  with  incompatible  ends  there  are  2  members  of  the 
Polymerase X family Polymerase   and   that can fill the 5‟single stranded extensions.  
Their activity is well suited in the NHEJ pathway as Pol   is capable of both template 
dependent and independent synthesis and Pol   has more flexibility than replicative 
polymerases (Lieber, 2010; Shrivastav et al, 2008). 
There are several other factors shown to be required for the repair of difficult DSBs by 
the NHEJ. These are: the MRE11/RAD50/NBS1 (MRN) complex, MDC1, 53BP1 and 
ATM kinase. While the MRN complex may be implicated in keeping the DNA ends 
together,  or  in  close  proximity,  MDC1,  53BP1  and  phosphorylation  of  the  histone 
variant H2AX seems to be required to the formation of this complex in foci fashion. 
ATM is one of the major kinase of H2AX following formation of DSBs therefore it has 
been suggested that ATM would induce the creation of chromatin microenvironment 
that allows the formation of the MRN foci. Fig 1.7 shows the most significant steps of 
the NHEJ pathway (Lieber, 2010). 
 
1.4.4.2.2 Homologous Recombination (HR) 
It  is  an  error  free  repair  process  that  requires  homologous  sequence  of  the  sister 
chromatid. All the homology directed repair is initiated by a 5‟-3‟ resection at the DSB 
end  and  ATM  activation  mediated  by  the  Mre11/Rad50  and  Nsb1  (MRN;  Mre11-
Rad50-Xrs2) complex that creates a single stranded DNA (Branzei & Foiani, 2008). 
From here, three main homology-directed repair pathways could take place. These are: 
Synthesis-dependent  strand  annealing,  double  Holliday-Junction  and  single  strand  
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annealing (Helleday et al, 2008). Following resection, in the synthesis-dependent strand-
annealing  subpathway,  Rad51  with  help  of  a  numerous  group  of  proteins  (BRAC2, 
RAD52, RAD54, RAD54B and also RAD51 paralogues RAD51B, RAD51C, RAD51D, 
XRCC2 and XRCC3) forms the nucleoprotein filament that searches for the homolog 
and initiates strand invasion (Shrivastav et al, 2008). The base pairing of the homolog 
and the invading strand creates a DNA heteroduplex that displaces one of the DNA 
strands forming a D-loop that enlarges as the synthesis proceeds. The annealed 3‟ strand 
is then elongated via repair synthesis mediated by polymerase   (pol  ). Several lines of 
evidence  have  suggested  that  pol    is  involved  in  HR,  however  several  other 
polymerases  can  compensate  in  his  absence.  Synthesis  must  continue  beyond  the 
original point of break to restore the missing information at the break point. On the other 
side of the D-loop an X -like structure, called the Holliday Junction, is formed at the 
border of the intersection between the invading strand and the homolog (Moynahan & 
Jasin, 2010). In order to release the newly synthesized strand the Holliday junction has 
to slide towards the same direction of the synthesis in a process  referred as branch 
migration. WRN, BLM, p53, RAD54, BLAP75, hMSH2, hMSH6 have all been shown 
to be able to modulate the sliding and the direction of the junction. This is necessary to 
allow  release  of  the  new  strand  however  the  sliding  process  and  the  regulating 
mechanism  are  not  fully  understood  (Helleday  et  al,  2007).  Once  free,  the  released 
strand is bound by RPA and if the opposite end of the DSB  is similarly fixed then 
simple annealing will take place via the help of Rad52 or possibly p53. Presence of 
damaged  bases  or  the  extent  of  the  synthesis  my  lead  to  flaps,  gaps.  In  this  case 
XPF/ERCC1 endonuclease activity is employed and the gaps are filled by the activity of 
other proteins such as DNA ligase I, PCNA and pol  /  (Adair et al, 2000; Batty & 
Wood, 2000). 
Sometimes there is the possibility that a double Holliday junction forms at either side of 
the D-loop. This normally happens when the opposite strand anneals to the D-loop and 
also starts synthesis creating a double intersection.  If the cleavage that release these 
heteroduplexes is made at the holliday junctions then flanking sequences continuity of 
the DSBs will be preserved otherwise it will result in a cross over event. 
If at the sides of the DSBs two adjacent repeat sequences are present, single strand 
annealing may be utilized to resolve the DSBs.  This is a process facilitated by rad52 
and RPA but Rad51-independent. If this HR subpathway is initiated then the sequence  
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between the repeats will be inevitably lost as well as one of the repeats. In the literature 
this sub pathway is also referred as an unintentional consequence of the need to create a 
single stranded DNA to initiate synthesis- dependent strand annealing. Fig 1.8 shows the 
steps of this pathway (Evers et al, 2010; Helleday et al, 2007; Shrivastav et al, 2008). 
 
 
Figure 1.7: Non Homologous end joining (NHEJ) pathway. (Chen & Nirodi, 2007)  
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Figure 1.8: Homologous recombination (HR) pathway. (Helleday, 2010) 
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1.5 DNAPKcs 
1.5.1 Structure 
The product of the PRDK gene is a 4128 amino acids polypeptide of 469 kDa. It is the 
largest  protein  kinase  in  biology  and  a  member  of  the  phosphoinositide  3-kinase-
likefamily  (PIKK)  of  protein  kinases.  DNAPKcs  is  specifically  activated  by  double 
stranded  DNA  ends  of  different  configurations.  DNAPKcs  alone  has  a  dissociation 
constant of 3x10
-9 M for blunt DNA ends. In presence of Ku at the DNA ends, the 
affinity  is  higher  with  a  dissociation  constant  of  3x10
-11  M.  DNAPKcs  N-terminal 
extends from amino acid 1-2908 (about 250 kDa) and contains a putative DNA-binding 
domain, a leucine rich  region  and  a series  of  HEAT repeats  (huntingtin,  elongation 
factor  3,  A  subunit  of  protein  phosphatase  2A  and  TOR1).  The  C-  terminal  region 
contains  a  FAT  [FRAP  (FKBP12-rapamycin-associated-protein)  ATM  (ataxia-
talangiectasia  mutated),  TRRAP  (transactivation/transformation-domain-associated-
protein)]  domain  (amino  acids  2908-3539),  the  PIKK  domain  (3645-4029)  and  the 
FATC domain (4906-4128).  Cells that lack DNAPKcs expression have been shown to 
be radiosensitive and also have defects in V(D)J recombination. In addition mammals 
with  DNAPKcs  also  showed  severe  combined  immunodeficiency  (SCID)  (Lieber, 
2010).  
 
1.5.2 DNAPKcs involvement in repair 
Despite its capability to bind DNA alone, DNAPKcs recruitment to damaged DNA is 
Ku dependent. The binding of these two proteins is mediated by a conserved region in 
the  extreme  C-terminus  region  of  Ku  and  C-terminal  region  of  DNAPKcs.  By 
translocating  inwards,  away  from  the  DNA  damaged  ends,  Ku  allows  DNAPKcs 
interaction to the DNA, providing sufficient space for two DNAPKcs molecules to bind 
to the DNA termini and interact in a synaptic complex that hold the ends tight together. 
The DNAPKcs-Ku-DNA complex is referred as the DNAPK complex, known to be the 
most central component of the NHEJ pathway (Collis et al, 2005; DiBiase et al, 2000). 
Although DNAPK phosphorylates Ku70, Ku80, XRCC4, XLF, Artemis and DNA ligase 
IV in vitro there is no evidence that these phosphorylation events are required in vivo for 
NHEJ (Douglas et al, 2005; Sibanda et al, 2010). The only in vivo validated substrate of 
DNAPK is DNAPKcs itself. Noteworthy is that the Ku component of DNAPK can only 
load or unload DNA therefore the kinase activity of the complex is mediated by its only  
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kinase component, DNAPKcs (Chan et al, 2002). There are 16 phosphorylation sites 
identified to contribute to DNAPKcs autophosphorylation in response to DNA damage.  
 
1.5.3 DNAPKcs phosphorylation 
The most in vivo characterized and IR inducible and DNAPK-dependent sites are the 
ABCDE cluster (Ser
2612,Ser
2624, Thr
2609, Thr
2620, Thr
2628, Thr
2647) and  Ser
2056, Thr
3950. In 
addition  IR-induced  phosphorylation  of  Ser
2612  Thr
2628  and  Thr
2647  occurs  following 
inhibition of the related protein ATM. In contrast other studies have shown that both 
ATM and ATR can phosphorylate Ser
2612, Thr
2609, Thr
2628 and Thr
2647 in response to IR 
or  UV.  Cell  type,  cell  cycle  stage  and  the  extent  of  the  DNA  damage  may  be  the 
determining factors that induce in vivo DNAPKcs phosphorylation by DNAPK or ATM 
or ATR. Proteomic screen have also revealed additional in vivo phosphorylation site 
(Ser
2674, Ser
2675, Ser
2677, Ser
3205) but the kinase responsible and the consequences of 
these events have not been yet determined (Chan et al, 2002; Collis et al, 2005; Sibanda 
et al, 2010). In vitro studies of DNAPKcs autophosphorylation have revealed that this 
process induces loss of kinase activity and dissociation of the phosphorylated DNAPKcs 
from  KU-DNA.  This  suggests  that  the  phosphorylation  event  may  regulate  the 
assembly/disassembly of the DNAPK complex (Bailey et al, 2004; Chen et al, 2005). 
Further studies have shown autophosphorylation of DNAPKcs is required for its release 
from  DSB  in  vivo  since  DNAPKcs  kinase  dead,  and  autophosphorylation  defective 
DNAPKcs  are  maintained  longer  at  the  site  of  DNA  damage.  DNAPKcs 
autophosphorylation can be highly complex in vivo because although it may be required 
for disassembly of the complex, phosphorylation at other regions, enhances the rate of 
HR and can either positively or negatively regulate DNA processing (Gu et al, 2010). 
 
1.6 DNA REPAIR REGULATION THROUGH THE CELL CYCLE 
Although the activation of a specific DNA repair pathway depends on the type of DNA 
lesion and its recognition, cell cycle is also a determining factor in this choice. Certain 
repair mechanisms can only take place during one phase of the cells cycle. NER factors 
will be usually required to repair SSB lesions in G1 cells (Branzei & Foiani, 2008). In 
contrast, DSBs are repaired by HR during S phase because of the presence of an intact 
and accessible sister chromatid but during the remaining phases of the cycle, being the 
chromatin already highly condensed, repair will be undertaken by NHEJ (Shrivastav et 
al, 2008). The recognition of the damage, the cell cycle and the DNA repair mechanisms  
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are highly linked and clearly dependent from each other. In order to maintain genome 
stability and integrity cells have evolved two important checkpoints during the cell cycle 
also called restriction points where DNA integrity is checked and damaged DNA is 
repaired to assure correct transmission of the genetic information. In presence of DNA 
damage,  cells  integrate  DNA  repair  pathways  with  transcription,  signalling,  and 
apoptosis  in  a  tightly  regulated  network  called  the  DNA  damage  response  (DDR) 
orchestrated by the checkpoint proteins. Recognition of damage usually becomes an 
activating signal that checkpoint transducers amplify to downstream targets activating 
DNA  repair  systems,  cell  cycle  arrest,  and  apoptosis  (Jackson,  2009).  Central 
components of the checkpoint machinery are the PI3K related proteins ATM, ATR and 
DNAPKcs. ATM and DNAPKcs respond to the presence of DSBs whereas  ATR is 
activated by SSBs and stalled replication forks. These proteins are usually recruited by 
interacting directly with their partners, NBS1, ATRIP and Ku respectively. ATM and 
ATR target many substrates including the checkpoint kinase 2 (CHK2) and checkpoint 
kinase 1 (CHK1) (Lobrich & Jeggo, 2007). While CHK2 activation is exclusively ATM 
dependent,  CHK1 is  activated by  ATR is  mediated by the protein Claspin  and also 
indirectly  by  ATM  that  activates  ATR.  CHK1  and  CHK2  target  cyclin  dependent 
kinases (CDK) whose activation modulates the cell cycle progression by regulating the 
cell cycle checkpoints (Branzei & Foiani, 2008). As mentioned above these restriction 
points  often  induce  cell  cycle  arrest  to  allow  repair  of  damaged  DNA  before  the 
synthesis of the cell cycle and prior to enter mitosis. Thus they control the transition to 
the most important phases of the cell cycle: G1/S and G2/M. 
The next sections will briefly review the cell cycle checkpoints, their role in recognising 
DNA damage and the consequence of unreparable damage 
 
1.6.1 Cell cycle checkpoints 
The interaction of three families of proteins regulates the checkpoints of the cell cycle: 
CDKs,  cyclins  and  the  cyclin  dependent  kinase  inhibitors  (CKI).  Each  of  these 
components is made of a great array of molecules and sub family members that are 
differentially  activated  during  the  cell  cycle.  Cyclins  expression  is  mediated  by 
transcriptional control and destroyed by ubiquitin mediated proteolysis, CDKs requires 
cyclin  binding  to  relieve  the  obstruction  of  their  catalytic  site  and  CKI  inhibits  the 
binding of the cyclin and CDKs rendering the CDKs inactive (Lee et al, 2008; Wojda, 
2000).   
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As shown in Fig 1.9 each cyclin preferentially binds to a specific CDK. An important 
substrate  of  the  CDKs  is  the  retinoblastoma  protein  pRb,  which,  in  its 
hypophosphorylated  status,  binds  and  inactivates  the  transcription  factor  E2F.  RB 
phosphorylation  by  the  CDK-cyclin  active  complex,  releases  E2F  which  mediates 
transcription of genes such as the DNA polymerase   and thimidine kinase allowing 
transition in S phase (Nevins, 2001). There are two main families of CKIs. The INK4 
family  (inhibitor  of  cyclin  dependent  kinase  4)  family  (p15
INK4,  p16
INK4,  p18
INK4, 
p19/p14
ARF),  which  specifically  binds  to  CDK4  and  CDK6  and  the  Cip/Kip  family 
(p21
Cip1/WAF1, p57
Kip2, p27
kip1), which have a wider specificity and bind to the CDK-
cyclin complex rather than CDK alone (Shan et al, 1996). 
 
Figure 1.9: Changes in cycle dependent kinase and cyclins during the cell cycle.  
The diagram outlines the production of cyclins during the different phases of the cell 
cycle  and  the  correspondent  CDK  binding  partner.  The  picture  is  taken  from:  The 
Biology of Cancer (© Garland Science 2007). 
 
 
1.6.1.1 Cell cycle arrest 
G1-S arrest is usually initiated by ATM and mediated by direct activation of CHK2 and 
direct/indirect activation of p53  (Shiloh, 2003). While CHK2 induces activation and 
consequent degradation of CDC25A, p53 induces transcription of p21
Cip1/WAF1. Both p21 
and  CDC25A  inhibit  the  CDK2/cyclinE  complex  formation  and  its  mediated  pRb 
phosphorylation(Lobrich & Jeggo, 2007; Meek, 2009). S phase arrest arises following 
ATR recognition of SS DNA due to collapsed or stalled replication forks replication  
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blocks.  Subsequent  activation  of  CHK1  induces  phosphorylation  and  degradation  of 
CDC25A.  This  prevents  the  initiation  of  a  new  replication  origin  and  slows  down 
replication (Zhou & Elledge, 2000). G2 cell cycle arrest is regulated via the inactivation 
of Cdk1 kinase (also known as Cdc2) (van Vugt et al, 2005). DSBs formation induces 
direct  recruitment  of  ATM  and  indirect  recruitment  of  ATR  by  the  ATM  strand 
resection. They activate CHK1 and CHK2 respectively inducing CD25A degradation 
and promote stabilization of p53 and consequent induction of p21. The phosphorylation 
of CDK1 and the inhibition of the complex formation  with  CyclinB induce the  G2 
arrest.  Also, p27 and Wee1 have been shown to induce CDK1 inhibition. Fig 1.10 
shows a summary of the above mentioned cell cycle arrest (Bassermann & Pagano, 
2010). 
 
 
 
Figure  1.10:  Mammalian  signalling  activating  cell  cycle  check  points  following 
DSBs formation.  The diagram shows the different response to DSBs according to the 
different cell cycle phase. ATM responds mainly to DSBs whereas ATR to SSBs. The 
recruitment  of  the  MRN  complex  amplifies  the  signal  and  involves  the  transducer 
kinases CHK1 and CHK2. In turn these transducers regulate inhibition of the cell cycle 
by inhibiting the cyclin/CDK complex formation. The diagram was taken from (Lobrich 
& Jeggo, 2007). 
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1.6.2 Apoptosis 
Despite all the activity and the tight network of pathways that aims at the repair of 
unwanted damage, cells have methods to detect defects and commit suicide. This is 
because tissue remodelling is too energetically expensive to sustain and the severity of 
DNA  damage  can  become  harmful  for  the  rest  of  the  body.  There  are  two  main 
pathways that can lead to cellular death: apoptosis and necrosis (Gramaglia et al, 2004). 
Apoptosis,  also  called  programmed  cell  death,  is  a  gene  directed  programme  that 
requires  protein  synthesis.  Although  a  clear  example  of  tissue  remodelling  during 
embryogenesis, apoptosis also takes place in adult cells. Apart from the unsustainable 
DNA damage, also the sudden withdrawal of growth stimulatory signals that halt the 
cell cycle and promote death signals can trigger apoptosis (Lowe & Lin, 2000). Two 
families of proteins are central for the apoptotic process to complete: caspases and the 
B-cell lymphoma-2 (BCL-2) family of proteins. Indeed many studies have shown the 
involvement of many kinases including receptor proteins in the activation of apoptosis, 
but one of the most known apoptosis initiator is the tumour suppressor gene p53.  Its 
pro-apoptotic activity is exerted via the transcription of members of the BCL-2 family 
such as Bax and Apaf1, that, together with Bad and cytochrome C, activate caspase 9 
leading to the activation of several member of the caspase family of proteins (Miyashita 
et  al,  1994).    Caspase  are  large  proteases  synthesized  as  inactive  precursors  (pro-
caspases). Their activation is triggered by the cleavage at aspartate residues within their 
protein sequence. In other words the activated proteases are themselves caspases that 
activate a series of proteolytic events that initiate the appearance of different caspases 
(Tsujimoto, 2003).  
The  balance  of  anti  apoptotic  BCL-2  protein  and  the  pro  apoptotic  protein  BAX  is 
determined  by  p53  and  growth  factors.  P53  induces  BAX  transcription  and  inhibits 
transcription of the Bcl2 gene resulting in equilibrium in favour of BAX complexes. 
BAX stimulates cytochrome C release from mitochondria which activates pro-caspase 9 
by binding to Apaf (Lo et al, 2005c). The cytochrome C/procaspase9/Apaf complex is 
also  known  as  the  Apoptosome  (Shi,  2002).  Caspase  9  also  activates  downstream 
caspases such as caspase 1, which digests actin, caspase 6 which digests nuclear lamin 
and caspase 3  that leads  to  the activation of DNAse. Withdrawal  of  growth factors 
induces  apoptosis  by  the  activation  of  the  BCL-2  death  associated  promoter  (Bad). 
During proliferation phosphorylated Bad is bound to the protein 14-3-3 that inhibits Bad 
pro-apoptotic activity (Adrain & Martin, 2009). Growth factors indirectly maintain Bad  
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phosphorylation via the activation of a member of the PI3K pathway, protein kinase B 
(Akt). In absence of growth factors Bad is dephosphorylated and following dissociation 
from 14-3-3 it binds BCL2 blocking its inhibitory effect on cell death. P53 seems to be 
involved in the activation of the Akt pathway responsible for Bad inactivation (Breen et 
al, 2007). Necrosis is commonly seen in the centre of solid tumours. Usually low or 
poor nutrient supply determines disruption of the energy dependent ion channels. The 
consequent  increase  in  cell  volume  and  loss  of  membrane  integrity  induces  the 
activation of proteases and nucleases. This type of cellular lysis is often associated with 
an inflammatory  response. Fig 1.11 shows the complexity of the apoptotic pathway 
(Weisz et al, 2007). 
 
Figure 1.11: Apoptosis signalling pathway (www.cellsignal.com). 
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1.7 CELLULAR SIGNALLING AND CANCER 
Despite the presence of an extensive array of molecules and mechanisms, evolved to 
protect cells from DNA damage and prevent its incorporation and transmission, cells 
still manage to acquire somatic mutations developing into malignancies. Interestingly, 
not even the induction of further DNA damage within these same cells via the usage of 
genotoxic agents and RT is, most of the time, sufficient to kill cancer cells (Savage et al, 
2009). One of the main aims of cancer therapy is to achieve tumour control with less 
toxicity. Targeting aberrant oncogenic factors or pathways that are specific to cancer 
cells has shown improvement in the outcome of cancer therapies without increasing 
toxicity (Nyati et al, 2006). The concept of resistance to treatments and to the innate 
cellular defence mechanisms is incredibly vast and the attempt to give a comprehensive 
picture, fair to all the molecules involved in these processes, would require volumes. 
This section is going to review the role of receptor tyrosine kinases and in particular the 
role of the epidermal growth factor receptor (EGFR) in tumorigenesis, cancer signalling 
and resistance to therapy. This is necessary to understand the role of molecular targeted 
therapy  within  cancer  management  and  the  importance  of  a  better  understanding  of 
cellular mechanism following radiotherapy or chemotherapy to design more efficient 
molecular target therapies. 
 
1.7.1 Oncogenic Receptor Tyrosine kinases (RTK) 
Growth factor and RTKs coordinate, through a complex system of signalling network, 
cellular survival, apoptosis, proliferation, differentiation and migration. 
There are 58 known RTKs in mammals distributed in 20 subfamilies and despite sharing 
a lot of structural homology and downstream signalling pathways each RTK associates 
uniquely  to  these  pathways  contributing  to  an  enormous  combinatorial  complexity 
(Lemmon  &  Schlessinger,  2010).  All  RTKs  have  a  ligand  binding  domain  in  the 
extracellular  region,  a  single  transmemebrane  helix,  and  a  cytoplasmic  domain 
containing  the  kinase  domain  and  an  additional  carboxyl  (C-)  terminal  and 
juxtamembrane  regions.  Their  mechanism  of  activation,  topology  and  downstream 
signalling  pathways  are  conserved  from  the  nematode  Caenorhabditis  elegans  to 
humans  (Amit  et  al,  2007b).  Mutation  in  RTKs  and  aberrant  activation  of  their 
signalling pathways have been linked to diseases such as diabetes, inflammation, bone 
disorders angiogenesis and arterosclerosis. Nearly 30% of the RTKs are involved in 
cancer or tumorigenesis via exerting their oncogenic potential (Bublil & Yarden, 2007;  
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Katz et al, 2007; Seger et al, 2008). Their aberrant activation is mediated by four main 
molecular mechanisms: autocrine activation, chromosomal activation, overexpression, 
or gain of functional mutations (Amit et al, 2007b). One of the main characteristics of 
RTKs and also one of the properties that renders them central in understanding and 
designing new molecular targets is their functional robustness, shown by their capability 
to maintain output reproducibility despite input variation (Citri & Yarden, 2006).  
 
1.7.1.1 The EGF receptor family 
The ERBB family of protein takes its name from their homology to the erythroblastoma 
viral gene product v-erb. It comprises four receptors: ERRB1-4, also known as HER1-4, 
and 13 polypeptide extracellular ligands which all contain a conserved epidermal growth 
factor  (EGF)  domain.  All  four  receptor  are  transmembrane  glycoproteins  whose 
activation takes place via ligand binding and/or homo or heterodimerisation (Bublil & 
Yarden,  2007).  The  vertebrate  family  of  receptors  evolved  from  the  single  ligand-
receptor pair expressed in nematodes. While in worms there is only one single EGF-like 
ligand (LIN-3), drosophila expresses four stimulatory ligands and one inhibitory ligand 
called ARGOS. The function of this family of receptor is  also  very  well conserved 
across the species. In worms, EGFR controls vulva development, differentiation of the 
male tail and posterior-ectoderm development, the drosophila. Likewise, the Drosophila 
EGF receptor (DER) controls the development of several organs during embryogenesis 
and the mammalian ERBBs control organogenesis in multiple epithelial tissues (Amit et 
al, 2007b). 
 
1.7.1.1.1 The evolution of the mammalian ERBB network 
The origin of the first ERBB receptor must have been the result of a gene fusion event 
that linked a cytoplasmic tyrosine kinase to a cell surface receptor. Amino acid sequence 
analysis  of  the  four  ERBB  has  revealed  that  a  gene  duplication  event  must  have 
occurred  to  generate  two  ancestral  receptors,  the  ERBB1/ERBB2  precursor  and  the 
ERBB3/ERBB4  precursor.  Following  subsequent  gene  duplication  these  precursors 
generated the 4 ERBB proteins. In parallel to the evolutionary events that lead to the 
segregation  of  4  receptors,  the  vertebrate  ligands  also  segregated  into  the  ERBB1 
ligands and the ERBB3/ ERBB4 ligands (Fig 1.12) (Amit et al, 2007b).  
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Figure  1.12:  Evolution  of  ERBB  signalling.  From  a  single  vertical  cascade  of 
signalling events, mediated by one receptor in invertebrate primordial specie (left), three 
scenarios may have evolved. Option A describes two events of RTK duplication leading 
to 4 cascades contributing to gene expression remaining isolated from each other. In 
option B the four cascades interact and establish a complex bow tie of layered signalling 
network.  Evolution  from  invertebrates  may  have  preferred  directly  option  B  or  the 
transit  from  option  A  (Option  C).  There  is  no  evidence  of  evolutionary  stability  of 
option A. Fig rearranged from (Amit et al, 2007b). 
 
1.7.1.2 ERBB ligands 
The  epidermal  growth  factor  (EGF),  transforming  growth  factor  alpha  (TGF- )  and 
amphiregulin (AR) bind selectively to EGFR. Betacellulin (BTC), heparin-binding EGF 
(HB-EGF)  and  epiregulin  (EPR)  bind  to  ERBB1  and  ERBB4.  The  third  classes  of 
ligands, the neuregulins (NRG1-4) bind and activate ERBB3 and ERBB4. ERBB2 lacks 
ligand association but it is known to be the most preferred partner for other ERBB 
interactions.  The  majority  of  the  ERBB  ligands  are  synthesized  as  type-1 
transmembrane proteins. The mature and soluble form of the ligand is released into the 
cellular  matrix  following  protease  cleavage  by  members  of  the  ADAM  family  (A 
disintegrin  And  Metalloproteinases)  of  metalloproteinases  (Zhou  et  al,  2006).  Each 
member of this family recognizes at least one feature of the EGF like motif of a ligand. 
This motif is made up of 6 spatially conserved cysteine residues (CX7 CX4-5 CX10-13 
CXCX8 C) that forms three peptide loops through the formation of disulfide bonds by 
the interaction of C1-C3, C2-C4, and C5-C6 (Nakamura et al, 2000). In some cases  
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(HB-EGF, TGF- , AR and BTC) the ligand binding molecule is not cleaved from the 
membrane and can function even if tethered to the plasma membrane through adjacent 
receptor  bearing  cells  (juxtacrine  signalling)  (Klein  et  al,  2004;  Lemmon,  2009; 
Lemmon & Schlessinger; Lemmon & Schlessinger, 2010; Ozcan et al, 2006).  
 
1.7.1.3 ERBB2 
Heterodimers containing HER2 have stronger signal output because of the larger subset 
of phosphoproteins that HER2 can bind, and the higher affinity and broader specificity 
that these heterodimers have with different ligands (Lazzara & Lauffenburger, 2009). 
Also the endocytosis rate of the HER2 heterodimers is slower compared to the other 
ERBBs  and  usually,  rather  than  degraded;  they  are  reshuffled  back  to  the  plasma 
membrane  (Madshus  &  Stang,  2009).  The  analysis  of  the  HER2  structure  has  also 
shown  that  differently  from  the  other  ERBBs  the  dimerisation  loop  of  ERBB2  is 
constitutively extended even in a monomeric state (i.e. resembles the same conformation 
adopted by ligand bound EGFR)(Alvarado et al, 2009; Bose & Zhang, 2009). The very 
strong interaction between the extracellular domains I and III render the ligand binding 
domain inaccessible by ligands. For these reasons ERBB2 is mostly recognized as a non 
autonomous amplifier (Fig 1.13) (Seger et al, 2008).  
 
1.7.1.4 ERBB3 
ERBB3  is  a  kinase  defective,  non-autonomous  receptor  forming  three  functional 
heterodimers.  It  evades  ligand  induced  degradation  and  in  association  with  ERBB2 
activates strongly PI3K (Fig 1.13) (Sergina et al, 2007; Shi et al).  
 
1.7.1.5 ERBB4 
ERBB4 is an autonomous receptor that shares many features with EGFR. In addition to 
sharing most of their ligands ERBB4 recruits some of the most characterised interacting 
partner of EGFR (Shc, Grb2 and STAT5) (Qiu et al, 2008) (Fig1.13). The incapability 
of recruiting a ubiquitin ligase, induces a slow receptor down-regulation. Proteolytic 
cleavage of ERBB4 cytoplasmic domain translocates the truncated receptor (discussed 
below) to the nucleus and might exert transcriptional activity (Zaczek et al, 2005).  
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1.7.1.6 Robustness of the ERBB signalling 
The  ERBBs  proteins  owe  their  specific  robustness  to  1)  the  network  architecture 
interfacing with several sources of input that diverges through a conserved core into 
several outputs 2) their modularity which configures this family into quasi autonomous 
sub systems, 3) an intrinsic positive and negative feedback control that maintains input 
balances and allows their dynamic interaction, 4) their redundancy and 5) the induction 
of buffering mechanisms that enable  damaged components of the system to maintain, to 
a certain extent,  their  function (for example the recruitment of chaperones to maintain 
protein  stability)  (Fig1.14)(Citri  &  Yarden,  2006),(Amit  et  al,  2007b),(Amit  et  al, 
2007a).  
 
 
 
Figure 1.13: ERBB family. ERBB structure and domains and their choice of binding 
partner are shown. Each receptor, except HER3, relies on homo or hetero dimerisation 
for activation. No ligand for HER2 has been identified. The structure of the ERBB 
receptor is shown on the right. The figure is a modified version of  (Linardou et al, 
2009).  
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Figure 1.14: ERBB ligand perspective and network robustness. This is a simplified 
version of the bow-tie architecture of the ERBB family of RTK. The heart of the system 
is a core process consisting of various interactions among the downstream kinases of the 
ERBB receptors while interfacing with three ERBB and a large group of redundant 
ligands.  The  result  of  the  core  output  is  gene  expression  through  the  activation  of 
transcription  factors  that  produce  different  cellular  responses.  The  robustness  of  the 
system is guaranteed by the modularity (inter-activation of kinases), by the functional 
redundancy together with a stringent control. ERBB2 (left side of the core) functions as 
a +ve regulator. Heterodimerization of ERBB2 with any other ERBB reinforces and 
prolongs the signal output. (Right) ERBB2 is chaperoned and also suppressed by the 
Heat  shock  protein  90  (HSP90).  (Left)  ubiquitin  ligase  E2  Cbl  controld  the  -ve 
feedback.  The  bistability  of  this  network  is  mediated  by  the  transcription  of  ERBB 
ligands (positive input) or negative regulators (MIG6/RALT, SPRY, LRIG1). The figure 
was taken from (Citri & Yarden, 2006). 
 
1.8 EPIDERMAL GROWTH FACTOR RECEPTOR 
 
1.8.1 Structure 
EGFR is synthesized from a 1210 residue polypeptide precursor. Following cleavage of 
the N-terminal sequence a 175kDa transmembrane glycoprotein consisting of one single 
polypeptide chain of 1186 amino acids is inserted into the cell membrane (Fischer et al, 
2003). The sequence identity with the other members of the EGFR family varies from 
37% identity (53% of similarity) with ERBB3 and 49% identity (64% of similarity) with 
ERBB2 (Jorissen et al, 2003; Lemmon & Schlessinger, 2010).  It is characterized by 
three domains: the extracellular ligand binding domain or ectodomain (642 amino acids) 
a  single  transmembrane  helix  domain  (23  amino  acids)  and  intracellular  domain  
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subdivided into three regions 1) the juxtamembrane domain (50 amino acids) 2) the 
kinase domain and 3) the carboxyl tail (542 amino acids). While the kinase domain has 
the  highest  sequence  identity  with  other  tyrosine  kinases  (average  of  59-81%)  the 
carboxyl terminal domains share the lowest identity (average of 12-30%) (Fiske et al, 
2009; Klein et al, 2004).  
 
1.8.1.1 EGFR ligand binding domain 
The extracellular region of EGFR contains four domains (I-IV). Domains I and III are 
each about 160 amino acids in length comprising a B-helix LRR solenoid like structure 
and together they bind to activating ligands. Domains II and IV are cysteine rich domain 
both consisting of around 150 amino acids, held together by one or two disulfide bonds 
(Lemmon, 2009). The x ray structure (Fig 1.15) of the extracellular domain revealed 
that a protruding structure form the domain II makes contact with domain II of the other 
dimerising  receptor  suggesting  that  the  dimerisation  is  entirely  receptor  dependent 
(Bublil & Yarden, 2007). Differently from all the other receptor tyrosine kinases, the 
EGFR ligand contacts two distinct sites within one single dimerising molecule (domains 
I and III) rather than crosslinking two separate molecules into a single receptor molecule 
(Lemmon  &  Schlessinger,  2010)  Following  the  ligand  binding  EGFR  extracellular 
domain  undergoes  a  conformational  change  which  releases  the  dimerisation  arm  in 
domain II (Chang et al, 2009; Hubbard, 2009; Jura et al, 2009). Before ligand binding, 
this arm is completely buried by intramolecular interaction with domain IV (Lemmon, 
2009). This tethered conformation stabilizes the receptor and autoinhibits ligand binding 
and dimerisation (Dawson et al, 2007; Mattoon et al, 2004). Ligand binding disrupts the 
tether (Mattoon et al, 2004) allowing the dimerisation arm II to interact with a second 
ligand bound receptor molecule (Dawson et al, 2007). 
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Figure  1.15:  EGF  receptor  activation.  Both  3  dimensional  and  schematic 
representation  of  the  EGFR  receptor  are  depicted  in  colour  co-ordination.    Ligand 
binding mediates the kinase activation by inducing EGFR dimerisation. In the inactive 
kinase both L834 (L858) and L837 (L861) are buried inside the domain facing the α-C 
helix,  preventing  the  formation  of  a  salt  bridge  between  the  E378  and  the  K721. 
Dimerisation induces the juxtaposition of the C lobe of an activator receptor to the N-
lobe of the receiver. The orientation of the L834 and L837, now facing the surface of the 
kinase, allows contact with the C-tail of the activating kinase. The α-C helix change in 
orientation allows the formation of the salt bridge between E378 and K721 necessary to 
keep  the  kinase  active  conformation.  In  this  diagram  only  one  receptor  C-tail  is 
activated; however the flexibility of the kinase region allows two receptors to switch 
their position inducing each other activation. (Bublil & Yarden, 2007) 
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1.8.1.2 Transmembrane domain and Juxtamembrane domain 
EGFR transmembrane domain is made up of one single a-helix that continues to the 
juxtamembrane  domain.  The  juxtamembrane  domain  has  a  number  of  different 
regulatory  functions,  such  as  downregulation  and  ligand  dependent  internalization, 
basolateral sorting in polarized cells and association as a docking site for several other 
molecules  (eps38,  calmodulin  and  PKC)  (Hubbard,  2001;  Hubbard,  2004;  Hubbard, 
2009; Kil et al, 1999; Macdonald-Obermann & Pike, 2009; Red Brewer et al, 2009). 
The versatility of this domain will be further discussed in the result chapter. 
 
1.8.1.3 Kinase domain 
Each  tyrosine  kinase  domain  is  uniquely  cis-autoinhibited  via  intramolecular 
interactions. The phosphorylation of the activation loop is a key regulatory element in 
most kinases and is necessary to destabilize the cis- autoinhibitory interaction, and to 
stabilize the receptor into an active configuration (Bublil & Yarden, 2007; Morandell et 
al, 2008; Morgan & Grandis, 2009). In addition to the activation loop other kinases are 
relived from the autoinhibition by elements outside of the TKD(Schlessinger, 2003). 
One  of  the  most  common  and  known  example  is  the  juxtamembrane  domain 
autoinhibition. The juxtamembrane region can make several contacts with the kinase 
domain,  including  the  activation  loop  acting  as  a  stabilizer  of  the  autoinhibited 
conformation  (example  KIT)  (Bose  &  Zhang,  2009;  Hubbard,  2004;  Mattoon  et  al, 
2004). Receptor dimerisation promotes the trans-phosphorylation of key tyrosine within 
the juxtamembrane domain that disrupts the autoinhibitory conformation and lead to 
receptor  activation  (Lemmon,  2009).  In  addition  to  the  juxtamembrane  also  the  c-
terminal domain has been shown to play a role in the auto-inhibition mechanism (Bose 
& Zhang, 2009). The region of the c-terminal domain containing tyrosine residues that 
undergoes  autophosphorylation  impedes  access  of  ATP  substrate  to  the  active  site 
within the kinase domain. Only following autophosphorylation the physical obstruction 
is released, and the receptor is stabilized into an active conformation (Mosesson et al, 
2008). The activation loop, juxtamembrane domain and carboxyl tail are determinant for 
the  kinase  domain  activation  of  RTKs  and  EGFR  is  not  an  exception.  However, 
differently from all the other allosteric models where one autoinhibited kinase domain 
trans-phosphorylate the other receptor kinase domain within a dimer, EGFR adopts an 
allosteric  model  that  resemble  the  activation  of  CDKs  by  cyclins  (Lemmon  & 
Schlessinger,  2010).  The  EGFR  tyrosine  kinas  domain  forms  an  asymmetric  dimer  
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whereby  the  c  lobe  of  one  TKD  (activator)  contact  the  N  lobe  of  the  other  TKD 
(receiver) inducing a conformational change that releases the autoinhibitory effect of the 
receiver (Jura et al, 2009). In this way the receiver kinase domain adopts an active 
conformation  without  the  necessity  to  phosphorylate  its  activation  loop.  The 
juxtamembrane  domain  has  been  shown  to  play  a  key  part  in  EGFR  allosteric 
conformational change by „exposing‟ the C lobe of the activator kinase in the dimer 
formation (Bublil & Yarden, 2007; Macdonald-Obermann & Pike, 2009; Red Brewer et 
al, 2009). In an inactive receptor the C-terminal region is found to obstruct the  site on 
the  Activator  where  the  receiver  juxtamembrane  region  docks  to    achieve  receptor 
activation supporting earlier studies that have previously indentified  autoinhibitory role 
of EGFR C-terminus (Fig 1.15) (Zhang et al, 2006). 
 
1.8.2 Autophosphorylation 
Following  kinase  activation,  autophosphorylation  of  tyrosine  residue  within  the 
carboxyl  tails  create  the  phosphotyrosine  biding  site  necessary  to  recruit  signalling 
molecules  containing  Src  homology  2  (SH2)  and  phosphotyrosine  binding  (PTB) 
domains. The EGFR phosphotyrosine may directly recruit these proteins or indirectly 
via  the  binding  to  other  docking  proteins  such  as  Grb2.  In  addition  to 
autophosphorylation EGFR is also trans-phosphorylated by other tyrosine kinases (such 
as Src) providing the required docking site for the adaptors and modifiers (Gandhi et al, 
2009; Gazdar & Minna, 2008; Morandell et al, 2008; Shtiegman et al, 2007; Zandi et al, 
2007). Autophosphorylation is not a prerequisite for EGFR signalling as several studies 
have shown that signalling is stimulated also by c-terminally truncated EGFR expressed 
alone or in combination with other ERBB. This is because other trans-phosphorylating 
proteins may mediate the phosphorylation of the docking sites (Wang et al, 2007; Zandi 
et al, 2007). Fig 1.16 shows the different phosphorylation sites together with the kinase 
responsible for the phosphorylation event and the interacting protein. 
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Figure 1.16: Tyrosine phosphorylation site on EGFR. Diagram shows amino acid 
kinase  inducing  the  phosphorylation  and  the  interacting  protein.  Bold  amino  acids 
residues are numbered according to gi-29725609 and gi-2811086; in brackets according 
to gi-4885199 sequence. From (Morandell et al, 2008). 
 
1.8.3 EGFR and cellular signalling  
There are four main pathways activated by EGFR: the mitogen activated protein kinase 
(MapK) pathway, the activation of the Sarcoma (Src) family of kinases, such as the 
Janus Kinase and the signal transducer and activator of transcription (JAKs – STATs) 
pathway  and  the  phospholipase  D  (PLD),  the    subunit  of  the  Phosphoinositide 
phospholipase  C  (PLC- )  and  phosphatidylinositol-3-kinase  (PI3K)  lipid  metabolism 
pathways. Each of these pathways can be activated by more than one phosphorylated 
tyrosine contributing to the high level of redundancy and robustness regulated by EGFR. 
Fig 1.17 highlights  the major EGFR-phosphorylation events  and their correspondent 
downstream signalling pathways. 
 
1.8.3.1 EGFR activation of the MapK pathway 
The key event for the activation of the downstream MapK kinase is the EGFR induced 
phosphorylation  of  the  proto-oncogene  Rat  sarcoma  (Ras).  Usually  EGFR 
autophosphorylation and kinase activation promotes the Src Homology 2 domain (SH2) 
mediated binding of the growth factor receptor-bound protein 2 (Grb2). Alternative the 
EGFR-Grb2 binding is indirectly mediated by the binding of EGFR to Sh2 that then 
recruits Grb2 (Grant et al, 2002; Katz et al, 2007). This adaptor protein is constitutively 
bound to the Ras exchange factor called Son of sevenless (Sos). The relocation of the  
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cytosolic Grb2/SOS complex facilitates the Ras association with SOS resulting in the 
exchange  of  Ras-  bound  Guanosine  diphosphate  (GDP)  for  Guanosine  triphosphate 
(GTP), hence inducing Ras activation (Katz et al, 2007). Ras in turn activates Raf1 
though  a  series  of  intermediate  kinases  leading  to  the  phosphorylation  of  the 
extracellular  signal-regulated  kinases  (Erks)  Erk1  and  Erk2  that  catalyse  the 
phosphorylation of transcription factor promoting proliferation (Fig1.18) (Huang et al, 
2007b).  
 
 
Figure1.17: Topology of EGFR residues inducing cellular signalling. The diagram 
enlarges  a  portion  of  the  kinase  domain  and  C-tail  highlighting  all  the  activating 
Tyrosine residues. Src-dependent phosphorylated tyrosines are highlighted in blue, EGF 
dependent  tyrosine  phosphorylation  in  orange.  K721  residue,  critical  for  the  ATP 
binding, and phospho-groups, are shown in light yellow. Arrows point the activating 
kinase  of  the  residue  followed  by  consequent  function  or  the  activated  signalling 
pathway. Where not indicated the activating kinase is EGFR itself. The picture was 
taken from (Wheeler et al, 2010). 
 
1.8.3.2 Src family of kinases 
It is still not clear whether the Src family of proteins is a signal transducer downstream 
of EGFR or a kinase for EGFR. The direct association of these proteins takes place via 
the Src SH2 domain although the EGFR binding site is not yet been recognized. Src 
does not bind to the major autophosphorylation sites but instead it phosphorylates Y891  
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and Y920 via its SH2 domain providing docking site for p85 subunit of the PI3K. The 
Src dependent Y845 phosphorylation has been linked to STAT5b activation however the 
role of this site in mitogenic signalling has been quite controversial (Fig 1.18) (Benhar 
et al, 2002; Yang et al, 2008). 
 
1.8.3.3 Stat and JAK 
STATs proteins are usually recruited at the intracellular domain of RTKs via the binding 
of  STAT  SH2  domain  and  the  receptor  phosphotyrosine  residues.  Tyrosine 
phosphorylation of key STAT phosphotyrosine (Y669 STAT5b, Y694 in STAT5a and 
Y701 in STAT1) and hetero and homodimerisation is required for STAT activation and 
nuclear translocation (Jorissen et al, 2003). STAT1, 3, 5 have been implicated in EGFR 
signalling. Differently from the other cytokine receptor EGF induced, EGFR-dependent 
STAT activation does not require JAK kinases. In addition STAT proteins do not bind 
the  EGFR  carboxyl  tail  but  indeed  it  appears  that  EGFR-STATs  are  constitutively 
associated however the STAT transcriptional activity is strictly dependent on the EGFR 
kinase activity (Fig 1.18) (Morgan & Grandis, 2009). 
 
1.8.3.4 Phospholipids metabolism 
EGF stimulation in cells induces the production of arachinoid acid (AA), phosphatidic 
acid  (PA)  and  phosphotidylinositol  turnover.  EGFR  activates  at  least  three  of  the 
enzymes involved in this process: phospholipase C-  (PLC- ), phospholipase D (PLD) 
and  PI3-K.  Despite  being  still  obscure  the  mechanisms  of  EGFR-  PLD  mediated 
activation seems  to  require  the physical  interaction of the two proteins  but  tyrosine 
phosphorylation  does  not  seem  to  be  an  absolute  requirement.  PLC-   instead  binds 
directly  to  the  EGFR  autophosphorylation  Y1173  and  Y992  residues  and  is 
consequently  phosphorylated  by  EGFR  on  Y771  and  Y1254  (Kamat  &  Carpenter, 
1997). Once activated it catalyses the hydrolysis of PtdIns(4,5)-P2 which accumulates 
the second messenger 1.2 diacylglycerol (DAG) and inositol 1, 3, 5, triphosphate (IP3). 
The  cellular  role  of  IP3  is  to  release  calcium  while  DAG  acts  as  a  cofactor  in  the 
activation of the protein kinase C (PKC) kinase.  Therefore EGFR can activate Ca
2+-
dependent pathways   such as the nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF B) and through the PKC indirect activation other signalling pathways such 
as MAPK, JUNK and possibly Na
+/H
+ exchange. PI3-Ks are members of one of the  
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most important family of kinases in the cell regulating proliferation, survival, adhesion, 
and migration (Liaw et al, 1998; Marais et al, 1998). Some members of this family are 
also  involved  in  DNA  repair  pathways  and  DNA  damage  response.  They  normally 
catalyse the phosphorylation of the 3‟ positon of phosphatydilinositols and are further 
classified  into  three  classes  according  to  their  substrate  and  lipid  structure.  Among 
these, only class I is regulated by RTKs. While the interaction of ERBB3 with PI3-K is 
direct and this receptor is the main activator of the pathway, EGFR requires the binding 
of  p85  subunit  that  then  interacts  with  the  PI3-K-SH2  domain  (Carpenter,  1993; 
Djordjevic & Driscoll, 2002). EGFR/ERBB3 heterodimers have been shown to activate 
PI3-K  following  EGFR  ligands  stimulation  as  well  as  Src  induced  EGFR 
phosphorylation  (Kim  et  al,  1994).    PI3-K  produces  phosphatidylinositol-3-,4,5 
triphosphate  (PIP3).  The  most  characterised  target  of  this  secondary  message  is  the 
serine threonine kinase AKT (PKB) (Fig 1.18). This protein normally binds to lipids but 
is translocated to the plasma membrane and activated by phosphoinositide-dependent 
kinase 1 (PDK1) on the threonine 308 (T308) (Nicholson & Anderson, 2002). Full AKT 
activation is  mediated by PDK-2 that phosphorylates the serine residue 473 (S473). 
Once  fully  activated,  AKT  localizes  both  in  the  cytosol  and  the  nucleus  where  it 
mediates survival, evasion of apoptosis, sustained angiogenesis and replicative potential. 
More  specifically  AKT  is  involved  in  the  regulation  of  the  cell  cycle  by  the 
phosphorylation of the CKI p21 and p27 that leads to their inhibition and prevents their 
nuclear translocation (Liang et al, 2002). Akt kinase activity has also been shown in the 
inactivation of the glycogen synthase and activation of glycolisis as well as glucose 
transport, hence playing a central role in energy metabolism. The most recognized and 
characterized function of this EGFR downstream target is its regulation of the anti-
apoptotic signal via the NFkB and the inactivation of BAD, CASP9 and the forkhead 
transcription  factor  (Luo  et  al,  2003).  Both  EGFR  and  ERBB3  activation  of  AKT 
signalling,  induced  by  ligand  or  IR,  is  a  major  mechanism  that  leads  to  tumour 
resistance against IR treatment (Engelman, 2009; Li et al, 2009; Toulany et al, 2008b).  
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Figure 1.18: Signalling pathways activated by EGFR. The pathways do not include 
all the components but only the first and last member of the pathway. Cross talk is not 
shown for clarity. The function of each pathway is highlighted in the colour boxes. Two 
inhibitors  (PTEN  and  MKP1)  are  shown  to  inhibit  Pi3K  and  MAPK  pathway 
respectively. The mediated transcriptional gene activation is also shown. Lawrence et 
al., Nature reviews Cancer 2006. 
 
1.8.4 EGFR biological downregulation: endocytosis mediated degradation 
Following activation EGFR undergoes a desensitization phase called endocytosis where 
the active complex of ligand-receptor is internalized and sorted either for degradation, or 
recycling or nuclear translocation (the latter will be further discussed later on) (Madshus 
& Stang, 2009). Just as important as activating cellular signalling is switching them off 
and although EGFR (as well as many RTKs) may spend hours or even days at the cell 
surface, its removal can happen within seconds after messenger stimulation (Oved & 
Yarden, 2002; Zwang & Yarden, 2009). In resting cells EGFR resides in lipid rafts of 
the  cell  membrane  enriched  in  caveolins  and  cholesterol.  Following  ligand  binding, 
EGFR exits these domains in Src dependent manner. Already within the lipid rafts the 
ligand bound receptor associate to coat adaptors such as adaptor protein 2 (AP2) and 
Eps15  involved  in  the  endocytic  machinery.  EGFR  endocytosis  takes  place  through 
clathrin  coated  pits  (CCPs),  via  cavoelae  mediated  endocytosis  (CavME),  or  via  
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macropinocytosis (Zwang & Yarden, 2009). While EGF dependent activation induces 
CCPs mediated EGFR endocytosis, IR induces EGFR CavMe endocytosis. These are 
certainly the most described and recognized internalization routes engaged by EGFR. 
Fig 1.19 shows the main endocytosis pathways. 
 
Figure  1.19:  Endocytosis  pathways.  The  diagram  illustrates  the  different  types  of 
endocytosis,  EGFR  final  destination  and  the  molecular  players  of  the  respective 
pathways. The first three (From left to right) are the routes engaged by EGFR. The 
diagram was taken from (Mosesson et al, 2008). 
 
1.8.4.1 CCps endocytosis  
At the cell surface lattices made up of clathrin triskelia recruit AP2 that mediates the 
formation of the clathrin coated pits at the plasma membrane. Two groups of GTPases 
are  determinant  factors  in  this  type  of  endocytosis:  dynamins,  which  promote  the 
constriction of the vesicle stalk and the Rab family members, which are involved in 
vesicle budding, fusion and motility (Sorkin & Goh, 2008; Zwang & Yarden, 2009). 
Another  protein  that  regulates  EGFR  endocytosis  via  CCps  is  the  ubiquitin  ligase 
Casitas B-lineage lymphoma protein (Cbl). Cbl recruitment to active EGFR is mediated 
by EGFR phosphorylation on the Y1045 (Tanos & Pendergast, 2006). Once bound to 
the receptor via its TKB domain or through Grb2, Cbl recruits E2 molecules promoting 
mono,  multi  (several  monoubiquitylated  sites  on  the  protein)  or  poly-ubiquitylation 
(several Ubiquitin (Ub) molecules on one single lysine) of EGFR either independently 
or  concurrently  (Stang  et  al,  2004;  Woelk  et  al,  2007).  Protein  ubiquitylation  is  a 
reversible  post-translational  mechanism  in  which  the  76  amino  acid  polypeptide 
ubiquitin (Ub) is attached to the   group of the lysine residue in target proteins. The Cbl  
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mediated  ubiquitylation  is  required  for  receptor  sorting  in  the  endosomes  and 
subsequent sorting into the lysosomal degradative compartment (Huang et al, 2007a). 
Epsin-1 and Cin85 facilitate EGFR translocation from the clathrin-coated pits to the 
plasma  membrane.  Cin-85  has  been  found  to  be  associated  to  Cbl  suggesting  that 
together they regulate EGFR endocytosis (Sigismund et al, 2008).  
Following  the  release  of  internalised  plasma  proteins,  endocytic  vesicles  undergo 
uncoating,  a  process  mediated  by  the  auxiliary  protein  Hsc70.  This  allows  EGFR 
induced  activation  of  Rab5  and  membrane  translocation  of  the  early  endosomes 
antigen1 (EEA1) determining the fusion of the vesicle with early endosomes (Massie & 
Mills, 2006; Mosesson et al, 2008). The  endocytic process then terminates with  the 
formation of the mutivesicular bodies (MVBs) from late endosomes by invagination of 
the endosomes membrane to produce intraluminal vesicles  (Puri et al, 2005). MVBs 
then fuse with lysosome or mature into lysosomes leading to the lysis of their protein 
content.  Three  multiprotein  complexes  mediate  the  MVBs  formation  of  EGFR-
concentrated-limiting  endosomal  membranes:  Endosomal  sorting  complexes  required 
for  transport  I,  II,  III  (ESCRT-I,  II,  III).  Alternatively,  EGFR  can  also  escape  the 
endosomal compartments via receptor recycling. While EGF-induced EGFR activation 
leads to endocytosis and receptor degradation, TGF-  induced-endocytosis is followed 
by receptor recycling (Yu et al, 2002). Recycling endosomes contain RAB4 or Rab1 
GTPases, which are involved in fast and slow recycling respectively (Mosesson et al, 
2003).  
Protein kinase C (PKC) has been shown to be involved in recycling by inducing EGFR 
threonine phosphorylation. Kinsin family member 16B (KIF16B) and the cytoskeleton 
associated  recycling  or  transport  (CART)  complex  also  regulate  recycling  by 
modulating  the  actin  filaments  and  facilitating  the  trafficking  to  the  recycling 
endosomes (Massie & Mills, 2006; Sorkin & Goh, 2008). Fig 1.20 shows a diagram of 
these  events.  Along  with  their  degradative  function  endosomes  have  also  been 
associated  with  signalling  pathways.  Endosomes  contain  many  cellular  kinases  and 
EGFR (in particular in its oncogenic status) has been shown to stimulate survival and 
proliferation  by  interacting  with  internalised  Ras,  Shc,  and  Grb2,  and  induce 
oncogenesis  by  coupling  with  internalized  c-Met  to  the  STAT3  pathway  (Oved  & 
Yarden, 2002; Warren & Landgraf, 2006; Woelk et al, 2007).  
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Figure1.20:  EGFR  life  cycle.  GF-activated  EGFR  is  internalized  through  CCP  or 
through  caveolae,  membrane  sub-domains  enriched  in  caveolin  (IR  stimulation). 
Authophosphorylated EGFR activates several signalling pathways by activating Ras and 
PLC  γ.  Central  molecule  to  both  endocytosis  pathways  are  shown  in  the  respective 
boxes. Within early endosomes (expanded circle), phosphorylated EGFR recruits Cbl. 
Next, Cbl recruits ubiquitin-loaded E2 molecules. This step is highly regulated, either 
negatively (by Rho guanine nucleotide exchange factor 7 (ARHGEF7 or COOL1) and 
SRC) or positively (by CIN85 and LRIG1). From the early endosome EGFR can be a) 
recycled back to the membrane, b) sorted into late endosomes (EE) and mutlivescicular 
(MVB) bodies. In this case the cytoplasmic tail is occluded to prevent further activation. 
Following  fusion  event  between  the  late  endosome  and  the  lysosomal  compartment 
EGFR is degraded. A third possibility consists in EGFR nuclear translocation. Escape 
from Cbl-mediated receptor degradation is common in tumours expressing mutant forms 
of  receptor  tyrosine  kinases  or  Cbl.  Proteins  whose  function  is  associated  with 
oncogenesis, along with displaying aberrant expression in human tumours, are shown in 
red, whereas those involved in tumour suppression are shown in gray. Fig adjusted from 
(Mosesson et al, 2008). 
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1.8.4.2 Cavoelae-mediated endocytosis (CavME) 
Cavoelae  are  specialized  lipid  rafts  generated  by  the  oligomerisation  of  the  protein 
caveolin. The first step of this mechanism consists in the inward budding of caveolin 
vesicles into larger caveolin enriched organelles called caveosomes. The vesicle release 
is  mediated  by  dynamins,  PKC,  and  Src  kinases(Sigismund  et  al,  2005;  Zwang  & 
Yarden, 2009). 
 
1.8.5 ONCONGENIC EGFR 
Despite  the  overwhelming  network  of  regulatory  mechanism  that  are  employed  in 
EGFR mediated cell signalling activation and inhibition, which increase the robustness 
of this system, the ERBB family and in particular EGFR represent a major player in 
many types of malignancies. As EGFR is involved in cell proliferation, motility and 
survival,  an  imbalanced  EGFR  system  can  easily  lead  to  neoplastic  transformation 
(Fischer et al, 2003). In 1980 it was found that addition of EGF to culture medium of 
human epidermoid carcinoma (A431) led to high yields of tyrosine phosphorylation, 
similarly to cells infected with oncogenic viruses. EGFR has been the first RTK to be 
associated with a human cancer and indeed deregulated EGFR is now associated with 
many human cancers. There are two main mechanisms by which the tight control of the 
EGFR system can be by passed: modulation of the EGFR-ligand system and by passing 
some of EGFR inherent controls. The first mechanism includes production of ligands in 
an  autocrine  fashion,  overexpression  of  EGFR  via  gene  amplification,  defective 
downregulation  of  EGFR  (defective  endocytosis)  and  cross  talk  with  heterologous 
receptor  systems  (Bublil  &  Yarden,  2007).  The  second  mechanism  includes  the 
acquisition  of  somatic  mutations,  which  give  rise  to  constitutive  active  EGFR 
variants.(Gazdar, 2009a; Nyati et al, 2006) 
These  mechanisms  of  aberrant  EGFR  expression  and  activation  induce  an  indirect 
deregulation of the cellular machinery (EGFR regulates its downstream kinases which 
then  promote  uncontrolled  growth,  proliferation,  migration  etc).  They  represent  the 
EGFR  mediated  contribution  towards  oncogenic  transformation  (Fry  et  al,  2009; 
Grandal & Madshus, 2008). In addition, the activation of EGFR signalling pathways 
following  radiotherapy  and  chemotherapy  also  play  an  important  part  in  acquiring 
resistance and tolerance to treatment. EGFR can also directly modulate cellular survival 
and proliferation by translocating into the nucleus and associate with nuclear proteins 
regulating  cell  cycle,  transcription  and  DNA  repair.  This  section  will  review  the  
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mechanisms that lead to EGFR deregulation and the molecular therapeutic attempts to 
inhibit EGFR in cancer cells. 
 
1.8.5.1 Autocrine mechanisms 
Both EGF and TGF-  are usually found co-expressed with EGFR in a variety of human 
cancers. Overexpression of TGF-  in transgenic mice induces tumour formation and 
also addition of EGF or TGF-  in mouse fibroblast expressing EGFR induces cellular 
transformation. However the effect of the ligand activation on cellular transformation is 
only detected when EGFR is overexpressed, as medium levels of expression do not lead 
to transformation (Zandi et al, 2007). Autocrine production of these ligands in EGFR 
overexpressed  tumours  (colorectal  cancer,  head  and  neck  cancer  squamous  cell 
carcinoma)  has  shown  to  lead  to  high  proliferation  and  worse  clinical  outcome.  As 
explained above TGF-  induced EGFR activation evades CCPs mediated endocytosis 
and degradation maintaining therefore recycling and signalling activation  (Gazdar & 
Minna, 2008). 
 
1.8.5.2 EGFR overexpression 
Elevated levels of EGFR expression have been correlated with increased survival in 
many cancer types including head and neck, bladder, ovarian, cervical and esophageal. 
Spontaneous receptor dimerisation, due to the numerous receptors at the membrane, 
induces constitutive activation resulting in ligand independent increased motility, and 
continuous  activation  of  downstream  signalling  contributing  to  a  more  malignant 
phenotype (Arteaga, 2002). Increased number of EGFR molecule by gene amplification 
has  been  observed  in  breast  carcinomas,  non  small-cell  lung  cancer  (NSCLC)  and 
particularly  glioblastoma  multiforme  (GBM).  Other  mechanisms  that  lead  to  EGFR 
overexpression  are:  increased  activity  of  the  EGFR  promoter  or  deregulation  at  the 
translational and post translational level (Gazdar & Minna, 2008). P53 has been shown 
to bind to the promoter of EGFR activating EGFR transcription. Therefore, as the levels 
of p53 are usually high in cancer cells, so the levels of the receptor will be. It has also 
been reported that a specific region of the EGFR gene has enhancer ability in some 
breast cell cancer lines over-expressing EGFR. These cell lines have also been shown to 
express  more  DNAase  H1  sites  in  the  intron  1  of  the  EGFR  gene  suggesting  that 
chromatin  structure  of  the  EGFR  regulatory  regions  may  have  a  role  in  its  
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expression(Kersting  et  al,  2008).  Again  in  intron1  the  number  of  polymorphic  CA 
dinucleotide seems to correlate with the EGFR expression  (Huang et al, 2009). The 
higher number of polymorphic sites the lower the EGFR expression (Kang et al, 2005). 
 
1.8.5.3 Evading degradative fate. 
EGFR  overexpression  and  over  activation  due  to  autocrine  and  paracrine  ligand 
activation and by spontaneous dimerisation may saturate the capacity of the CCps and 
endosomal adaptors (Stang et al, 2004). A single amino acid mutation within the Cbl 
zinc  finger  domain  renders  the  protein  ligase  defective  therefore  impairing  EGFR 
ubiquitylation (Shtiegman et al, 2007). Indeed ERBB2 has been often associated with 
Hsp90,  which  stabilise  the  protein  rendering  it  a  poor  substrate  for  lysosomal 
degradation; hence EGFR/ERBB2 dimer may undergo the same by pass (Yang et al, 
2006). Several reports have implicated the Src family of kinases in control of Cbl half-
life.  Interaction  with  Src  redirects  the  Cbl  ubiquitin  ligase  activity  towards  itself 
resulting  in  Cbl  proteosomal  degradation.  Therefore  the  uncoupling  of  the  Cbl 
mechanism  may  be  one  of  the  facets  of  the  EGFR-Src  interaction  during 
oncogenesis(Huang & Sorkin, 2005; Zwang & Yarden, 2009). Several ligands including 
EGF induce transcription of Sprouty proteins, which displace RTKs from Cbl. Ligands 
increase  Sprouty  tyrosine  phosphorylation  thereby  sequestering  Cbl  from  activated 
EGFRs (Sorkin & Goh, 2008). 
 
1.8.5.4 EGFR mutations 
The somatically acquired mutations in the EGFR gene are not randomly distributed but 
rather clustered in specific areas, which assumes the role of mutational hot spots. There 
are 1380 mutations of the EGFR gene sequenced from tumour samples. 30% (413 of 
1380)  are  found  in  adenocarcinoma,  2%  in  NSCLC  (16  of  1380).  The  number  of 
sequenced EGFR mutations is incredibly high and will be categorized according to their 
location within the EGFR domains (Gazdar, 2009a). All the mutations are shown in Fig 
1.21 and 1.22. The most relevant to this study will be discussed. 
 
1.8.5.4.1 Extracellular mutations 
Mutations of the extracellular domain are particularly found in Glioblastoma. EGFR 
type I, II, III variant (EGFRvI, EGFRvII, EGFRvIII) are the most known and contain 
deletions of exons encoding parts or the entire extracellular domain(Zandi et al, 2007).  
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These  truncated  mutants,  despite  having  impaired  ligand  binding,  are  found 
constitutively active and highly tumorigenic. EGFRvI lacks most of the extracellular 
domain, is ligand independent and constitutively active (Pines et al). EGFRvII has an in 
frame deletions of 83 amino acids (exon14-15) and therefore still a capable of ligand 
binding. The oncogenic role of this truncated receptor is still unclear (Grandal et al, 
2007). The most frequent and also most characterized mutation is the EGFRvIII also 
described as de2-7 EGFR or  2-7 EGFR which is the result of an in frame deletion of 
exons 2-7. These exons encode domain I and two thirds of domain II of the extracellular 
domain and the deletions of amino acid 2-273 results in the loss of most of the ligand 
binding area. Like EGFR, EGFRvIII activates the RAS/RAF/MEK/ERK pathway and 
Jun N-terminal kinase via PI3K (Grandal et al, 2007; Modjtahedi et al, 2003). EGFRvIII 
is trapped in a partially activated state which is sufficient for oncogenic signalling but 
not for degradation (Zandi et al, 2007). In fact despite its internalization this truncated 
receptor  fails  to  be  ubiquitylated  promoting  also  intracellular  oncogenic  signalling. 
Another truncated receptor is the EGFRvIII/D12-13, which in addition to the deletion of 
exon 2-7, this mutant also lacks part of domain III (exon 12- 13). Besides these deletion 
mutants there is also the report of a mutant that contains duplication of exon 2-7: EGFR 
TDM/2-7. This mutant contains an extra cysteine reach domain I and part of domain II 
which do not impair its ligand binding dependency. Genomic analysis of the EGFR gene 
has revealed that both exon 1 and exon 7 contain an Alu element where DNA breaks are 
centred (Fenstermaker & Ciesielski, 2000).  The recombination of these Alu elements 
have been implicated in the mechanism of deletion/duplication of the region they are 
flanking explaining why the extracellular domain is subject to these types of mutations 
(Wong et al, 1992). Fig 1.21 show a diagram of the mutation above mentioned. 
 
1.8.5.4.2 Intracellular mutations: Kinase domain mutations 
All the somatic mutation falling in this category target the residues around the adenosine 
triphosphate  (ATP)  binding  pocket  leading  to  ligand  independent  activation  of  TK 
activity (Gazdar, 2009a). They are divided into three classes. Class I mutation are in 
frame deletions in exon 19 (various sets of deletions from  amino acid 746 to 753) 
which almost always include deletion from Leucine (L) 747 to Glutamic acid (E) 749 
accounting for about  44% of all the EGFR mutations. Class II mutations comprises 
single point mutation which cause a missense mutation. The most characterised is the 
single point mutation in exon 21 of Leucine (L) 858 into Arginine (R).  L858R has the  
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highest prevalence of any other single point mutation of the EGFR TK domain (41% of 
all activating mutations). To classII belongs the mutation of Glycine (G) 719 into Serine 
(S),  Alanine  (A)  or  (C)  Cysteine  (4%  of  all  the  activating  mutations)  (Sharma  & 
Settleman,  2009).  Other  missense  mutations  account  for  another  6  %  of  EGFR 
mutations (Gazdar, 2009a). Class III mutations are in frame duplications or insertions in 
exon 20. This class accounts for the remaining 5% of all the activating mutations. There 
is  a  remaining  portion  of  low  frequency  (<1%)  mutations  in  exon  20  such  as  the 
Threonine (T) 783 into Alanine (A) and the Valine (V) 765 into Alanine (A) (Gandhi et 
al, 2009). Mutations in exon 19 and the L858R mutation represent about 90% of all the 
activating mutations and for this reason they are also named classical mutations(Gazdar 
& Minna, 2008). The L858R mutation is located next to the conserved aspartic acid-
phenyalanine-glycine sequence (DFG) that has the function to stabilize the activation 
loop.   This  mutation and also  the G719X (X indicates S, A or C) result in  similar 
configuration changes which destabilizes the helical axis narrowing the ATP binding 
site and conferring kinase activation and higher protein stability (Gazdar et al, 2004; 
Murray et al, 2008; Sharma & Settleman, 2009). Fig 1.22 shows a diagram o f all the 
kinase mutations 
 
1.8.5.4.3 Intracellular mutations: C- terminal mutations   
These mutations target the C-terminal domain and are best described in GBM models. 
While EGFRvIV lacks exon 25-27, EGFRvV is truncated from amino acid 958 and 
lacks the rest of the C-tail (exon 25-28) (Frederick et al, 2000). EGFRTDM 18- 25 and 
EGFRTDM 18-26, which contain duplication of exons 18-25 and 18-26 respectively, 
also belong to this category. Of these four mutants, only EGFRvIV has been shown to 
have  oncogenic  properties.  The  removal  of  exon  25-27  removes  the  autoinhibitory 
regulation of the carboxyl on the TK domain resulting in constitutive kinase activity 
(Zandi et al, 2007).  Fig 1.21 shows all the mentioned mutations. 
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Figure  1.21:  Schematic  representation  of  EGFR  mutations.  From  left  to  right: 
wtEGFR,  deletions  or  duplication  of  EGFR  (EGFRvI-EGFRvV,  EGFRvIIID12-13, 
EGFRTDM/2-7, and EGFRTDM18-25/26). Modified from(Zandi et al, 2007). 
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Figure 1.22: Schematic representation of EGFR mutation in the kinase domain. 
The  cartoon  shows  relative  position  of  EGF  binding  domain,  TM,  tyrosine  kinase 
domain and the autophosphorylation domain. The relative position of the correspondent 
exons is also indicated. Only exons 18-21 are expanded. The list of mutations is divided 
in  two.  The  bottom  part  shows  the  acquired  somatic  mutations  that  correlate  with 
gefitinib or erlotonib sensitivity whereas the top part shows the mutation that correlate 
with resistance to these drugs. The most frequent mutations in both panels are shown in 
bold. The overall mutation frequency is also shown. This diagram has been taken from 
(Sharma & Settleman, 2009). 
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1.8.5.5 EGFR nuclear expression 
In addition to the canonical role of EGFR as the initiator of the signalling events that 
originate at the plasma membrane in response to ligand binding, accumulating evidence 
from the research of several group in the past 10 years, shows that EGFR and other 
members of the EGFR family shuttle from the cell surface to the nucleus transducing 
growth,  proliferation  and  modulation  of  DNA  repair  response.  This  section  will 
illustrate  the  molecular  mechanism  that  mediates  nuclear  translocation,  the  recent 
findings on EGFR nuclear expression and their significance in terms of tumorigenesis 
and resistance to chemo and radiotherapy. 
 
1.8.5.5.1 Mechanism of nuclear translocation 
The design of eukaryotic cells separates the cytosol and also its components from the 
nucleus via the nuclear envelope. The regulation of the transport across this cellular 
barrier facilitates the control of important cellular process such as gene expression, cell 
cycle progression, signal transduction and mediates the recognition and recruitment of a 
specific cytosolic protein (cargo), its translocation through the nuclear envelope an the 
release of the cargo in the nucleus (Lange et al, 2007). While small macromolecules 
<40-50 kDa  can  freely  move across the nuclear pore complexes  by diffusion, large 
molecules  must  contain  a  specific  recognition  signal  (Kaffman  &  O'Shea,  1999; 
Moroianu, 1999). The carrier proteins that transport macromolecules across the nucleus 
are collectively referred as karyopherins ( - karyopherins or Importin   is the most 
representative superfamily) with those involved in the import called importins and those 
involved in the export called exportins (Corbett & Krebber, 2004; Lange et al, 2007). 
Although  the  majority  of  the  cargo  proteins  bind  directly  to  -  karyopherins,  the 
interaction between them can also be mediated by the adaptor molecule importin . The 
energy required for the transport is provided by the small Ras GTPases, Ran that binds 
and exchanges both GDP and GTP (Kaffman & O'Shea, 1999; Powers & Dasso, 2004). 
The constant cycling between these two bound states is determined by the Ran guanine 
nucleotide  exchange  factor  (Ran  GEF),  and  the  Ran  GTPase-activating  protein 
(RanGAP). Because these modulators are segregated in different cellular compartment 
the different forms of Ran are also differently distributed with RanGTP in the nucleus 
and  RanGDP  in  the  cytosol  (Kaffman  &  O'Shea,  1999;  Madrid  &  Weis,  2006; 
Moroianu, 1999). Importin   recognizes and binds the cargo protein in the cytoplasm  
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linking it with the importin  . Importin   mediates the transport of the formed trimeric 
complex through the nuclear pore into the nucleus and dissociates by the binding of the 
RanGTP. This association causes a conformational change in the importin   resulting in 
the release of the cargo- importin  (Wente & Rout). The release of the cargo is then 
mediated by importin   IBB (importin   binding) domain, the nucleoporin NP2 and the 
export receptor Cse1/Ran GTP. The latter then recycles the importin   in the cytoplasm 
for another round of import  (Lange et  al,  2007). Fig 1.23 shows the mechanism of 
nuclear translocation. 
 
1.8.5.5.2 Nuclear localisation signals 
In order to discriminate among all the molecules in the cytosol, proteins destined for 
transport into the nucleus contain specific recognition target amino acid sequence called 
nuclear  localisation  signal  (NLS).  The  best  characterised  are  the  classical  signals: 
monopartite consisting of one and bipartite consisting of two stretches of basic amino 
acids sequences spaced by 3 or 10 stretches of amino acids.  The most known examples 
are  the  monopartite  signal  is  the  SV40  large  T  antigen  NLS  (126PKKKRRV)  and 
bipartite  nucleoplasmin  NLS  (155KRPAATKKAGQAKKKK170)  (Chuderland  et  al, 
2008;  Kaffman  &  O'Shea,  1999;  Lange  et  al,  2007).  The  nuclear  import  and 
accumulation  of  the  cargo  is  dependent  on  the  affinity  of  the  NLS  cargo  to  the 
importin , and on the concentration of the importin  (Zaidi et al, 2004). Importin   is 
composed of 10 armadillo motifs each made up of three   helices (ARM domain) and a 
N-terminal domain required for binding to the importin   and for cargo dissociation. 
The 10 armadillo motifs generate a curved molecule in which the two NLS binding sites 
are located within the concave faces of the molecule. Both pockets are made up of 
conserved  tryptophan  and  4  downstream  asparagines.  The  N-terminus  major  pocket 
binds the monopartite NLS, the minor pocket binds the smaller stretch of basic amino 
acid residues of the bipartite NLS (Cyert, 2001; Lange et al, 2007). The cargo NLS runs 
anti-parallel within the curved importin  , the NLS lysine or arginine (basic) amino 
acids side chain lie between the conserved side chains of the tryptophans forming salt 
bridges  with  the  negatively  charged  residues  present  in  the  binding  groove.  The 
downstream asparagines make key chain contact. The N-terminal region of the importin 
  contains  an  autoinhibitory  region  consisting  of  basic  amino  acids  (KRR)  that 
competes with the cargo NLS for binding (Chuderland et al, 2008; Lange et al, 2007;  
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Weis, 2007; Wente & Rout; Zaidi et al, 2004). During import the binding of importin   
inhibits this region but once in the nucleus the two molecules dissociate allowing the 
autoinhibitory region to fold over and interact with the major NLS binding pocket of the 
importin . Because both mono and bipartite signals bind the major pocket, the binding 
of the autoinhibitory domain affects the affinity of importin   to the NLS facilitating the 
release of the cargo in the nucleus preventing the NLS cargo to re-bind to the importin 
(Lange et al, 2007). Fig 1.23 shows the dynamics of the nuclear import cycle. 
The import is further regulated at different levels. Cargo post translational modification 
may affect the affinity for the importin, both the cargo and the importin may be bound 
by an insoluble cellular component compromising the nuclear transfer; the nuclear pore 
could undergo deregulation affecting the transport (Corbett & Krebber, 2004; Lange et 
al, 2007; Rout & Aitchison, 2001; Strambio-De-Castillia et al; Weis, 1998; Weis, 2007; 
Wente & Rout). 
 
Figure 1.23: Nuclear translocation mechanism. The NLS containing cargo is bound 
by the heterodimeric complex importin /importin  in the cytoplasm.  Following nuclear 
localisation, RanGTP induces importin  dissociation. Nup2 and Cse1 then mediate NLS 
cargo release. Importin   autoinhibitory domain folds back preventing re-binding to the 
NLS  cargo  and  the  new  Cse1/RanGTP/importin   translocates  back  to  the  cytosol. 
(Lange et al, 2007). 
 
1.8.5.5.3 EGFR Nuclear translocation 
Nuclear EGFR was firstly observed in hepatocytes during liver regeneration (Kamio et 
al, 1990; Marti et al, 1991). Many studies have now reported nuclear EGFR in the form  
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of uncleaved receptor in the nuclei of various tissues such as  thyroid  cells,  ovarian 
epithelial cells, immortalized renal cells and also primary tumours including those of the 
bladder, breast, oesophagus and thyroid (Dittmann et al; Hoshino et al, 2007; Kamio et 
al, 1990; Lo et al, 2005b; Marti et al, 2001; Xia et al, 2009; Xu et al, 2009b). Hsu et al., 
that characterized the EGFR tripartite NLS 645RRRHIVRKRLLRRR657, provided the 
initial analysis of the mechanism of EGFR nuclear translocation in 2007. Despite not 
being the only characterised tripartite NLS, this type of NLS lacks a specific model of 
binding  with  importin    and  the  EGFR  mechanism  of  nuclear  import  is  still  not 
completely understood. Sequence analysis reveals that the EGFR NLS sequence is well 
conserved among different species and also among the other ERBB family members 
with  the  exception  of  ERBB3  (Hsu  &  Hung,  2007).  While  the  ERBB4  nuclear 
localisation takes place via sequential receptor cleavage, the mechanisms for EGFR and 
ERBB2 is still not clear. Ligand binding to ERBB4 or activation of PKC by phorbol 
esters stimulates an initial metalloproteinase mediated cleavage of ERBB4 that release 
the extracellular 120 kDa part of the receptor, leaving  behind an 80kDA membrane 
bound intracellular domain that includes the kinase domain . There is now sufficient 
evidence showing that ADAM17 (a disentigrin and metallopeptidase 17) is responsible 
for this event. The 80 kDa fragment has two possible fates: it can be ubiquitylated and 
subsequently degraded, or further cleaved by presenilin-dependendent   secretase that 
release the soluble intracellular domain within the cytoplasm which is then translocated 
to the nucleus (Fig 1.24) (Wells & Marti, 2002).  
ERBB2 colocalises with importin   in the endosomes and form a tricomplex with it and 
the nucleoporin Nup358 (usually found at the cytoplasmic filaments of the nuclear pore 
complex) that translocates near the nuclear envelope (Wang et al, 2010b). 
EGFR ligand stimulation and radiation treatment have been shown to stimulate EGFR 
nuclear localisation. Following activation and receptor internalization EGFR can have 
three possible fates: recycling, degradation or routed from the early endosomes to the 
Golgi  and  the  ER  by  retrograde  transport.  This  retrotranslocation  would  then  allow 
binding with the importin   leading to receptor nuclear translocation (Dittmann et al, 
2008a; Dittmann et al, 2010b; Hsu et al, 2009; Lo, 2010; Wang et al, 2010a; Wang et al, 
2010b; Wang et al). Despite this being the only published mechanism (discussed further 
in chapter 3) it still unclear how EGFR (having a transmembrane domain) can pass 
through the aqueous channels of the NPC. One possibility, yet to be confirmed, is that it  
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follows the model presented by the FGFR. Differently form EGFR, FGFR undergoes a 
clathrin  independent  endocytosis,  and  its  unusual  -sheet  (rather  than  -helical) 
transmembrane domain is known to associate unstably with membrane creating a sort of 
dynamic equilibrium between membrane bound and soluble cytosolic FGFR (Wang et 
al,  2010b).  The  unstable  transmembrane  seems  to  recruit  chaperone-like  accessory 
proteins that internalise the protein without requiring endosomes. The chaperone masks 
the  hydrophobic  transmembrane  domain  allowing  the  receptor  to  translocate  to  the 
nucleus via the association with importin   (Fig 1.25) (Wells & Marti, 2002). Another 
mechanism proposed for the translocation of integral membrane proteins consist in the 
initial  insertion  of  integral  membrane  proteins  into  the  Endoplasmic  reticulum  (ER) 
membrane where the NLS is recognized by the importins  (Liao & Carpenter, 2007; 
Wang et al, 2010a; Wang et al, 2010c).  
 
Figure 1.24 Nuclear localisation mechanisms require masking of the hydrophobic 
transmembrane domain. Like FGFR, EGFR may employ and accessory-like protein to 
internalise in the cytosol and mask the hydrophobic transmembrane domain. Nuclear 
translocation  can  take  place  via  the  binding  of  the  importin    through  the  aqueous 
environment of the NPC. ERBB4 escapes the hydrophobicity issue by undergoing 2  -
secretase mediated cleavages. The truncated intracellular soluble part can then easily 
translocate to the nucleus. (Wells & Marti, 2002) 
 
Then the protein is directed to the inner nuclear membrane by moving through the ER 
membrane into a contiguous outer nuclear membrane (ONM) reaching the nuclear pore 
complex. This model predicts that an integral membrane protein (such as EGFR) arrives 
at  the  inner  nuclear  membrane  (INM)  by  moving  through  the  different  adjacent  
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membranes  (ER-ONM-INM)  still  membrane  bound.  This  would  allow  its 
transmembrane hydrophobic domain to hide from the aqueous nuclear pore complex 
environment and trick its way to the nucleus. The receptor is then released from the 
INM by an INM sorting motif that is recognized by importin   isoform and released in 
the nucleoplasm (Wang et al, 2010a; Wang et al, 2010b) (Fig 1.25). 
 
Figure  1.25:  Integral  membrane  protein  translocation  to  the  inner  nuclear 
membrane. Integral membrane protein are initially inserted into the ER and then via 
membrane interaction to the outer nuclear membrane (ONM) and the trough the nuclear 
pore complex (NPC) into the nucleus via the inner nuclear membrane (INM). In this 
way the embedded transmembrane hydrophobic domain does not have to pass through 
the soluble NPC environment. Inner nuclear membrane proteins (INM pr.) utilize this 
mechanism with the help of ribosomes. (Wang et al, 2010a) 
 
1.8.5.5.4 EGFR modulates transcriptional regulation  
During the past 10 years accumulating evidence has shown that EGFR escapes receptor 
internalization  and  degradation  and  that  it  translocates  into  the  nucleus  not  only  in 
response to ligand binding, but also following ionizing radiation heat shock, H2O2 and 
chemotherapy. Upon EGF stimulation EGFR translocates to the nucleus and binds to A-
T- reach regions (ATRS) working as a transcription co-factor via its functional trans-
activation domain (Lin et al, 2001). Nuclear EGFR binds the proximal region of the 
promoters of several important genes: cyclinD1 (Lo et al, 2006a), involved in cell cycle 
progression and inducible nitric oxide synthase (iNOS) (Lo et al, 2005a; Lo & Hung,  
83 
 
2006), TWIST and cyclooxygenase-2 (COX-2) (Husvik et al, 2009; Lo et al, 2010; Xu 
et al, 2009a). The binding of EGFR to STAT proteins has been shown to compensate its 
inability to directly bind DNA (due to the lack of a DNA binding domain). Nuclear 
EGFR cooperates with STAT3 to upregulate expression of COX-2 and iNOS genes, 
with  E2F1  to  activate  transcription  of  the  B-MYB  gene  (an  important  regulator  of 
cellular proliferation) (Hanada et al, 2006). In addition the physical association of EGFR 
with STAT5 has been shown to enhance the expression of the AURORA-A gene (Hung 
et al, 2008) (Fig 1.26). Increased expression of Aurora-A is involved in centrosome 
amplification and microtubule disorder. Another mechanism that shows EGFR mediated 
gene regulation is its recently shown interaction with the Mucin1 (MUC1) (Bitler et al, 
2010). This interaction promotes chromatin-bound EGFR and colocalisation of EGFR 
with phosphorylated RNA polymerase II (Huo et al).  
 
1.8.5.5.5 EGFR modulation of DNA repair 
In addition to the transcriptional regulator function nuclear EGFR has been involved in 
DNA  repair.  Recent  studies  have  shown  that  EGFR  is  normally  present  in  the 
perinuclear region of the cells and that following IR treatment it is internalized in the 
nuclear compartments and binds DNAPKcs and the regulatory subunit ku70 (Wheeler et 
al,  2010).  This  interaction  has  been  shown  to  correlate  with  DNAPKcs  T2609 
phosphorylation and enhanced DNAPK kinase activity  (Dittmann et al, 2010b). The 
resulting  modulation  in  both  formation  of  -H2AX  foci,  which  are  involved  in  the 
recognition of damaged DNA, and the slower DNA repair kinetics suggested that EGFR 
modulates the repair kinetics of DNA strand breaks following IR via the association 
with DNAPKcs (Dittmann et al, 2008a; Dittmann et al, 2008b; Rodemann et al, 2007; 
Wang & Hung, 2009). In addition the role of EGFR in DNA repair was also shown by 
the activated nuclear EGFR dependent Y211 phosphorylation of the proliferation cell 
nuclear antigen (PCNA) that is essential for the DNA sliding clamp involved in both 
DNA replication and DNA repair (Wheeler et al, 2010). This showed that nuclear EGFR 
tyrosine kinase activity could also regulate proliferation and DNA repair by regulating 
PCNA function. 
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Figure 1.26: EGFR nuclear activity. The diagram shows the binding partner utilised 
by EGFR to modulate transcription of iNOS, B-Myb, Aurora A. Cyclin D1 is the only 
gene for which an EGFR binding partner is still unidentified. The arrow also shows 
EGFR modulation of DNA repair by association with DNAPKcs and PCNA. (Wheeler 
et al, 2010) 
 
1.8.5.5.6 EGFR radio-protector function 
Indeed, EGFR involvement in response to IR treatment is the most understood (Gazdar, 
2009a;  Nyati  et  al,  2006).  EGFR  mediates  three  important  stages  to  overcome  IR 
induced DNA damage. Following IR the very early response (1-4 h) is mediated by 
EGFR  nuclear  translocation,  binding  with  DNAPKcs,  and  enhanced  DNA  repair 
(Rodemann et al, 2007). Exposure to radiation induces a first round of rapid cell death in 
a caspase3 mediated apoptosis fashion that precedes cell division. Then a second cell 
death phase occurs due the unrepaired DSBs that emerge from the radiation induced cell 
cycle arrest (Rodemann et al, 2007). Experimental evidence has shown that radiation 
induced EGFR activation protects cells from apoptosis by the activation of the AKT anti 
apoptotic signalling pathway (second phase 4-24 h) (Chen & Nirodi, 2007; Feng et al, 
2007; Toulany et al, 2007; Toulany et al, 2008a; Toulany et al, 2006; Toulany et al, 
2008b; Wang & Greene, 2005). The third phase of EGFR mediated radioprotection is 
shown  by  EGFR  ligand-independent  phosphorylation  and  activation  of  the 
Ras/Raf/Mek/Erk  and  STAT  signalling  that  offer  a  critical  survival  advantage  by  
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promoting repopulation and tumour progression (>24 h) (Baumann et al, 2007; Russo et 
al, 2009; Ruzzo et al; Toulany et al, 2006). Fig 1.27 shows the EGFR radioprotective 
model. 
 
 
Figure  1.27:  A  model  of  EGFR  radioprotection.  EGFR  radioprotection  can  be 
didvided into three phases. 1) Immediate early: EGFR translocates to the nucleus and 
enhance DNA response. 2) Early: EGFR mediates antiapoptotic signalling via activation 
of AKT. 3) Post DSB repair: EGFR mediates tumour progression and repopulation by 
activation of the MAPK pathway. Chen D. J. et al, Clinical cancer research 2007 
 
Expression  of  nuclear  EGFR  correlates  with  overall  survival  in  breast  cancer,  with 
significant  increase  if  local  recurrence  and  decrease  in  disease  free  survival  in 
oropharyngeal  squamos  cell  carcinoma.  Interestingly  in  a  study  of  small  cohort  of 
esophageal cancer patients nuclear located phosphorylated EGFR was correlated with 
higher tumour node metastasis, nodal metastasis and poor treatment outcome (Gazdar, 
2009a) (Epperly et al, 2006; Ibrahim et al, 1999; Psyrri et al, 2008; Reiter et al). Nuclear 
expression of EGFRvIII has been correlated with invasive breast cancer, brain tumour 
and  prostate  cancer  (Andersen  et  al,  2009;  Golding  et  al,  2009;  Lo  et  al,  2010; 
Mukherjee et al, 2009; Viana-Pereira et al, 2008). In addition in hormone refractory 
prostate cancer EGFRvIII  nuclear expression was  associated with  decreased time to 
death from biochemical relapse and decreased overall survival (Wheeler et al, 2010). In  
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glioblastoma the nuclear association of EGFRvIII with STAT3 upregulates iNOS and 
also found to mediate the EGFRvIII induce glial transformation  (de la Iglesia et al, 
2008; Lo; Lo et al, 2010; Wheeler et al). The inhibition of EGFR nuclear trafficking by 
means of molecular inhibitors (discussed below) has shown suppression of cyclinD1 
expression  and  also  tumour  growth  and  has  also  shown  induced  radiosensitivity 
(Agelaki et al, 2009).  
 
1.8.5.6 EGFR targeted therapy 
Despite the great variety of anticancer treatments (listed above) the overall prognosis for 
cancers such as lung cancers still remains 5 years survival rate of 15% of all stages. In 
addition the high toxicity of the drugs together with poor tissue conservation also has 
been  for  many  years  the  big  disadvantage  of  conventional  therapy(Hynes  &  Lane, 
2005).  The  development  of  EGFR  targeted  therapy  stems  from  two  important 
observations. Tumour cells harbouring oncogenic EGFR alleles acquire dependency on 
the survival signals transduced by the hyperactive, over-expressed EGFR such that acute 
disruption leads to rapid death of tumour cells (Arteaga, 2002). Many cancer are not 
only accompanied by over expressed EGFR and over activation of its  down stream 
signalling pathways but the majority of the most aggressive forms of cancer show EGFR 
somatically acquired mutations which express a gain of function and also nuclear EGFR 
(Gazdar & Minna, 2008; Wheeler et al). The design of EGFR targeting molecules has 
generated a great deal of interest following the observation that the acquired mutations 
may predict the sensitivity for tyrosine kinase inhibitors and therefore allow a more 
specific design of cancer therapy and that the abrogation of EGFR nuclear translocation 
has been shown to correlate with better therapy response. 
There are two main approaches utilized to inhibit EGFR activation: 1) targeting the 
ligand binding domain by use of monoclonal antibodies which inhibit dimer formation 
and kinase activation leading to subsequent receptor degradation and 2) targeting kinase 
domain by using Tyrosine kinases inhibitors which compete with ATP for the binding of 
the  activating  ATP  pocket  domain  leading  to  inhibition  of  kinase  activity  and 
consequent inhibition of downstream signalling pathways (Debucquoy et al).   
 
1.8.5.6.1 EGFR inhibitors 
These types of inhibitors are mainly reversible inhibitors although irreversible kinase 
inhibitors have also been synthesized. Some act by mimicking the tyrosine moiety and  
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attaching  to  the  binding  region  a  non-phosphorilable  peptide,  other  instead  target 
downstream signals by targeting the binding site of intracellular adaptor proteins. 
 
1.8.5.6.1.1 Tyrosine kinase inhibitors 
Reversible TKI are: Gefitinib, Erlotonib, Lapatinib, Imatinib, Dasanitib, BMS-599626 
and AEE788 (Gazdar, 2009a; Gazdar, 2009b). Erlotonib is a selective low molecular 
weight inhibitor that (like gefitinib) competes with ATP for binding in the TK domain. 
In  addition  to  the  inhibitory  activity  exerted  on  EGFR,  it  can  also  target  ERBB2, 
causing inhibition of the AKT pathway and MAPK signalling, and target the formation 
of ERBB2/ERBB3 dimers (Chang et al, 2007; Xu et al; Yeo et al). Lapatinib is a dual 
inhibitor for both EGFR and ERBB2 causing inhibition of receptor phosphorylation and 
of downstream signalling pathways (Carter et al, 2009; Kim et al, 2009a; Kondo et al; 
Wang et al, 2006). Clinical studies have shown its activity in advanced breast cancer 
and in advanced metastatic cancers.  Both  BMS-599626 and AEE788 target EGFR, 
ERBB2  and the vascular endothelial  growth  factor receptor (VEGFR).  They mainly 
target the receptor kinase activity and inhibit cellular proliferation by heterodimerisation 
and downstream signalling pathways.  Imatinib is a competitive inhibitor of multiple 
tyrosine  kinases  (EGFR,  c-kit,  platelet  derived  growth  factor  receptor  (PDGFR). 
Dasanitib is a dual inhibitor of Src-Abl used in patients that show imatinib resistance in 
chronic myelogenous leukaemia (Carter et al, 2009). 
 
1.8.5.6.1.2 Gefitinib Iressa
TM, ZD1839 
Gefitinib  is  a  low  molecular  weight  anilinoquinazoline  acting  as  a  reversible  ATP-
competitor. Both in vitro and in vivo studies have demonstrated the efficacy of this 
inhibitor  in  blocking  EGFR  autophosphorylation  and  kinase  activity  (Gelibter  et  al, 
2003; Golsteyn, 2004; Yano et al, 2003). Gefitinib has also been shown to modulate cell 
cycle progression by disrupting cdk2 regulation possibly by upregulation of the CKI 
p27kip1 (Yano et al, 2003). The antitumour activity of gefitinib has been shown in a 
subset of patients with NSCLC: 10% of European patients and 30% of patients from 
East  Asia.  Sequencing  of  the  EGFR  gene  has  shown  that  in  those  patients  whose 
tumours exhibited EGFR mutations, the response rate to gefitinib is about 75%.  Some 
studies also showed that EGFR activating mutations (class I and II) not only impact 
response rate but also progression free survival (PFS) in patients with NSCLC treated 
with gefitinib. The INTEREST study showed 7.0 vs 4.1 months PFS in patients with  
88 
 
mutation treated with gefitinib compared to those treated with docetaxel alone whereas 
those patients expressing wild type EGFR trended in favour of docetaxel (1.7 vs 2.6 
months) (Gazdar, 2009b). A similar association was  also  found in the I-PASS trial, 
which compared first line gefitinib with carboplatin/paclitaxel in Asian patients with 
advanced NSCLC and with no history of smoking. In these studies those patients with 
mutation had a significantly longer PFS whereas those expressing wtEGFR had better 
PFS with chemotherapy (Armour & Watkins). The EGFR activating mutations have 
become independent predictors for time to treatment failure with the deletion of exon 19 
and the L858R mutation being the best predictor for longer time to treatment failure 
(Giaccone, 2005; Morita et al, 2009; Paez et al, 2004; Pallis et al, 2007; Sequist et al, 
2008; Soh et al, 2007; Sorscher, 2004; Tam et al, 2009; Ushiki et al, 2009; Zhu et al, 
2008). In addition to the improvement in the regimen of NSCLC, Gefitinib has been 
also shown to improve survival of patients with advanced pancreatic cancer, head and 
neck cancer and GBM (Pedersen et al, 2005; Rossler et al, 2009; Sundberg et al, 2003).  
Two clinical studies of gefitinib in combination with gemcitabine and cisplatin and in 
combination with paclitaxel and carboplatin have not confirmed the previously obtained 
result in vitro (Choong et al, 2006; Giaccone et al, 2004b; Maemondo et al). Moreover, 
gefitinib treatment of early NSCLC has been also unsuccessful suggesting that EGFR 
activating mutations may be utilized as a prognostic factor rather that predictive factor 
for TKI efficacy (Wu et al). The controversial issues on the gefitinib efficacy can be 
partially resolved by two important facts. First, not all the activating mutations lead to 
all TKI sensitivity in fact tumours expressing the L858R mutation are significantly more 
sensitive  to  gefitinib  than  those  expressing  the  G719S  mutation  (Chen  et  al,  2006).  
Second,  tumours  might  have  additional  genetic  lesions  that  relieve  the  tumour 
dependency on the EGFR signalling pathway. Indeed, it is largely recognized now that 
the efficacy of gefitinib is of limited duration due to the emergence of another somatic 
mutation in the tyrosine kinase domain. The Threonine 790 to Methionine (T790M) is 
found in about 50% of the patients that show resistance to TKI. The mechanism and the 
structural reconfiguration that this mutation confers to EGFR are unclear. It has been 
proposed that as the L858R mutations shows higher Km for ATP and a lower Ki for 
gefitinib (i.e. the affinity for ATP is lower and for gefitinib is higher) the secondary 
mutation T790M re-establishes the affinity for the ATP resulting in a reduced potency 
of an ATP competitive agent (Bean et al, 2007; Costa et al, 2008; Engelman et al, 2007; 
Kwak et al, 2005; Tam et al, 2009).  The Aspartic acid 761 to Threonine (D761T)  
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mutation  has  also  been  implicated  in  conferring  TKI  resistance  and  it  has  been 
suggesting that these mutations may  weaken the interaction of the  TKI  with  EGFR 
(Gazdar, 2009a; Gazdar, 2009b; Ushiki et al, 2009).  
 
1.8.5.6.1.3 Irreversible TKI 
The  attempt  to  overcome  the  resistance  to  the  T790M  mutation  has  lead  to  the 
production  of  irreversible  TKI.  These  kinases  inhibitors  form  irreversible  covalent 
bonds to the kinase active site by reacting with a nucleophilic cysteine residue. This 
irreversibly blocks the binding of ATP to the kinase domain rendering EGFR inactive. 
The clinically most advanced irreversible inhibitors of EGFR are HKI-272, BIBW2992 
and PF00299804 (Citri et al, 2002; Engelman et al, 2007; Gazdar, 2009a; Harada et al; 
Kwak et al, 2005; Sebastian et al, 2005; Yu et al, 2007).  
 
1.8.5.6.2 Monoclonal antibodies 
While the TKI target EGFR intracellular domain, mAB target the extracellular domain 
and  modulate  the  intracellular  cascade  of  signalling  events  by  interfering  with  the 
receptor homo and hetero dimerisation (Rivera et al, 2008; Schmiedel et al, 2008). The 
most widely used in the clinic is Cetuximab (Erbitux
®, IMC-C225) (Reade & Ganti, 
2009).  Cetuximab  is  a  chimeric/human  antibody  containing  approximately  30%  of 
murine sequences with proven second or third line efficacy in colorectal and head and 
neck cancer. It competes with ligand for the ligand binding site on EGFR domain III for 
which it has a five times greater affinity. It inhibits EGFR not only by impeding ligand 
binding  but  also  by  sterically  prohibiting  EGFR  to  adopt  the  extended  active 
conformation  (Benavente  et  al,  2009;  Li  et  al,  2008;  Morgan  &  Grandis,  2009; 
Vallbohmer et al, 2005).  
 
 
1.9 AIMS AND OBJECTIVES 
EGFR has a major role in oncogenesis, cancer progression and cancer therapy. The aim 
of this investigation is to study the role of nuclear EGFR in the modulation of DNA 
repair following IR and cisplatin treatment. To this end, the following questions will be 
addressed: 
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  Does  the  mutation  of  the  EGFR  NLS  sequence  determine  impaired  nuclear 
translocation (Chapter 3)? 
  How does the NLS mutation affect EGFR? (Chapter 3) 
  Does EGFR impaired nuclear translocation inhibit repair of cisplatin induced 
ICLs or IR induced SBs (Chapter 4)? 
  How does EGFR impaired nuclear translocation inhibits repair of IR or cisplatin 
induced damage (Chapter 4-5)? 
  What are the consequences of cisplatin damage in terms of survival (Chapter 5)? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
91 
 
 
 
 
 
 
 
 
CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 MATERIALS 
2.1.1 EGF 
EGF was obtained from Sigma Aldrich.  
 
2.1.2 Cell lines and culture conditions 
NIH3T3 wild type cell line were obtained from CRUK and were grown in DMEM 
supplemented with 10% heat inactivated (at 56
oC for 30 minutes) foetal calf serum, 1% 
of  200mM  L-glutamine  (Autogen  Bioclear,  UK),  1%  of  10,000  units  Penicillin  – 
10mg/ml Streptomycin (Sigma-Aldrich, UK) and incubated at 37
oC in 5% CO2. 
 
2.1.3  Chemotherapeutic drugs and other reagents 
Clinical  grade  Gefitinib  (Iressa,  ZD  1839)  was  kindly  provided  by  AstraZeneca 
(Macclesfield, UK). Cisplatin (DBL, Warwick, UK) were obtained from The Middlesex 
Hospital (UCL Hospital, London, UK). Details of the compounds used for this study are 
described in Table 2.1. Stock solutions were either prepared in advance or fresh prior to 
experiments according to stability of each compound. Cisplatin was obtained pre-diluted 
at the indicated concentrations from the hospital.  
 
 
Table 2.1: Compounds used in DNA repair studies 
2.1.4 Plasmids  
The plasmid DNA used was the pUSEamp vector (Upstate Cell Signaling Solutions, 
NY, USA). Fig 2.1 shows the plasmid map. 
The  wtEGFR  and  the  L858R  constructs  were  kindly  provided  by  Daphne  Bell  and 
Matthew Myerson  from the MGH Cancer Centre, Harvard Medical  School,  Boston, 
USA.  
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The  NLS  mutant  constructed  during  the  project  used  the  wtEGFR  and  the  L858R 
plasmid as template. The two designed and SDS purified mutagenic primers (Forward 
5‟cctcttcatggcagcggcccacatcgttgcgaaggccacgctggcggcgctgctgcagg3‟  and  Reverse 
5‟cctgcagcagcgccgccagcgtggccttcgcaacgatgtgggccgctgccatgaagagg3‟)  were  utilized 
according to the Site directed mutagenesis XL kit protocol (Stratagene) to change the 
EGFR  NLS  sequence  645-RRRHIVRKRTLRR-  657  into  645-AAAHIVAKATLAA-
657.  EGFRvIII  was  kindly  provided  by  Edith  Blackburn  from  the  Department  of 
Biosciences University of Kent, Canterbury, England. 
The repair assay utilised other EGFR plasmids: EGFR M1, M12 KMT  NLS enconding 
point  mutations  of  the  EGFR  NLS  sequence  (M1:  AAAHIVRKRTLRR,  M12: 
AAAHIVAAATLRR), the deletion of the NLS sequence ( NLS) and a mutation within 
the  kinase  domain  (KMT:  K821A).  These  plasmids  were  obtained  from  Prof.  M.C. 
Hung (MD Anderson Cancer Center, USA). These constructs were all cloned into the 
pCDNA3.1 (Invitrogen) shown in Fig 2.2. 
Table 2.2 shows the list of all the plasmids utilised in this study together with their most 
relevant characteristics. 
 
Length 5400 bp 
 
Figure  2.1:  pUSEamp  plasmid  map.  This  vector  was  used  for  expressing  various 
EGFR constructs. Picture from: Upstate Cell Signaling Solutions (www.upstate.com). 
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Figure 2.2: pcDNA3 plasmid map. This plasmid carries the resistance gene ampicillin 
and  neomycin.  Unique  restriction  sites  are  indicated  on  the  plasmid. 
(www.invitrogen.com).  
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Table2.2: List of plasmid used in this study 
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2.1.5 Primers 
All the primers were self designed and ordered from MWG 
 
2.1.5.1 Mutagenic primers 
 
Table2.3: List of mutagenic primers 
 
2.1.5.2 Sequencing primers 
 
Table 2.4: List of sequencing primers 
2.1.5.3 Screening primers 
 
Table 2.5: List of screening primers  
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2.2 METHODS 
2.2.1 Tissue culture 
2.2.1.1 Cell lines maintenance 
All  cell  lines  were  grown  in  75cm
2  flasks  (T75),  in  humidity-saturated  (95%) 
incubators  (Forma  Scientific,  UK),  at  37
oC  with  5%  CO2.  All  procedures  were 
carried out in Class II MDH biological safety cabinet (Intermed MDH, UK) using 
aseptic techniques (cabinet was cleaned with 70% industrial methylated spirit – IMS 
– as well as the equipment used inside the cabinet). Cells were routinely passage 
twice a week, at 80-90% confluence. As all cell lines were adherent, media was 
removed and cells were washed with 3ml of sterile 0.01M phosphate-buffered saline 
solution  (PBS,  Sigma-Aldrich,  UK)  to  remove  the  residual  serum.  Cells  were 
subsequently detached using 5ml of 1xTrypsin/EDTA (Autogen Bioclear, UK) at 
37
oC. 5ml of complete medium was then added to inactivate the trypsin and cells 
were pelleted by centrifugation at 1200rpm for 5 minutes at room temperature. The 
supernatant was discarded and cells were resuspended in 10ml of complete medium. 
Cells were finally seeded into new flasks at a ratio of 1/2 to 1/5 according to the cell 
line. All cell lines were passaged to a maximum of 30 times, after which point fresh 
cells were retrieved from the liquid nitrogen stock. 
 
2.2.1.2 Storage and retrieval from liquid nitrogen 
In order to store cell lines, frozen cell stocks were prepared. Cells were grown in 
175cm
2 flasks (T175) to 80% confluence. Cells were trypsinised and resuspended to 
a  concentration  of  1x10
6cells/ml  in  freezing  medium  (FCS  containing  10% 
dimethylsulphoxide  –  DMSO  –  Sigma-Aldrich,  UK).  The  cell  suspension  was 
aliquoted  in  1ml  cryotubes  and  frozen  at  -80
oC  for  one  day.  Tubes  were  then 
transferred to a liquid nitrogen tank. Cells were recovered from liquid nitrogen by 
thawing the cryotubes rapidly in a 37
oC water bath. The cell solution was added to a 
25cm
2  flask  (T25)  containing  9ml  of  complete  growth  medium.  Flasks  were 
incubated at 37
oC with 5% CO2. The medium was changed after 24 hours (once cells 
have re-attached to the bottom of the flask) to avoid toxicity due to the DMSO from 
the freezing mixture. 
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2.2.1.3 Cell count 
Cells were counted, once resuspended in 10ml of complete growth medium (see cell 
line maintenance), using a haemocytometer. A haemocytometer has two chambers 
and each chamber has a microscopic grid etched on the glass surface (4 squares each 
containing 16 smaller square all connected by a 25 square grid). The chambers are 
overlaid with a glass coverslip that rests on pillars exactly 0.1mm above the chamber 
floor. 15µl of cell suspension was mixed with 15µl of trypan blue (Sigma-Aldrich, 
UK) in order to exclude dead cells (1 in 2 dilution). 15 µl of this Dilution was loaded 
into  one  chamber.  The  number  of  cells  present  in  the  original  solution  was 
determined by counting the number of cells within the 4 large squares. The obtained 
numbered  was  then  divided  by  4  (number  of  squares)  and  then  multiplied  by  2 
(dilution 1:2). The total number of cells obtained was multiplied by 1x10
4, giving the 
number of cells per ml of suspension. 
 
2.2.1.4 Cell doubling time 
NIH3T3  cells  were  plated  to  an  initial  cell  number  of  1x  10
5  per  25cm
2  flask 
containing 8 ml of growing media. Single flasks were utilised for each time point 
until confluence. Every 24 hours cells were trypsinised, centrifuged, resupended and 
counted. The doubling time was calculating by plotting the number of counted cells 
(Y) against the number of hours (X). This resulted in 1 doubling time every 20-24 
hours. 
 
2.2.2  Drug treatments 
Prior to drug treatment, cells were seeded in flasks, 96 or 6 well plates and incubated 
at 37
oC in 5% CO2 for 24 hours. Cells were then treated at a range of concentrations 
and lengths of exposure (Table 2.6). Optimal concentration was determined by the 
DNA  repair  response  curve.  Appropriate  schedules  were  used  for  the  different 
experiments, as outlined in the methods detailed previously. 
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Table 2.6: Range of concentrations and lengths of exposure for drugs used in 
the different experiments. The ranges of concentration indicated in the table reflect 
the minimum and maximum concentrations used. 
 
2.2.3 Irradiation condition 
In radiotherapy, the potency of IR is referred to the measurement of charge deposited 
within a tissues and usually corresponds to exposure (coulomb/kg). For living tissue 
the energy deposited is expressed in Gray or Gy, being 1 Gy the amount of radiation 
required to deposit 1 Joule of energy in 1 kg. This represents the absorbed dose. 
During this thesis there will be a general reference to IR, however alpha or beta, 
gamma rays and X-rays are all different types of ionising radiation. The biological 
damage  produced  by  each  of  these  different  types  is  measured  in  Sievert.  This 
corresponds to the absorbed dose multiplied by the quality factor which, for alpha 
particles is 20 while for X-rays is 1. In this study it was chosen to study the effect of 
X-rays. These are measured in Gy. 
 For  irradiation  conditions  cells  were  plated  at  a  concentration  of  1  x  10
5/ml. 
Following 48 hours transfection, cells were serum starved for 24 hours and irradiated 
with 4 Gy (for the interaction and nuclear translocation studies) or 12.5 - 15Gy (for 
the repair studies) using the A.G.O. HS 321kV X-ray system. The x-ray machine was 
calibrated by a nuclear engineer to a dose rate of 4.39 Gy/min; 250 KV/12.5mA at a 
30cm distance using a filter made of 0.25mm Cu and 1.00 mm Al.   
 
2.2.4 The Comet assay 
2.2.4.1 DNA damage level 
Cells  were  plated  at  10x10
4cells/ml  in  25cm
2  flasks  (Nunclon,  VWR,  UK)  and 
incubated for 24 hours at 37
oC in 5% CO2. In order to analyse DNA damage and 
repair, cells were treated with the appropriate chemotherapeutic drug at a range of 
concentrations. Drugs were left in contact with the cells for a short period of time (1 
to  2  hours  according  to  the  drug)  and  left  to  incubate  in  drug  free  media  (if 
necessary), for DNA damage to reach its peak (e.g. 9 hours for cisplatin). From this,  
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a fixed drug concentration was determined to treat the cell and observe the repair of 
drug-induced DNA damage. For IR induced strand breaks the dose producing a tail 
moment  (see  section  2.10.2)  of  9-10  was  used.  For  interstrand  crosslink  agents 
(cisplatin), the drug concentration giving about 70% decrease in tail moment (see 
section 2.10.2) was useed. 
2.2.4.2 DNA repair study 
Once the concentration was selected, fresh cells were plated at 1x10
5 cells/ml in 6 
well plates and incubated at 37
oC in 5% CO2 for 24 hours. Cells were then treated for 
the appropriate time and the drug was subsequently replaced by drug free media. 
Cells  were  incubated  in  drug  free  media  for  various  period  of  time  in  order  to 
measure DNA damage repair. Cells were collected by trypsinisation, pelleted and 
resuspended in 1ml of foetal calf serum containing 10% DMSO, before to be stored 
at -80
oC.  
 
2.2.4.3 Assay methodology 
When  studying  damage  caused  by  a  crosslinking  agent,  cells  were  thawed  and 
resuspended  in  ice  cold  media  to  a  concentration  of  2.5x10
4cells/ml.  Those  cell 
suspensions were divided into two samples, one of which being irradiated (12.5Gy) 
using the A.G.O. HS 321 kV X-ray system to deliver a fixed number of random 
DNA strand breaks (procedure carried out on ice), immediately before analysis. For 
strand  breaking  agents,  cells  were  thawed  and  diluted  to  a  concentration  of 
2.5x10
4cells/ml without any irradiation. 
In both cases, the following methodology was the same. All procedures were carried 
out  on  ice  and  in  subdued  light.  Cells  were  embedded  in  1%  type  VII  agarose 
(Sigma-Aldrich, UK) (1ml of agarose + 0.5ml of cell suspension) on duplicate 1% 
type  1A  agarose  (Sigma-Aldrich,  UK)  pre-coated  microscope  slides.  Cells  were 
lysed, in the dark on ice, for one hour in ice cold lysis buffer (100mM disodium 
EDTA, 2.5M NaCl, 10mM Tris-HCl pH 10.5) containing 1% Triton X-100 (Sigma-
Aldrich, UK) added fresh. Slides were subsequently washed every 15 minutes in ice 
cold distilled water for 1 hour. Slides were then incubated in ice cold alkali buffer 
(50mM  NaOH,  1mM  disodium  EDTA,  pH  12.5)  for  45minutes  followed  by 
electrophoresis in the same buffer for 25 minutes at 18 V (0.6V/cm), 250mA. The 
slides were finally rinsed in neutralising buffer (0.5M Tris-HCl, pH 7.5) then saline  
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(PBS). Slides left to dry overnight were re-hydrated for 20 minutes with distilled 
water and stained with propidium iodide (2.5µg/mL) for 30 minutes (in the dark) 
then rinsed in distilled water. Finally, slides were left to dry in a drying oven and 
stored. 
 
2.2.4.4 Data analysis 
Images (illustrated in Fig 2.3) were visualised using a NIKON inverted microscope 
with  high-pressure  mercury  light  source,  510-560nm  excitation  filter  and  590nm 
barrier filter at x20 magnification. Images were captured using an on-line charge-
couple device (CCD) camera and analysed using Komet Analysis software (Kinetic 
Imaging,  Liverpool,  U.K.).  For  each  duplicate  slide  25  individual  cells  were 
analysed.  Tail  moment  for  each  cell  was  calculated  using  the  Komet  Analysis 
software as the product of the percentage DNA in the comet tail and the distance 
between the means of the head and tail distributions, based on the definition of Olive 
et al. (2002).  
For  strand  breaks,  tail  moment  data  were  analysed  as  a  function  of  time  post-
incubation or drug concentration. Fig 2.4 illustrates the effect of a drug inducing 
strand  breaks.  Data  shown  in  this  study  were  the  result  of  three  independent 
experiments and included corresponding standard deviation bars. 
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Figure 2.3: Screen display of Komet analysis software. The Fig show untreated 
irradiated  cells.  Red  arrows  are  showing  the  head  and  the  tail  of  comet.  The 
background is also taken into consideration by the software for calculation of the tail 
moment. 
 
 
 
Figure 2.4: Repair of DNA damage caused by IR treatment. Comet tail appears to 
be reduced over time 
 
For  crosslinking  agents,  results  were  expressed  as  percentage  decrease  in  tail 
moment compared to untreated controls calculated by the following formula (tail 
moment was calculated from the same software as previously described): 
 
 
 
where  TMdi = tail moment of drug-treated irradiated sample 
  TMcu = tail moment of untreated, unirradiated control 
  TMci = tail moment of untreated, irradiated control 
 
Time post-
treatment (hours) 
0  1  4  24  
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Percentage  decrease  in  tail  moment  data  were  the  result  of  three  independent 
experiments,  with  corresponding  standard  error  bars.  Fig  2.5  represents  DNA 
damage repair profile of irradiated cell treated with cisplatin. The short comet tail 
after 9 hours is  due to  the presence of interstrand crosslinks,  delaying  the DNA 
migration. Hence, as crosslinks are unhooked (repaired), the comet tail in irradiated 
cells is restored. For cisplatin the peak of crosslinking is observed after 9 hours post-
incubation. 
 
 
 
 
 
Figure 2.5: DNA damage repair profile of irradiated cells treated with cisplatin. 
Cells were treated with cisplatin for 1 hour and subsequently incubated in drug-free 
media for various times. After 9 hours crosslinking reached its maximum (60-70% 
crosslinks) as the tail appears much shorter (crosslinks are causing the delay in DNA 
migration). At 24 and 48 hours, the unhooking (repair) of cisplatin crosslinks causes 
the comet tail to re-elongate. 
 
2.2.5 Statistical Analysis 
The two way ANOVA and Bonferroni post tests were used for calculating the 
significance of the differences in unhooking crosslinks and in the repair of the DNA 
SBs.  All the cell lines were compared to the wtEGFR expressing cell line, statistical 
values of P < 0.01 were considered significant. 
 
2.2.6 MTT 
Cells were diluted 2.5 X 10
4/ml and 500 (100 l) or 1000 (200 l) cells were plated in 
each well of a 96 well plate and incubated overnight in full serum media. Cells were 
incubated with 50  M cisplatin for one hour in serum free media and then left in full 
serum media over a period of 72 hours. Following 24, 48 and 72 hours cells were 
incubated  with  20  l  of  5mg/ml  Thiazolyl  Blue  Tetrazolium  Bromide  (MTT 
solution) for 3 hours at 37 C. Next, the media was replaced with 200  l Dymethil 
sulfoxide (DMSO). Each plate was left on the shaker for 5 minutes. Cell density was 
Time post-treatment 
(hours) 
           0                9             24       48  
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read  at  560  nm,  corrected  with  background  reading  and  correlated  to  untreated 
control to calculate % survival.  
 
2.2.7  Western blotting analysis 
2.2.7.1 Total protein extraction 
Cells were washed twice with ice-cold PBS buffer. Sigma lysis buffer containing 
fresh 1.5 X protease inhibitor and 1.5 X phosphatase inhibitor (Roche, UK), was 
added to the cells (kept on ice) for few minutes. Then, cells were scraped using cell 
scrapers (VWR, UK) and left rotating for 15 minutes at 4
oC. Samples were then 
pelletted by centrifugation for 15 minutes at 4
oC (13,000rpm). The total cell lysate 
(supernatant) was placed in a fresh eppendorf tube and stored at -80°C. 
 
2.2.7.2 Nuclear and cytoplasmic protein extraction 
Nuclear and cytoplasmic separation was achieved using the Nuclear extract kit from 
Perbio  (Cramlington,  UK).  Cells  were  grown  and  treated  in  25cm
2  flasks  (T25). 
Briefly, cells were washed gently twice with cold PBS and scraped in 2ml of cold 
PBS.  Cell  solutions  obtained  were  transferred  to  a  pre-chilled  15ml  falcon  tube 
(VWR, UK) and centrifuged 5 minutes at 500g at 4
oC (supernatant was discarded). 
Cell  pellets  were  resuspended  in  300µl  of  cold  PBS  and  transferred  to  a  cold 
eppendorf  tube  and  centrifuged  at  500g,  4
oC  for  5  minutes  (supernatant  was 
discarded – all the PBS must be removed). Pellets were finally resuspended in 100 l 
of  ice-cold  CERI  (Cytoplasmic  Extraction  Reagent  I)  buffer,  containing  protease 
inhibitor,  and  vortexed  at  high  speed  for  15  seconds.  The  cell  suspensions  were 
incubated 10 minutes on ice before adding 5.5 l of CERII (Cytoplasmic Extraction 
Reagent II) buffer. Cell solutions were vortexed for 5 seconds and incubated for 1 
minute on ice. Solutions were vortexed once more for 5 seconds and centrifuged for 
5 minutes at 16,000g at 4
oC. The supernatant corresponds to the cytoplasmic fraction 
and was stored at -80
oC (the last few microliters of supernatant were discarded to 
avoid contamination with the nuclear pellet). 
The nuclear pellets were resuspended in 50 l of NER (Nuclear Extraction Reagent) 
buffer containing protease inhibitor and vortexed 15 seconds at high speed. Samples 
were vortexed for 15 seconds every 10 minutes for 40 minutes. Lysed nuclei were  
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centrifuged for 10 minutes at 16,000g at 4
oC and the nuclear fractions (supernatant) 
were stored at -80
oC. 
 
2.2.7.3 Protein quantification 
Once extracted, proteins were quantified using the RC DC protein assay from Bio-
Rad Laboratories. This assay is based on the Lowry protocol (Lowry et al., 1951), 
using  reagents  A,  S  and  B.  Briefly,  2µl  of  each  lysate  was  mixed  with  18µl  of 
distilled water, then 100µl of the mix of reagent A and S (20µl of reagent S with 1ml 
of reagent  A) was  added. Finally 800µl  of reagent  B is  added and solutions  are 
incubated  for  15  minutes  at  room  temperature.  Absorbance  (OD)  was  measured, 
against  a  blank  containing  only  distilled  water  at  750nm  on  a  Philips 
spectrophotometer  (Beam  PU8620  Series  UV/Vis  single)  and  total  protein 
concentration was determined with the following formula: 
 
Concentration in µg/µl = OD*25 
 
Once the concentration was  determined, loading dye (250mM  Tris  HCl, pH 6.8, 
500mM DTT, 10% SDS, 0.5% Bromophenol Blue, 50% glycerol and distilled water 
were  used  to  make  a  5  times  stock)  was  added  to  50µg  of  protein  (volume 
equivalent). Samples were boiled at 70°C for 10 minutes and then stored at -20
oC 
until immunoblotting. 
 
2.2.7.4 Immunoblotting 
Samples prepared as in section 2.7.1 and 2.7.2 were centrifuged for 5 seconds and 
loaded onto 3-8% Tris acetate gels (Novex pre-cast gels, Invitrogen, UK), using the 
XCell  SureLock™  Mini-Cell  module  (Invitrogen,  UK)  with  NuPAGE  tri-acetate 
SDS running buffer (60.5g Tris Base, 89.5 Tricine, 10.0g SDS and distilled water 
added to a volume of 1 litre were used to make a 20 times stock) in order to separate 
proteins at 150V, at room temperature. Proteins smaller than 40kDa were separated 
on 4-12% Bis-Tris gels (Novex pre-cast gels, Invitrogen, UK) using the same module 
as above but with MES running buffer (97.6g MES, 60.6g Tris Base, 10g SDS, 3g 
EDTA and distilled water added to a volume of 500ml was used to make a 20 times 
stock). Kaleidoscope marker (Bio-Rad, UK) was used as a size marker.   
106 
 
Proteins  were  transferred  electrophoretically  (35  V  at  RT  for  2.5  hours)  onto 
activated immobilon P membranes (Sigma-Aldrich, UK) (membranes are activated 
by immersion in 100% MeOH for 30 seconds,  followed by 2 minute in distilled 
water and 5 minutes in transblot buffer), using the XCell II Blot module (Invitrogen, 
UK)  with  transblot  buffer  (100ml  of  running  buffer  stock  x10  (30.3g  Tris  Base, 
144.1 Glycine and distilled water to 1 litre – pH 8.3), 200ml MetOH and distilled 
water to  2 litre). Unbound sites  on membranes  were subsequently blocked using 
blocking buffer: 5% BSA (Bovine Serum Albumin – Sigma-Aldrich, UK) in TBS 
with 0.1% Tween 20 for phosphorylated proteins. Proteins were probed using the 
appropriate  antibody  (see  dilutions  and  preparation  in  Table  2.7).  Finally,  the 
primary antibody was probed with HRP-conjugated polyclonal antibodies (Mouse or 
Rabbit – 1/2000, cell signalling – see Table 2.7) for chemiluminescence detection 
(ECL system, Amersham Biosciences, UK, Millipore GeHealthcare). To this end, 
blots  were  dried  and  incubated  5  minute  shaking  vigorously  with  ECL  reagents 
before covering them with cling film and exposing them to Kodak X-OMAT™LS 
film for various times (2 seconds to 1 hour). 
For all experiments using total protein lysate,  -tubulin or calnexin were used as a 
loading control.  However, for the nuclear and cytoplasmic separation, lamin  was 
used for the nuclear fraction and calnexin for the cytoplasmic fraction.  
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Table 2.7: List of antibody 
 
2.2.8 Immunoprecipitation 
Protein Sepharose G/A
TM 4 Fast Flow (Amersham Biosciences, Sweden) beads were 
washed as follows: 1 ml of Protein Sepharose was added to 14 ml of sterile PBS into 
a  15  ml  falcon.  The  sample  was  mixed  and  then  centrifuged  at  5000  rpm  for  5 
minutes in a cold centrifuge. The supernatant was discarded at the pelleted beads 
were cleaned twice as described above. The beads were then resupsended in PBS 
with a ratio 1:4. 
Stably expressing NIH3T3 cell lines were plated at 2 X 10
5 /mL or 4 X 10
5/mL in a 
10 cm dish (Nunc) and left overnight before treatment. Exponentially growing cells 
were then left in growing medium, or treated with 50μM cisplatin for one hour in 
serum free media and then left in drug free growing medium for 18 hours, or serum 
starved  for  24-36  hours  or  serum  starved  for  24-36  hours  and  treated  with  EGF 
(Sigma) 100ng/ml or treated with 4 gy IR and left 20 minutes in serum free media. 
Following appropriate treatments, approximately 5x10
6 cells were lysed on ice in 
500μl of CelLytic
TMM Cell lysis reagent (Sigma) supplemented with Protease and  
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Phospahatases  inhibitor  (Roche)  and  Benzonase  (Merck)  according  to 
manufacturer‟s protocol. Following lysis, 1.5 mg of protein sample was incubated 
with 2μg of anti-EGFR antibody (clone R19/48 Invitrogen) and left rotating at 4 C 
for 2.5 hours. Then, 10 μl (1:4 PBS) of packed A Sepharose beads (Amersham) were 
added  and  the  eppendorfs  were  left  rotating  for  an  additional  30  minutes. 
Immunocomplexes  were  pulled  down  from  cleared  lysates  with  the  A  sepharose 
beads  and  washed  1%Triton  X-100  PBS.  Pulse  spin  centrifugation,  washing  and 
mixing was repeated three times. Following the final wash the beads were drained by 
vacuum  suction  using  a 25G x5/8‟‟ needle (Terumo) and resuspended  in  sample 
buffer for Western blot analysis. 
 
2.2.9 Densitometric Analysis  
To  compare  the  intensity  of  bands  produced  by  immunoblotting  the  ImageJ 
densitometric  analysis  tool  was  used.  Briefly,  blots  were  scanned  and  bands  of 
interest were selected. Intensity was measured by calculating the plotting area of 
each of individual bands. Background values and control values were then detracted 
to determine the fold increase. Fig  illustrates the methodology 
 
 
Figure 2.6: Densitometry programme 
 
 
 
  
109 
 
2.2.8 Cloning 
2.2.8.1 Site directed mutagenesis 
Primers were designed according to manufacturer protocol 
Forward 5‟cctcttcatggcagcggcccacatcgttgcgaaggccacgctggcggcgctgctgcagg3‟  
Reverse 5‟cctgcagcagcgccgccagcgtggccttcgcaacgatgtgggccgctgccatgaagagg3‟ 
Primers were designed to contain all the desired mutation flanked by 10-15 bases of 
correct sequence and SDS purified (MWG). 
The melting temperature of the mutagenic primers was calculated according to the 
equation: 
Tm= 81.5+0.41(%GC)-675/N 
=81.5+ 0.41(57)-675/22 
=81.5+23.37-30.68= 
= 75 
Mutagenesis reaction: 
5 μl of 10x reaction Buffer 
X μl  (5, 10, 20 or 50 ng) double stranded DNA template 
X μl (125ng) Forward Primer 
X μl (125ng) Reverse Primer 
1 μl of dNTP mix 
5 μl of QuikSolution 
1 μl PfuUltra HF DNA polymerase (2.5U/ μl) 
Cycles: 
1      95 
oC 2minutes 
        95 
oC 1 minute 
2      60 
oC 50 seconds    18 times 
        68 
oC 9 minutes 
3      68 
oC 7 minutes 
4        4
  oC 2 minutes or more 
 
Following the mutagenesis/ amplification, the reactions were incubated with 2 μl of 
DpnI (10U/μl) for 2 hours at 37 
oC to digest the maternal strand. Reactions were then 
transformed using the XL10-Gold Ultracompetent Cells (Stratagene). 
 
2.2.8.2 Plasmids transformation and amplification  
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In  order  to  transform  the  plasmids  into  E.  coli,  100µl  of  TOP10F  chemically 
competent E. coli (Invitrogen, UK) was mixed with 5µl of plasmid and incubated for 
15 minutes on ice. Cells were heat shocked for 90 seconds at 42
oC before incubation 
for 2 minutes on ice. 800µl of SOC medium was added and cells were pelleted for 
6.5 minutes at 4,000rpm, at room temperature. Finally, 750µl of the supernatant was 
removed  and  the  pellet  was  resuspended  in  the  rest  of  the  supernatant.  Each 
transformed  plasmid  was  plated  on  a  pre-warmed  LB  (Luria-Bertani)  agar  plate 
(Invitrogen, UK), containing either 50μg/ml of ampicillin (Sigma-Aldrich, UK) or 
30μg/ml of kanamycin (Sigma-Aldrich, UK) selective agent. Plates were incubated 
overnight at  37
oC. After selection, colonies  were picked and  grown overnight in 
10ml of LB broth base (Lennox L Broth Base) medium (Invitrogen, UK) containing 
50μg/ml  of  ampicillin  (Sigma-Aldrich,  UK)  or  30μg/ml  of  kanamycin  (Sigma-
Aldrich,  UK),  in  an  incubator  shaker  (37
oC,  300rpm).  Cells  were  harvested  and 
plasmids were extracted using the QIAprep Spin Miniprep, Highspeed Maxiprep kit 
(Qiagen,  UK)  and  quantified  at  260nm  using  a  NanoDrop
®  ND-1000  UV-Vis 
Spectrophotometer (NanoDrop, UK) 
Following site directed mutagenesis plasmids were digested and ligated into a newly 
linearised backbone plasmid.  
 
2.2.8.3 Plasmid digestion 
After extraction, integrity and purity of the plasmids was checked. For the restriction 
reactions, 2 l of plasmid DNA was incubated with 0.5 l of the appropriate enzyme 
(see Table 2.8), 1.5 l of the corresponding 10x buffer (supplied with the enzyme), 
1 l  of  30.3mg/ml  RNAseA  (Sigma-Aldrich,  UK)  and  distilled  water  to  15 l. 
Reactions were incubated for 2 hours at 37 
oC and run on a 1% agarose ethidium 
bromide gel. The gel was electrophoresed at 100V and photographed using a dual 
intensity ultraviolet transilluminator coupled with camera (UVP, UK). A 1Kb DNA 
ladder  was  used  to  determine  the  size  of  each  fragment  obtained.    Bands  were 
excised  and  purified  using  the  gel  extraction  kit  from  Qiagen  according  to 
manufacturer protocol. 
The expected sizes were as follow: EGFR   4.0Kb; pcDNA3   5.4Kb; pUSEamp   
5.4Kb; NLS123  4.0Kb; L858R   4.0Kb; LNLS123   4.0Kb; M1   3.9Kb; M12  
3.9Kb; ∆NLS   3.9Kb; KMT   3.9Kb, EGFRvIII   3.1Kb  
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Table 2.8: List of enzymes used for plasmids restriction. Enzymes were chosen 
according to the position of the insert on the plasmid. 
 
2.2.8.4 Ligation 
Excised and purified bands were quantified at 260 nm using the nanodrop.  
 Ligation was carried out by using the DNA ligation Kit Ver 2.1 (Takara). 
30-50 ng of linearised Vector were used per reaction. The correct amount of the 
insert was calculated by the equation: 
(ng Vector x Kb Insert)/Kb Vector=ng Vector 
This correspond to the ng of the insert necessary for a 1:1 ratio (Vector:Insert). In 
order  to  maximise  the  chances  of  successfulness  Ligation  reactions  were  always 
prepared using a 1:3, 1:5 and 1:8 ratio (Vector:Insert). 
To  the  Vector:Insert  initial  mix  was  then  added  the  correspondent  volume  of 
Solution I from the DNA ligation kit. The reaction was incubated at 16 
oC for 30 
minutes. Prior to transformation, 1  l of Solution III was added to 9 l of ligation 
reaction to increase the number of transformants. When the initial ligation reaction 
over-exceeded 10  l, ligated DNA was precipitated with ethanol and dissolved in a 
volume of 10  l TE Buffer.  
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2.2.8.5 Colonies screening 
Bacterial colonies were screened by PCR using EGFR screening primers. 
Briefly,  PCR  reaction  was  prepared  according  to  the  Promega  GOtaq  protocol. 
Individual  colonies  were  picked  and  gently  submerged  into  individual  tubes 
containing a single reaction mix to provide sufficient template DNA for PCR. The 
same  colony  was  then  incubated  in  a  1.5  ml  Eppendorf  (labelled  accordingly) 
containing LB media at 37 
oC over the period of the PCR amplification and gel 
electrophoresis. Positive colonies were then further incubated overnight at 37 
oC by 
pouring the content of the Eppendorf in 250 ml of LB media. 
 
2.2.8.6 Sequencing  
Samples were sent for sequencing to MWG Company (Germany) 
 
2.2.8.7 Plasmids transfection 
Transfection was achieved using GeneJuice
® transfection reagent (Novagen
® EMD 
Biosciences Darmstadt, Germany). Exponentially growing NIH3T3 cells were plated 
in 6 well plates (Nunclon™, VWR, UK) at a concentration of 1 x10
5cells/ml (1.5 ml 
per well), without any antibiotics and incubated for 24 hours at 37
oC (5% CO2). 3 l 
was vortexed with 100 l of DMEM FCS free and incubated for 5 minutes in an 
eppendorf.  1 g  of  plasmid  was  added  to  the  solution  and  incubated  at  room 
temperature for 15 minutes. Media from the plates was removed and replaced by 
fresh  complete  media  with  no  antibiotics.  Each  plasmid/GeneJuice  mixture  was 
added  dropwise  to  one  well.  Cells  were  incubated  at  37
oC  (5%  CO2)  until 
confluence.  Cells  were  subsequently  trypsinised  (0.5ml  of  trypsin)  and  pelleted 
before being plated in T25 flasks with media containing antibiotics and selective 
agent G418 (Sigma-Aldrich, UK). Transfected cells were incubated for 3 to 4 weeks 
to allow clones to grow (media was regularly changed to keep selective pressure). 
All the clones used were grown as stable transfected cell lines, maintaining selective 
pressure in the media. 
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2.2.9 Confocal Microscopy 
2.2.9.1 Immunofluorescence Staining 
2 X 10
4 Stable and transfected NIH3T3 were plated on 13mm cover glass (VWR) in 
a  24  well  plate  overnight  before  treatment.  Cells  were  then  treated  with  50μM 
cisplatin for one hour in serum free media and/or left growing in drug free growing 
medium; serum starved for 24-36 hours or/and then treated with 4 Gy IR.18 hours 
following the treatment with cisplatin and 20 minutes following the IR treatment 
cells were washed twice in ice cold PBS followed by fixing with 4% PFA for 15 
minutes at room at RT. Cells were then permeabilised with PBS containing 0.5% 
Triton X-100 for 10 minutes  washed  3X with PBS and blocked in PBS 5% BSA 
(Sigma) for 1 hour at room temperature. Respective primary antibodies were added 
as  follows:  anti-rabbit  EGFR  (1:50,  clone  15F8  cell  signaling)  and  anti-mouse 
DNAPKcs (1:50 AbCam) in PBS 1% BSA and incubated in a humid chamber at 4ºC 
overnight. Slides were then washed 3X with PBS 0.1% Triton X-100 for 10 minutes 
and protein expression was visualized by incubating the cells with corresponding 
secondary fluorescent conjugated Abs, as follows: 1:100 Alexa Fluor 647 goat anti-
rabbit and 1:100 Alexa Fluor 488 goat anti-mouse (Molecular probes and Invitrogen 
Life Technologies) for 2 hours at RT. Fluorescent label- antibodies were added alone 
as negative controls. Following 3 washes with PBS 0.1% Triton X-100 Nuclei were 
stained using Dapi (Sigma) and mounted onto glass slides with fluorescent mounting 
medium (Dako). Cells were then visualised by confocal microscopy (objective X40, 
Leica TCS SP2). Nuclear slices images were acquired by sequential scanning using 
the LAS AF Lite programme.  
 
 
2.2.9.2 Proximity Ligation assay 
Stables NIH3T3 grown on 13 mm cover glass (VWR) were left in growing medium, 
or treated with 50μM cisplatin for one hour in serum free media and then left in drug 
free  growing  medium  for  18  hours,  or  serum  starved  for  24-36  hours,  or  serum 
starved for 24-36 hours and treated with 4 gy IR and left 20 minutes in serum free 
media. Cells were washed with chilled PBS and fixed with 4% paraformaldehyde for 
15 min, blocked, permeabilized, and incubated overnight  with   anti-rabbit EGFR 
(clone 15F8 cell signalling 1:50), anti-mouse DNAPKcs (AbCam 1:50) as described 
above.  Cells  were  then  incubated  with  secondary  antibodies  conjugated  with  
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oligonucleotides (PLA probe minus: anti-mouse and plus: anti-rabbit) for 90 minutes 
at 37 C in a humidity chamber. Following 2 washes for 5 minutes with 1X PBS 
0.1% Triton X-100, the hybridization solution, consisting of two oligonucleotides, 
was diluted in high purity water (1:5) and added to the cells for 15 minutes at 37 C. 
Cells were then washed once for 3 minutes to remove the hybridization solution. 
Next, the ligation solution was diluted in high purity water (1:5) and 1.5  l of ligase 
to a final volume of 60  l (per cover glass). The ligation reaction was then added to 
the cells for 15 minutes at 37 C. Following 2 washes for 2 minutes, the amplification 
solution was diluted in high purity water (1:5) and 0.75  l of polymerase to a final 
volume of 60  l per cover glass. The slides were then incubated for 90 minutes at 
37 C. Next the cells were washed 2 times for 3 minutes and the detection solution 
was diluted in hi purity water (1:5)  and added to the cells for 60 minutes at 37 C. 
Finally cells were washed 2 times with 1X PBS 0.1% Triton X-100 for 2 minutes, 1 
time with 0.5 X PBS 0.05% Triton X-100 for 2 minutes, 2 time with high purity 
water for 2 minutes and 1 time with 70% ETOH for 1 minutes. The slides were left 
to dry for 3 minutes at RT and then mounted onto a glass slide with fluorescent 
medium (Dako).  Cy3 signal amplification was utilised for the assay. Cells were then 
examined with a confocal microscope (objective X40, Leica TCS SP2).  
 
 
2.2.10 DNA-PK Functional Assay 
DNA-PK  activity  was  detected  using  the  Promega  SignaTECT  DNA-PK  assay 
system, according to the manufacturer‟s protocol. The SignaTECT utilises the unique 
SAM
2TM Biotin Capture Membrane and results in high density of streptadavidin on 
the  membrane  matrix.  This  provides  rapid,  quantitative  capture  of  biotinylated 
substrate molecules, based on the strong affinity of biotin for streptadavidin (Kd=10-
15M). This system overcomes the problem of non-specific substrate binding by using 
a biotinylated DNA-PK p53 derived peptide substrate. The high binding capacity of 
the  SAM
2TM  Biotin  capture  membrane  for  the  DNA-PK  biotinylated  peptide 
substrate and the low background observed with this system, maximises the signal-
to-noise ratio.  Briefly, 50μg of Benzonase treated whole-cell extract, was incubated 
with  DNA-PK,  biotinylated  peptide  substrate,  [ -32P]  ATP,  and  either  DNA-PK 
activation buffer or DNA-PK control buffer for 5 minutes at 30 ºC. Termination  
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buffer was added, and 10 μl of each reaction sample were spotted onto a SAM
2TM 
biotin capture membrane. The SAM2TM membrane squares were washed and dried 
before analysis by scintillation counting. The enzymatic activity of DNA-PK was 
expressed as a percentage decrease of control DNA-PK activity. 
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CHAPTER 3 
CHARACTERISATION OF THE 
EGFR NLS MUTANTS 
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3.1 INTRODUCTION 
 
3.1.1 EGFR endocytosis is required for receptor degradation, recycling 
and nuclear translocation   
In resting cells the epidermal growth factor receptor (EGFR) resides at the lipid rafts 
of the cell membrane rich in cavoelae and cholesterol  (Zwang & Yarden, 2009). 
Upon  ligand  binding  EGFR  exits  these  domains  in  a  Src-dependent  manner  and 
releases the auto-inhibition of its catalytic function via homo or hetero-dimerisation 
with members of the ERBB family (Sorkin & Goh, 2008; Wang et al, 1999). The 
dimerised receptors trans-phosphorylate a plethora of effector molecules including 
MAPK  and  AKT  (Grandal  &  Madshus,  2008;  Puri  et  al,  2005).  Following  the 
stimulation of these intracellular signalling pathways EGFR is bound by the SH2 
domain of Cbl leading to EGFR polyubiquitination and internalisation in the early 
endosomes  (Mosesson  et  al,  2008;  Tvorogov  &  Carpenter,  2002).  The  receptor 
endocytosis takes place through the formation of clathrin-coated pits (CCPs) or, in 
the presence of high doses of ligand, via cavoelae (Sigismund et al, 2005; Sorkin & 
Goh,  2008).  Clathrin-mediated  endocytosis  (CME)  is  the  major  receptor 
internalisation pathway (Sigismund et al, 2008; Zwang & Yarden, 2009). Membrane 
receptors can spend limteless time at the membrane, however following activation, 
they  will  be  internalised  within  seconds  to  assure  immediate  inactivation  of  the 
downstream signalling events (Mosesson et al, 2008; Oved & Yarden, 2002). 
 
3.1.1.1 EGFR phosphorylation mediates nuclear translocation  
Internalised  EGFR  can  undertake  three  different  routes:  1)  recycling  to  the 
membrane in an inactive form, 2) lysosomal degradation into the late endosomes or 
3) nuclear translocation (Mosesson et al, 2008; Waterman & Yarden, 2001). The 
decision is made according to the expression level and the activation status (Zwang 
&  Yarden,  2009).  EGFR  high  expression  saturates  the  degradation  machinery 
leading  to  the  recycling  of  the  receptor  at  the  transmembrane.    In  addition, 
internalised active EGFR represents a very poor substrate for lysosomal degradation 
inducing EGFR sorting into the Golgi and ER leading to nuclear translocation (Liao 
& Carpenter, 2007). A large body of evidence has shown that EGFR, either alone or  
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associated to ERBB2, can be further phosphorylated once internalised into the early 
endosomes (Mosesson et al, 2008). This is suggested to prevent degradation and 
contribute further to nuclear translocation.  Following sorting through the Golgi and 
ER, EGFR association with sec61 results in a retro-translocation to the cytosol where 
EGFR  is  stabilised  following  association  with  HSP70.  Binding  of  importin  β, 
mediated  through  the  NLS  sequence,  translocates  the  receptor  to  the  nucleus 
(Dittmann  et  al,  2008a;  Hsu  &  Hung,  2007;  Liao  &  Carpenter,  2007;  Lo  et  al, 
2006a). 
 
3.1.2 EGFR NLS sequence is a functional NLS sequence  
Nuclear  translocation  requires  energy,  physiological  temperature,  a  NLS  and  a 
soluble transporter. The study of this very complex mechanism has revealed that the 
last  two  components  are  known  to  be  the  “conditio  sine  qua  non”  for  nuclear 
translocation. The import takes place following three important steps: docking at the 
nuclear pore complex, translocation and deposition. During the docking phase the 
molecule that needs to be imported (the cargo molecule) binds to a soluble molecule 
known as importin via the recognition of the NLS sequence.  Therefore in absence of 
one of these two components nuclear localisation is impaired.  
 
3.1.2.1 The criteria for a functional NLS 
The recognition of a NLS sequence via a bioinformatic approach is only valuable for 
predicting putative NLS motifs. The functionality of a NLS sequence in any protein 
is determined by four criteria: 
1. The putative NLS sequence must be necessary for import. The transport of the 
cargo  protein  into  the  nucleus  is  therefore  hindered  when  the  sequence  is 
deleted or altered. The most common approach to verify whether a sequence is 
necessary for import is to mutate the consensus residues (basic amino acids – 
R/K)  into  Alanine  and  verify  that  the  nuclear  translocation  of  the  protein 
decreases (Hsu & Hung, 2007). 
2. The sequence must be sufficient to target an unrelated protein into the nucleus. 
Usually this is demonstrated by fusing the putative NLS sequence to the N-
terminus of the Green Fluorescent Protein (GFP) and the location of the protein 
is assessed visually (Hsu & Hung, 2007).  
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3. The  protein  of  interest  (containing  the  NLS)  must  interact  with  the  import 
receptor (importins) and the interaction must be mediated via the putative NLS 
sequence. This is addressed by performing an in vitro binding experiment with 
the purified proteins and with RanGDP and RanGTP that, as explained in the 
introduction chapter, provide the energy for association and dissociation (Liao 
& Carpenter, 2007; Lo et al, 2006a; Lo et al, 2006b). 
4. The transport machinery must be disabled to show that nuclear import of the 
protein of interest is mediated by a nuclear transport mechanism that can only 
take place via the NLS sequence (Liao & Carpenter, 2007; Lo et al, 2006a). 
Table 3.1 describes the criteria met by EGFR.   
 
 
Table 3.1: Experimental evidence for nuclear EGFR. The table shows individual 
criterion, the experimental design utilised to validate the criterion requirement and 
the published research article where the evidence is shown. 
 
3.1.3  The  NLS  sequence  affinity  for  the  importin  molecule  is  highly 
regulated 
The  NLS  sequence  is  pivotal  during  the  entire  nuclear  translocation  mechanism 
because it is the only known biological signature that can successfully obtain binding 
with  importin  molecules  and  its  success  is  dictated  by  the  affinity  of  the  NLS 
sequence  with  the  importin  molecule.  In  many  cases  such  affinity  is  further  
120 
 
positively  or  negatively  regulated  via  phosphorylation  and/or  via  intramolecular 
association (Moroianu, 1999). For example, phosphorylation of the serine residue 
contained  in  the  NLS  of  the  transcription  factor  Pho4  reduces  affinity  with  the 
importin molecule (Kaffman & O'Shea, 1999). Unphosphorylated pho4 localises to 
the  nucleus  whereas  phosphorylation  lowers  affinity  with  its  importin  molecule 
triggering  nuclear  export  and  impeding  re-import.  Another  example  is  the 
transcription factor NF-AT. Unphosphorylated NF-AT localises to the nucleus and 
when  phosphorylated  undergoes  a  conformational  change  that  masks  its  NLS, 
impeding  binding  with  the  importin  molecule  (Zaidi  et  al,  2004)  SWI5  is 
phosphorylated  on  three  Serines,  two  of  which  lie  in  proximity  of  its  NLS. 
Unphosphorylated  SWI5  is  nuclear  localised  whereas  when  phosphorylated  the 
transcription factor is restrained in the cytoplasm (Kaffman & O'Shea, 1999; Wells & 
Marti, 2002). From this last study it was suggested that phosphorylation of the sites 
in  the  vicinity  of  the  basic  NLS  prevents  binding  of  the  import  machinery  and 
therefore cytoplasmic localisation. 
 
3.1.4 EGFR NLS sequence mutation 
The  principal  aim  of  this  study  is  to  investigate  the  role  of  EGFR  nuclear 
translocation in the modulation of DNA repair. In the introduction chapter the role of 
the  EGFR  acquired  mutations  in  therapy  and  their  importance  in  predicting 
sensitivity have been outlined. The  EGFR NLS  sequence is  a tripartite sequence 
made  up  of  three  clusters  of  basic  amino  acid  residues  RRRHIVRKRTLRR  and 
published data have demonstrated that mutation of the first two clusters of basic 
amino acids into Alanines leads to a 78% decrease in nuclear EGFR following ligand 
binding (Hsu & Hung, 2007). There is no published evidence investigating whether 
the  remaining  22%  of  nuclear  EGFR  is  sufficient  to  mediate  the  transcriptional-
mediated  EGFR  nuclear  function.  In  addition,  there  is  no  published  study 
investigating  the  nuclear  translocation  of  EGFR  NLS  mutants  following  IR  (the 
second  most  studied  inducer  of  EGFR  nuclear  translocation  (Das  et  al,  2007; 
Dittmann  et  al,  2005a).  For  these  reasons  wtEGFR  and  EGFR  L858R  (L858R) 
mutant expressing plasmids were utilised as a background to construct two NLS-
EGFR  mutants  bearing  a  mutation  of  all  the  Arginine  residues  into  Alanine 
(RRRHIVRKRTLRR  into  AAAHIVAKATLAA):  EGFRNLS123  (NLS123)  and 
L858RNLS123 (LNLS123).   
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3.1.5 NIH3T3 cells as a cellular model 
Stable transfection of the human EGFR into the murine fibroblast NIH3T3 cells and 
EGF  supplementation  into  the  growth  medium  were  shown  to  be  necessary  and 
sufficient to achieve cellular transformation of this cell line (Di Fiore et al, 1987), 
making this system an unbiased and optimal cellular model to study the modulation 
of EGFR on DNA damage repair. 
 
3.1.6 CHAPTER AIMS: 
  Validation of the NIH3T3 cellular system 
  wtEGFR and L858R expression following transient transfection 
  Validation of the constructed mutants 
  Sequence  analysis  and  restriction  digest  to  prove  site  directed 
mutagenesis 
  Characterisation of the expressing EGFR constructs 
  Phosphorylation of wtEGFR and mutants following ligand binding, IR 
or chemotherapy 
  Activation  of  downstream  signalling  pathways  following  ligand 
induction 
  Nuclear localisation following EGF or IR stimulation 
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3.2 RESULTS   
3.2.1 EGFR expression in NIH3T3 (EGFR null) cells 
Following transient transfection of NIH3T3 cells, wtEGFR and L858R expression 
was confirmed via western blotting analysis over a period of 72 hours. This was 
necessary  to  determine  the  maximal  expression  of  the  EGFR  constructs  in  the 
NIH3T3 cells. Fig 3.1 shows that EGFR expression peaks at 48 hours following 
transient transfection while no expression was detected in the vector control (VC) 
transfected cell line (Fig 3.1). 
 
 
 
Figure 3.1: EGFR expression peak at 48 hours following plasmid transfection. 
NIH3T3 cells were transiently transfected with 2 μg of plasmid DNA encoding for 
wtEGFR or L858R or with the backbone plasmid (V.C.). Cells were seeded and 
lysed over a period of 72 hours. Whole cell lysates were resolved on a denaturing gel 
and blotted for total EGFR and α-tubulin. 
3.2.2 EGFR NLS site directed mutagenesis 
To examine the modulation of EGFR nuclear translocation, NLS sequence mutants 
(NLS123,  LNLS123)  were  generated  as  described  in  the  Materials  and  Methods 
section.  The  expected  mutagenesis  was  validated  via  enzymatic  digestion  of  the 
obtained plasmids and by sequencing. Fig 3.2A shows the result of the EcoRV-XhoI 
double digestion and of the EcoRI single digestion whereas Fig 3.2B and C show the 
nucleotide  and  amino  acid  alignment  of  the  obtained  sequences.  The  mutated 
constructs were sequenced three times to confirm correct mutagenesis and absence of 
any other mutation in the remaining DNA sequence. 
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Figure  3.2:  Enzymatic  digestion  and  sequencing  confirmed  the  NLS 
mutagenesis. A) In the left panel 2μg of plasmid DNA was digested with EcorV-
XhoI to generate the expected fragments of 3.994 KB (EGFR cDNA) and 5.426 KB 
(pUSEamp) and with EcorI to generate the expected fragments of 0.02, 0.5, 0.8, 1.8 
and 6.3 KB (right panel). Digested DNA was then resolved on a 1% Agarose gel and 
samples  were  visualised  using  a  UV  transilluminator.  B)  NLS123  nucleotide 
sequence  obtained  by  MWG  sequencing  service  was  blasted  against  the  Human 
genome database. The Fig represents a snapshot from the whole sequence alignment. 
C) The cDNA sequences obtained by the MWG sequencing service were translated 
into an amino acids sequence using the Expasy tool and then were aligned using the 
clustalW 2.0.5 multiple sequence alignment. The alignment file was then processed 
with BOXSHADE 3.21. The  Fig represents a snapshot from the whole sequence 
alignment. 
A 
B 
C  
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3.2.3 Mutant characterisation 
3.2.3.1 EGF stimulation induces EGFR activation  
The  activation  of  EGFR  upon  ligand  binding  has  been  fully  described  in  the 
introduction  chapter.  Being  the  EGFR  specific  ligand,  EGF  has  a  strong  and 
immediate  effect  on  EGFR  dimerisation  and  phosphorylation.  EGF  is  known  to 
promote  kinase  autophosphorylation  leading  to  the  activation  of  many  important 
cellular  responses  (Oved  &  Yarden,  2002;  Toulany  et  al,  2007;  Tvorogov  & 
Carpenter, 2002). Physiological EGF levels typically range from 10 to 100 ng/ml 
(Sigismund et al, 2005) and in fact as little as 10 ng/ml can activate EGFR within 
minutes. It has been shown that 100 ng/ml of EGF is the dose necessary to induce 
EGFR nuclear translocation (Hsu & Hung, 2007). Therefore the effects of this dose 
on the tyrosine phosphorylation over a period of 1 hour were investigated and the 
activation  of  the  downstream  MAPK  and  AKT  pathways  and  the  timing  of  the 
nuclear translocation examined. This is necessary to elucidate the correlation of these 
events and the significance of their timing. 
 Fig  3.3A  shows  the  western  blots  of  NIH3T3  cells  transiently  transfected  with 
wtEGFR, NLS123, L858R, LNLS123 or VC treated with 100 ng EGF over a period 
of 1 hour. This illustrates EGF-dependent EGFR phosphorylation and activation of 
MAPK  and  AKT  downstream  signalling  pathways.  Fig  3.3  B-D  show  the  fold 
increase of Y1068 (B), AKT (C) and MAPK (D) activation.  
Cells transfected with wtEGFR showed a time dependent Y1068 phosphorylation 
increasing 3.13-fold by 30 minutes, remaining at this level at 60 minutes. Similarly, 
phosphorylation  of  both  AKT  and  MAPK  increased  3.20  and  2.06-fold  by  60 
minutes.  L858R transfected cells showed constitutive receptor activation and MAPK 
phosphorylation. In contrast, there was a 2.2-fold increase in AKT phosphorylation 
by 60 minutes. NLS123 transfected cells showed lack of Y1068 phosphorylation and 
no  upregulation  of  either  AKT  or  MAPK.  LNLS123  expressing  cells  showed 
constitutive  receptor  activation,  however  this  was  reduced  compared  to  Y1068 
phosphorylation shown in wtEGFR cells. LNLS123 cells showed no upregulation of 
either AKT or MAPK.  
In light of the lack of EGFR-Y1068 phosphorylation in the NLS123 transfected cells 
following EGF induction, the overall receptor phosphorylation was assessed together 
with the ligand dependent and independent phosphorylation in wtEGFR and EGFR 
mutant-expressing cell lines. Fig 3.4 shows the western blots of cells transfected with  
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wtEGFR, NLS123, L858R, LNLS123 or VC, treated with 100 ng/ml of EGF for 1 
hour  following  serum  starvation.  The  obtained  cell  lysates  were  then 
immunoprecipitated  with  anti-EGFR  and  total  receptor  phosphorylation  was 
determined by blotting with a pan phospho-tyrosine PY99 antibody (Fig 3.4). EGF-
induced activation was observed in wtEGFR transfected cells, constitutive activation 
in both L858R and LNLS123 transfected cells and lack of activation in the NLS123 
transfected cells.             
 
 
Figure 3.3 (A): EGF induces EGFR and downstream signalling activation in 
EGFR transfected cells. NIH3T3 cells where transfected with wtEGFR, NLS123, 
L858R,  LNLS123  or  VC  48  hours  following  transfection  the  cells  were  serum 
starved for 24 hours and then treated with EGF 100 ng/ml. Cells were collected over 
a period of 1 hour and 40μg of protein lysate was analysed via western blot. Samples 
were immunoblotted using anti EGFR, anti PY1068, anti PAKT (ser473), anti α-
tubulin, anti AKT, anti PMAPK (p42-p44) and anti MAPK antibodies.  
 
 
A 
  
126 
 
D 
 
 
 
 
 
Figure 3.3 (B-D): Graphic representation of the densitometry analysis of Figure 
3.4  A  blots.  In  each  lane,  left  graphs  show  the  fold  increase  compared  to  their 
individual negative control (EGF untreated – serum starved) and right graphs show 
the comparison when densitometry was done compared to the untreated wtEGFR 
sample. In order the graphs show: the fold increase of Y1068 phosphorylation (B), 
AKT phosphorylation (C) and MAPK phosphorylation (D). 
 
 
 
B 
C 
D  
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Figure  3.4:  EGF  treatment  does  not  activate  the  EGF  receptor  bearing  the 
NLS123 mutation.  60 minutes following EGF treatment 500 µg of protein lysate 
was used to immunoprecipitate EGFR. Samples were then analysed via western blot 
and immunoblotted with PY99 and for total EGFR. + indicates treated sample  – 
indicates non-treated sample. Numbers represent fold increase calculated as a mean 
density of the first two exposures. 
 
3.2.3.2 Dose-dependent cisplatin activation of EGFR 
To extend our knowledge of the nature of the NLS123 mutation and its impact on the 
receptor phosphorylation, this study investigated the receptor activation in transiently 
transfected cells treated with different doses of cisplatin (Fig 3.5). This is because 
cisplatin has been shown to induce ligand-independent EGFR phosphorylation on the 
Y845 residue  (Benhar et  al,  2002). Since both  the  L858R and  LNLS123 mutant 
receptor have shown that EGF treatment induced EGFR activation, this assay was 
performed only on the wtEGFR and the NLS123. 
Fig  3.5  shows  the  western  blot  results  of  cells  transfected  with  wtEGFR  and 
NLS123.  Following  48  hours  transfection,  cells  were  treated  for  one  hour  with 
cisplatin with a dose range of 10-150 µM in serum-free media. Cell lysates were then 
blotted  with  PY845  antibody  that  recognises  ligand-independent  kinase  domain 
activation.    In  wtEGFR  transfected  cells,  phosphorylation  increased  in  a  dose 
dependent  manner  peaking  at  50µM  cisplatin,  whereas  NLS123  cells  showed  no 
Y845 phosphorylation.  
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Figure 3.5: EGFR activation following cisplatin treatment. NIH3T3 cells were 
transfected with wtEGFR NLS123 and V.C. 48 hours following transfection cells 
were treated with 10, 25, 50, 100, 150 µM of cisplatin in free serum media for one 
hour. Cells were collected one hour following treatment and whole protein lysate was 
extracted.  50  μg  of  the  protein  lysate  was  loaded  on  a  denaturing  SDS  gel  and 
analysed via western blotting. Samples were blotted against anti EGFR, anti pY845 
anti calnexin. Numbers represent mean fold increase of the PY845 density exposures 
compared to untreated control. 
 
3.2.3.2.1 EGFR activation following cisplatin treatment  
The lack of Y845 activation, observed in cells transfected with NLS123 following 
cisplatin treatment induced us to test a wider range of phosphorylation events.  Since 
cisplatin  stimulates  EGFR  autophosphorylation  and  ligand  independent 
phosphorylation  of  the  receptor  (Benhar  et  al,  2002),  wtEGFR  and  NLS123 
transfected cells were treated with 50µM cisplatin for one hour in serum-free media. 
Cell lysates were then immunoprecipitated with anti-EGFR and blotted with the pan 
phosphotyrosine PY99 antibody to detect the presence of any phosphorylation event 
following cisplatin. Fig 3.6 shows the results of the immunoprecipitation.  While 
cells transfected with wtEGFR showed some increased phosphorylation following 
cisplatin treatment (visible in the early exposure of the blot), NLS123 transfected 
cells showed no phosphorylation event following cisplatin  as shown by the very late 
exposure of the blot.   
 
Cisplatin 
M  
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Figure 3.6: Cisplatin treatment does not activate the EGF receptor bearing the 
NLS123 mutation. wtEGFR, NLS123, or VC transfected NIH3T3 cells were treated 
with 50 μM cisplatin in serum free media, 48 hours after transfection. Cells were 
seeded 60 minutes following cisplatin treatment and 500 µg of the protein lysate was 
used to immunoprecipitate EGFR. Immunoprecipitated samples were then analysed 
via western blot and immunoblotted with anti PY99 or anti EGFR. + indicates treated 
sample – indicates non treated sample. 
 
3.2.4 EGFR nuclear translocation is induced by ligand stimulation and 
by IR treatment 
Several reports have shown that EGF induction or IR treatment induce EGFR nuclear 
translocation (Dittmann et al; Dittmann et al, 2005a; Dittmann et al, 2008a; Dittmann 
et al; Hsu & Hung, 2007; Lo et al, 2006a). 100 ng/ml is the EGF dose shown to 
induce nuclear translocation in CHO cells transfected with wtEGFR (Hsu & Hung, 
2007).  However,  reports  suggest  that  the  EGF  concentration  is  not  strictly  the 
determining factor for EGFR translocation (Liao & Carpenter, 2009). In a cancer cell 
the overexpression of EGFR is often accompanied by the autocrine production of 
several ligands such as EGF. Therefore 100 ng/ml is the concentration of EGF that 
can mostly mimic this and show the response of an EGFR over-expressing cell line 
(Gazdar & Minna, 2008; Zandi et al, 2007). Published evidence has also shown that 
4 Gy is the IR dose sufficient to induce EGFR nuclear translocation in some of the 
most widely characterised EGFR over-expressing cancer cell lines including A431 
and A549 (Rodemann et al, 2007).  In this study the same dose has been utilised to  
130 
 
test wtEGFR nuclear translocation within the NIH3T3 cells and determine whether 
the NLS123 mutation impairs EGFR nuclear translocation.  
 
3.2.4.1 EGF induction of EGFR nuclear translocation 
NIH3T3 cells transfected with wtEGFR, NLS123, L858R and LNLS123 were used 
in this study. Cells were serum starved for 24 hours and then 100 ng/ml of EGF was 
added to the serum-free medium. Cells were then fixed with 4% PFA, 30 and 60 
minutes following addition  of EGF and then probed using anti-rabbit EGFR and 
stained using DAPI and goat anti-rabbit alexa fluor 568. Fig 3.7 shows the result of 
the staining of the fixed cells visualised via confocal microscopy. Cells expressing 
wtEGFR showed EGFR time-dependent nuclear translocation. 30 minutes following 
EGF  stimulation  wtEGFR  showed  cytosolic  internalisation  and  initial  nuclear 
expression  followed  by  marked  nuclear  translocation  at  60  minutes  confirming 
published reports (Hsu & Hung, 2007; Liao & Carpenter, 2007; Liao & Carpenter, 
2009; Lo et al, 2006a). In contrast, NLS123, L858R and LNLS123 transfected cells 
showed no EGFR nuclear translocation at either time point with clear membrane and 
cytosolic accumulation. 
 
3.2.4.2 EGFR nuclear translocation induced by IR  
Having  established  EGFR  nuclear  translocation  following  EGF  stimulation  in 
wtEGFR expressing cells and the effects of the NLS123 mutation, EGFR nuclear 
translocation was investigated in wtEGFR, NLS123, L858R or LNLS123 transfected 
cells following treatment with 4 Gy IR. Prior to irradiation, cells were starved for 24 
hours. 
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Cells were collected over a period of 20 minutes from the time of irradiation and the 
cytosolic  fraction  was  separated  from  the  nuclear  compartment.  Densitometric 
analysis  was  used  to  quantify  receptor  nuclear  accumulation.  To  normalise  the 
densitometric  data  and  take  into  account  cytosolic  contamination  of  the  nuclear 
fraction, the ratio between the densities of cytosolic EGFR/calnexin was subtracted 
from the ratio between the densities of nuclear EGFR/calnexin (contamination). The 
ratio of cytosolic untreated EGFR/calnexin represents the physiological amount of 
EGFR in the cytosol in relation to the amount of cytosolic marker calnexin present in 
the blotted cellular extracts. By subtracting this amount from all the ratios of nuclear 
EGFR/calnexin  it  is  possible  to  determine,  and  exclude,  if  EGFR  nuclear 
accumulation is due to any cytosolic contamination (shown by the calnexin bands in 
the nucleus) and therefore the real fold increase of EGFR nuclear accumulation over 
time can be determined.  
Fig 3.8 shows the results of samples obtained from wtEGFR transfected cells. These 
cells showed a time-dependent EGFR nuclear accumulation with a corresponding 
time-dependent  cytosolic  reduction.  Densitometric  analysis  shows  a  2.16-fold 
increase in EGFR nuclear accumulation by 20 minutes. NLS123 (Fig 3.9) and L858R 
(Fig  3.10)  transfected  cells  show  no  EGFR  nuclear  accumulation  over  time  as 
indicated by the densitometric values which fall below 1 following IR treatment. In 
both these transfected cell lines there was a time dependent accumulation of EGFR in 
the cytosolic fraction.  LNLS123 transfected cell lines (Fig 3.11) showed lack of 
EGFR nuclear accumulation as indicated by the negative value.  Considering the 
potent effect of IR on EGFR phosphorylation, the phosphorylation of the Y1068 and 
Y845 residues in both cellular compartments following IR was investigated in all the 
transfected cell lines. Cytosolic fraction from wtEGFR (Fig 3.8), L858R (Fig 3.10), 
LNLS123 (Fig 3.11) showed activation at both Y845 and Y1068 phosphorylation 
residues following IR treatment. Only the wtEGFR nuclear fraction (Fig 3.9) showed 
increased Y845 phosphorylation following IR treatment. NLS123 transfected cells 
(Fig  3.10)  showed  no  receptor  activation  either  in  the  cytosol  fraction  or  in  the 
nucleus.  
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Figure  3.8:  IR  induced  nuclear  translocation  in  NIH3T3  cells  transiently 
transfected with wtEGFR. (A) Cells were serum starved for 24 hours and then 
irradiated at 4 Gy. Cells were seeded 5, 10, 15, 20 minutes following treatment and 
nuclear  fractionation  was  obtained.  40μg  of  protein  lysate  was  loaded  onto 
denaturing gel and bands were obtained via immunoblotting with anti EGFR, anti 
PY1068, anti PY845, anti Calnexin and anti Lamin A/C. Numbers (black) represent 
fold increase compared to untreated, (blue) EGFR/calnexin density ratio, (red) fold 
increase of nuclear EGFR once subtracted density of cytosolic contamination (blue 
underlined). (B) EGFR cellular distribution is shown in the graph.  
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Figure 3.9: IR does not induce EGFR nuclear translocation in NIH3T3  cells 
transiently transfected with NLS123.Cells were serum starved for 24 hours and 
then irradiated at 4 Gy. Cells were seeded 5, 10, 15, 20 minutes following treatment 
and  nuclear  fractionation  was  obtained.  40μg  of  protein  lysate  was  loaded  onto 
denaturing gel and bands were obtained via immunoblotting with anti EGFR, anti 
PY1068, anti PY845, anti Calnexin and anti Lamin A/C. Numbers (black) represent 
fold increase compared to untreated, (blue) EGFR/calnexin density ratio, (red) fold 
increase of nuclear EGFR once subtracted density of cytosolic contamination (blue 
underlined). (B) EGFR cellular distribution is shown in the graph.  
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Figure 3.10: IR does not induce EGFR nuclear translocation in NIH3T3 cells 
transiently transfected with L858R. (A) Cells were serum starved for 24 hours and 
then irradiated at 4 Gy. Cells were seeded 5, 10, 15, 20 minutes following treatment 
and  nuclear  fractionation  was  obtained.  40μg  of  protein  lysate  was  loaded  onto 
denaturing gel and bands were obtained via immunoblotting with anti EGFR, anti 
PY845, anti Calnexin and anti Lamin A/C. Numbers (black) represent fold increase 
compared to untreated, (blue). EGFR/calnexin density ratio, (red) fold increase of 
nuclear EGFR once subtracted density of cytosolic contamination (blue underlined). 
(B) EGFR cellular distribution is shown in the graph.  
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Figure 3.11: IR does not induce EGFR nuclear translocation in NIH3T3 cells 
transiently transfected with LNLS123. (A) Cells were serum starved for 24 hours 
and  then  irradiated  at  4  Gy.  Cells  were  seeded  5,  10,  15,  20  minutes  following 
treatment and nuclear fractionation was obtained. 40μg of protein lysate was loaded 
onto denaturing gel and bands were obtained via immunoblotting with anti EGFR, 
anti  PY845,  anti  Calnexin  and  anti  Lamin  A/C.  Numbers  (black)  represent  fold 
increase  compared  to  untreated,  (blue)  EGFR/calnexin  density  ratio,  (red)  fold 
increase of nuclear EGFR once subtracted density of cytosolic contamination (blue 
underlined). (B) EGFR cellular distribution is shown in the graph. 
LNLS123 
I.R. 4gy  
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Table 3.2 A-D: Analysis of the densitometric values acquired via ImageJ on the 
cytosolic - nuclear separation blots for (A) wtEGFR, (B) NLS123, (C) L858R, 
(D) LNLS123. 
A 
B 
C 
D  
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3.3. DISCUSSION  
3.3.1 EGFR expression in NIH3T3 cells 
Over-expression  of  the  EGF  receptor  is  considered  to  be  one  of  the  principal 
characteristics of many types of cancer cells (Moasser et al, 2001). Our data showed 
that following transient transfection, the EGF receptor expression peaks at 48 hours 
remaining  constant  for  the  next  24  hours  (Fig  3.1).  Although  sufficient  receptor 
expression  was  already  detectable  from  12  hours  following  transfection,  all  the 
treatments  were made 48 hours following transfection to  mimic the EGFR over-
expression of other cancer cells. 
 
3.3.2 NIH3T3 cells as the most suitable cellular model 
Although the plasmids utilised express human EGFR, NIH3T3 mouse fibroblast cell 
line was employed for this study. These cells do not express EGFR and they have 
been shown to become tumorigenic if cultured with EGF and overexpressing the 
EGF receptor (Di Fiore et al, 1987). Moreover, in addition to the intrinsic identity of 
the two genomes (human and mouse genome share 97% identity of their translated 
sequence)  that  have  conserved  the  same  cellular  mechanisms;  the  necessity  of 
employing an EGFR negative system is clearly primary. Among the other organisms 
whose genome has high homology to humans, the Green monkey COS7 and the 
hamster CHO cell lines are also EGFR negative. However, the CHO cell lines have a 
great  practical  disadvantage  since  there  are  not  many  commercially  available 
antibodies  or  assays  that  guarantee  cross  reactivity  with  the  hamster  species 
rendering our molecular approach, potentially, difficult to interpret. The COS7 cells, 
although  more  closely  related  to  humans,  have  not  been  shown  to  undergo 
transformation following over-expression of EGFR and therefore, among these three 
cellular systems, negative in the expression of EGFR, the mouse fibroblast NIH3T3 
cell line was chosen. Despite the fact that a mouse-derived cell line cannot fully 
recapitulate the cellular circuits and the mechanisms of EGFR induced DNA repair 
regulation of human cancer cell lines, there are other biological disadvantages that 
have led to the NIH3T3 choice. Among the published cancer cell lines there are only 
two lines that do not express EGFR: ZR75 and DU4475 (Moasser et al, 2001). These 
cancer  cell  lines  express  HER2  and  therefore  the  modulation  of  DNA  repair  by  
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another  member  of  the  ERBB  family  could  have  not  been  excluded.  The  final 
category, which was examined as a possible candidate for our model, includes those 
cancer  cell  lines  that  express  EGFR  and  are  also  EGFR  dependent.  There  are 
disadvantages of knocking out the existing receptor and knocking in our mutants and 
also  the  high  expression  of  other  members  of  the  ERBB  family  of  receptors. 
Moreover there are several reports showing that silencing the EGF receptor in an 
EGFR-dependent cell line results in spontaneous cell death (Park et al, 2009). 
 
3.3.3 EGFR expression mediated signalling dependence in NIH3T3 cells  
This chapter has confirmed that the NIH3T3 cells are EGFR negative (Fig 3.1) and 
also shown that upon EGFR transient expression, two main signalling pathways are 
activated in response to the ligand-induced upstream activation of the receptor (Fig 
3.3). This demonstrates the adaptability of our cellular system and at the same time 
the influence of the EGF receptor on the NIH3T3 endogenous AKT and MAPK 
pathway (Klein & Levitzki, 2009). This was important to confirm the validity of this 
system  to  examine the EGFR modulation of DNA repair in  this  cell line and to 
compare the  cellular responses in  the presence of the somatic or the constructed 
EGFR mutants. Interestingly, despite the constitutive activation of the L858R, the 
densitometric analysis revealed a lower AKT and MAPK pathway compared to the 
activation measured in cells transfected with wtEGFR. This is a novel finding which 
has not been reported elsewhere. The downstream signalling activation of the L858R 
receptor  has  not  been  extensively  analysed  since  this  somatic  mutant  is  often 
expressed  together  with  the  wtEGFR  and  discerning  the  actual  activator  of  the 
signalling pathway is virtually impossible. As outlined in the Chapter1, the activation 
of one EGFR molecule relies on dimerisation and on the activation of the receiver 
kinase by the activator kinase. L858R may exert its oncogenic potential by playing 
the part of the activator with the wtEGFR molecule that will induce the activation of 
the  downstream  pathways.  In  contrast,  the  NLS123  showed  lack  of  receptor 
phosphorylation and there was no detectable upregulation of the AKT and MAPK 
signalling pathways.  
 
3.3.4 Conformational change is required for EGFR activation 
The results so far reported indicate that the mutation of the NLS sequence of the 
EGFR receptor compromises receptor activation. The classical model of activation of  
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the EGFR molecule describes that symmetrical ligand binding to the ectodomains of 
two  receptors  triggers  juxtaposition  of  their  cytoplasmic  kinase  domains  and 
subsequent  autophosphorylation.  This  causes  catalytic  activity  and  formation  of 
several docking sites for other signalling proteins (Domagala et al, 2000; Klein et al, 
2004; Ozcan et al, 2006; Schlessinger, 2002). Nevertheless, studies on the EGFR 
juxtamembrane  domain  have  shed  new  light  on  EGFR  activation  (Bae  & 
Schlessinger, 2010; Choowongkomon et al, 2005; Lemmon & Schlessinger, 2010; 
Zhang et al, 2006). According to the latest published model the C-lobe of a cyclin-
like  “donor”  molecule  contacts  the  residues  of  the  N  lobe  of  an  “acceptor”  like 
molecule resulting in  an allosteric activation of  the acceptor molecule (Fig  3.12) 
(Jura et al, 2009; Lemmon & Schlessinger, 2010; Mustafa et al; Thiel & Carpenter, 
2007) 
 
 
Figure 3.12: EGFR asymmetrical activation. The Fig shows the activation of the 
EGF receptor by the asymmetrical mode. The activation of the EGF receptor requires 
conformational  change  and  dimerisation  to  achieve  the  phosphorylation  of  the 
correspondent  molecule  carboxyl  tail.  The  C  lobe  and  the  N  lobe  of  the  kinase 
domain are marked to show how the N lobe of the first receptor comes to contact to 
the C lobe of the second. 
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3.3.5  The  Juxtamembrane  domain  regulates  the  cellular  fate  of  the 
receptor 
The majority of the literature reports have portrayed the ligand binding domain, the 
kinase  domain  and  the  carboxyl  tail  as  the  most  important  domains.  This  is 
confirmed further by the design of EGFR-specific inhibitors. Nevertheless, despite 
its  short  length,  also  the  Juxtamembrane  domain  (JX  segment)  contains  many 
regulatory motives that dictate the fate of the entire receptor (Aifa et al, 2006a; Jura 
et al, 2009) (Fig 3.13). 
 
Figure 3.13: The Juxtamembrane domain sequence of the EGF receptor. The 
coloured amino acids highlight the four amino-acid signals present in this domain 
 
The two basolateral signals: the dominant, proline rich core 667PXXP670, and the 
recessive, leucine rich 658LL659 and the lysosomal signal, 679LL680 are the residue 
and the motif that dictate the distribution of the molecule across the membrane and 
its recycling (Choowongkomon et al, 2005; Red Brewer et al, 2009). Essentially, 
when EGFR is inactive the only signal accessible is the basolateral dominant which 
recycles EGFR into an inactive form to the basolateral surface. The other signals are 
sterically obstructed and therefore inaccessible. This signal seems to be sufficient for 
targeting the receptor released at the trans Golgi to the basolateral plasma membrane 
and  redirect  the  endosomal  recycled  receptor  to  the  basolateral  membrane 
(Choowongkomon et al, 2005). Upon ligand binding the lysosomal import becomes 
the  only  alternative  because  the  homo  or  heterodimerisation  of  the  molecules 
removes the inhibition of the lysosomal signal. The JX segments of the dimerising 
molecules come closer together exposing the lysosomal signal for recognition. The  
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active molecule following its activation is therefore degraded and recycled back to 
the surface membrane into an inactive state (Thiel & Carpenter, 2007).  
 
The characterisation of the NLS mutation herein reported suggests that the NLS123 
mutant is kinase dead. EGF, cisplatin or IR do not stimulate the kinase activity of the 
receptor, down-regulating the signalling pathways that are normally controlled by 
EGFR. This pattern suggests that the impairment of kinase activity observed in this 
mutant  receptor  may  be  the  result  of  an  obstructed  conformational  change  that 
impedes the allosteric activation and the EGFR kinase-kinase juxtaposition. The NLS 
mutation seems therefore to be responsible for this dramatic kinase impairment.  
 
3.3.6  The  NLS  sequence  is  a  recognition  sequence  for  the  allosteric 
activation of the receptor 
It has been shown that the 13 amino acids 645-657 (NLS sequence) containing the  
Threonine 654 (T654) not only represent the NLS sequence of the receptor but they 
are  indispensable  to  achieve  the  conformational  change  that  allows  receptor 
dimerisation and subsequent activation. Upon ligand binding the receptor undergoes 
a conformational change in the intracellular domain at the site of the JX segment 
whereby the tyrosine kinase domain presents its carboxyl tail to the correspondent 
dimerised sister molecule (and vice versa) allowing a reciprocal phosphorylation of 
their residues (Aifa et al, 2006a; Aifa et al, 2006b). Some studies have shown that the 
phosphorylation  of  the  T654  by  protein  kinase  C  (PKC)  regulates  the  allosteric 
activation  of  the  receptor.  The  phosphorylation  of  the  T654  not  only  seems  to 
suppress the kinase activity but also seems to re-route the receptor to the basolateral 
surface. The proposed model infers that this phosphorylation event may disrupt the 
helical structure causing the recessive basolateral signal to become accessible and to 
dominate over the lysosomal sorting signal (Choowongkomon et al, 2004; Dittmann 
et al; Macdonald-Obermann & Pike, 2009). 
However, contrasting published evidence has shown that full length EGFR lacking 
these NLS 13 amino acids does not dimerise or autophosphorylate suggesting that 
the  phosphorylation  of  T654  (residue  contained  in  the  NLS  sequence)  is  neither 
necessary nor indispensable to switch off the kinase activity of the receptor and that 
the phosphorylation may be a consequence (rather than the reason) of the lack of the 
conformational  change  that  favours  this  post-translational  modification.  The  
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undetected phosphorylation of the NLS123 mutant suggests that the phosphorylation 
of the T654 is not necessary to determine or signal the phosphorylation inhibition. 
However, the undetected phosphorylation of the T654 (located in the middle of the 
NLS sequence) could be the consequences of an obstructed protein structure which 
does  not  allow  addition  of  a  phosphate  group  (the  juxtamembrane  stretch  is  not 
accessible) or, if accessible, to the neutral charge of the NLS caused by the alanine 
substitution which does not attract negatively charged groups. 
 Truncated mutants, deprived of the extracellular region but with an intact p13 (NLS 
sequence  is  a  peptide  of  13  amino  acids),  dimerise  and  achieve  a  carboxyl  tail 
autophosphorylation (Aifa et al, 2006b). This suggests that ligand binding is not the 
key  component  for  the  receptor  activation.  Collectively,  these  findings  have 
proposed a model whereby the thirteen amino acid peptide corresponding to the NLS 
sequence, p13+ (mainly because the threonine residue is surrounded by basic amino 
acids  and  therefore  positively  charged)  of  the  JX  segment  will  electrostatically 
interact  with  another 13 amino acids  peptide of exact  but  opposite charge, p13-, 
where the carboxyl tail faces the kinase domain of the other molecule allowing the 
reciprocal autophosphorylation (Aifa et al, 2006a). 
 
3.3.7 The NLS third core of Arginine is required for dimer stabilisation 
It has been recently shown that the last two arginines of the NLS sequence 656-RR-
657 are responsible for adopting an α helical conformation that is indispensable for 
EGFR activity (Jura et al, 2009). The authors of this work compared the differential 
activation  of  these  two  arginines  mutated  into  alanines  (which  would  basically 
represent a charge removal) to the replacement by glycine (which would weaken the 
helix).  The effect of the alanine substitution is smaller compared to the glycines 
substitution however the impairment  on kinase activity  of the receptor following 
EGF activation is significant for both.  
In the model presented by Jura et al. 2009; the juxtamembrane segment JM-A forms 
an antiparallel helical dimer to allow the binding of the asymmetric kinase dimer. 
The JM-B allows stabilising contact between the acceptor and donor lobe; however, 
there is no functional involvement of this part of the Juxtamembrane domain (Fig 
3.14). The model showed clearly the importance of the last core of the Arginine 
residues within the NLS sequence, whose mutation is probably the main responsible 
for  the  kinase  inactivation  of  the  NLS123  mutant.  In  the  original  study  that  has  
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characterised the EGFR NLS sequence, Hsu et al., showed that the mutation of the 
last  core  of  basic  amino  acid  within  the  EGFRNLS  sequence  induced  only  a 
reduction in EGFR activation (Hsu & Hung, 2007), therefore the alanine substitution 
of the first two cores of basic amino acids within the EGFR NLS sequence have 
contributed to the complete kinase inactivation of the NLS123 mutant shown in this 
study. This sugegsts that the mutation of all the three Arginine‟ cores is required to 
impair conformational allosteric change and consequent kinase activation. 
 
 
Figure 3.14: Formation of the asymmetric dimer. The JM-A forms an antiparallel 
helical dimer (interconnecting yellow lines) to allow and stabilise the formation of 
the asymmetric kinase dimer. The C lobe of the activator donor kinase interacts with 
the N lobe of the receiver/acceptor kinase leading to kinase activation of the receptor 
and phosphorylation of the carboxyl tail. 
 
3.3.8 The L858R mutant does not require conformational change and 
allosteric activation  
Despite the NLS123 mutant showing a complete lack of phosphorylation following 
both EGF, cisplatin or I.R, the LNLS123 showed only a reduction compared to its 
parental L858R. Fig 3.3, 3.4 and 3.11 showed LNLS123 phosphorylation activation 
on the PY1068 following EGF treatment and on the PY845 following I.R  despite the  
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presence of the same NLS mutation as in the NLS123 responsible for its kinase 
inactivation. The LNLS123, and its parental construct (L858R), also bear a kinase 
point mutation (Leucine 858 into Arginine- L858R) that enhances the affinity of the 
ATP binding site to ATP like molecules rendering the receptor more prone to auto-
phosphorylation. This mutation allows a thermodynamically stable conformation of 
the protein that enables autophosphorylation of the Y845 residue that resides in the 
same activation loop of the residue in position 858. (Yang et al, 2008) The reduced, 
rather  than  abolished,  phosphorylation  confirms  that  the  L858R  mutation  of  the 
receptor  in  non  small  cell  lung  cancer  (NSCLC)  confers  to  the  EGF  receptor  a 
constitutive  activation  (Gazdar,  2009a).  This  study  suggests  that  this  mutation 
permits  a  mode  of  activation  that  escapes  the  necessity  of  undergoing  a 
conformational change required by WT receptor. This would explain why, despite 
the mutation on its NLS sequence/p13+ peptide, the LNLS123 mutant still shows 
activation following ligand or IR treatment. The reduced activation requires further 
explanation.  It  has  been  reported  that  even  minute  amounts  of  EGFR  receptor 
activation are sufficient to activate downstream signalling pathways and therefore 
also low levels must be taken into account (Arteaga, 2002; Bublil & Yarden, 2007). 
Moreover,  although  a  clear  reduction  compared  to  its  parental  is  observed,  the 
phosphorylation levels presented by the LNLS123 are not negligible. Therefore, the 
activation potential of this construct will be categorised in this study as constitutive 
as with its parental L858R.  
Structurally,  the  mutation  to  the  nuclear  localisation  signal  changed  the  arginine 
residues into alanine residues. As a result, the affinity to the importin molecule is lost 
and the receptor nuclear translocation is impaired. In addition, the mutation itself 
seems to be sufficient to disturb the conformational change necessary for the receptor 
activation as shown in the results.   
 
3.3.9 EGFR nuclear localisation signal mutation impairs both nuclear 
translocation and protein activation 
Our data have shown the successful mutation of the wtEGFR and L858R constructs 
NLS  sequence.  The  mutated  tripartite  NLS  signal  of  the  NLS123  and  LNLS123 
constructs has resulted in marked reduction of EGFR nuclear localisation following 
EGF or IR treatment.   
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The  western  blot  analysis  on  the  protein  lysate  of  the  separated  cellular 
compartments showed increase of wtEGFR nuclear translocation over time whereas 
in the other mutants only a significant impairment of nuclear translocation. On the 
other hand the results shown by the confocal microscopy following EGF treatment 
show clear lack of nuclear accumulation in NLS123, L858R, LNLS123 both at 30 
and 60 minutes following EGF treatment.  Therefore the residual EGFR expression 
detectable on the western blots of the nuclear compartments of NLS123, L858R and 
LNLS123 expressing cells, is most probably due to the reported cytoplasmic fraction 
contamination  rather  than  the  actual  receptor  translocation  as  confirmed  by  the 
densitometry analysis. This study also indicates that only phosphorylated wtEGFR 
on Y845 residue was found in the nucleus following IR treatment. However, both 
L858R  and  LNLS123  also  undergo  PY845  autophosphorylation,  and  the  lack  of 
PY845  signal  within  the  nuclear  fraction  suggests  that  nuclear  EGFR  expression 
found in the blots from cells transfected with the other mutants is due to cytosolic 
contamination. This suggests that Y845 phosphorylation is not the post-translational 
modification causing the nuclear translocation but that it is a consequence of an a 
priori  event  that  allows  nuclear  translocation.  Taken  together,  the  constitutive 
activation of the L858R and its lack of nuclear accumulation suggest that kinase 
activation  per  se  is  not  sufficient  for  EGFR  nuclear  expression  and  that  the 
mechanism is more complex. 
The confocal microscopy analysis following EGF treatment shows a cytosolic and 
membrane  accumulation  of  the  receptor  in  the  NLS  mutants  and  in  the  L858R 
expressing cells as opposed to the gradual EGFR nuclear accumulation shown by the 
wtEGFR transfected cells. The EGFR staining pattern of the wtEGFR expressing 
cells shows EGFR localised primarily to endocytic vesicles in the perinuclear region 
at 30 minutes following treatment which is shown by the circle-like structure around 
the  membrane  and  the  nucleus.  Differently  from  the  other  mutants,  the  cell 
membrane  of  wtEGFR  expressing  cells  shows  a  punctuated  staining  since  the 
receptor undergoes endocytosis and retrotranslocation. The nuclear distribution of 
the  wild  type  receptor  at  60  minutes  shows  again  the  circle-like  internalisation 
pattern whereas the remaining mutants show a cytosolic accumulation. Considering 
the lack of kinase activation in NLS123 expressing cells, the cytosolic accumulation 
is  most  probably  indicating  receptor  degradation  in  the  lysosomal  compartment  
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whereas the constitutive activation shown by the L858R and LNLS123 suggests that 
the receptors are reshuffled back to the transmembrane. 
The impairment of nuclear localisation following EGF and IR could be explained by 
the reduction of affinity between the receptor molecule and the importin machinery 
due to a lack of conformational change and asymmetric dimer stabilisation due to the 
NLS123 mutation or to an alternative mode of activation.  
 
3.3.10 NLS mutation impairs EGFR protein expression 
Despite efforts to achieve equal protein expression (i.e. transfecting cells with 2-8 μg 
of  plasmid  DNA)  the  levels  of  the  NLS123  are  always  different  to  its  parental, 
wtEGFR, levels. This may reflect : 
a) An intrinsic incapability of the cells to cope with this kinase mutant  
b) The fact that the stable inactive (immature) conformation of the receptor renders 
the molecule more susceptible to degradation and/or reshuffling producing a reduced 
accumulation of the receptor both at the membrane and in the cytosol or  
c) The inactivity of the receptor does not stimulate the degradation and synthesis of 
new receptor molecules. 
 
3.3.11 CONCLUSION 
This chapter has validated the NIH3T3 cellular system as a good model to study the 
effect of EGFR expression. The kinase activity of the constructs as well as their 
capability  of  translocating  to  the  nucleus  has  been  shown.  Differently  from  the 
published  mutants,  the  NLS123  mutation  shows  completely  abolished  nuclear 
translocation. Interestingly, the somatic mutant  L858R and the LNLS123 mutant, 
have also shown inhibition of nuclear translocation suggesting that kinase activation 
does  not  determine  nuclear  import  and  that  a  specific  receptor  structural 
conformation  is  required  to  mediate  the  binding  to  the  NLS  sequence.    The 
understanding of the different behaviour of these constructs is necessary to critically 
analyse their influence on DNA repair following IR or cisplatin (discussed in the 
next chapter). 
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CHAPTER 4: 
NUCLEAR EGFR MODULATION 
OF DNA REPAIR 
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4.1 INTRODUCTION 
EGFR nuclear localisation requires receptor allosteric conformational change. This is 
central to expose the NLS sequence for recognition and binding (Jura et al, 2009; 
Macdonald-Obermann & Pike, 2009; Red Brewer et al, 2009; Thiel & Carpenter, 
2007). Although receptors, regardless of their active or inactive conformation will be 
internalised in the cytosol (Madshus & Stang, 2009), their nuclear translocation is 
dependent on the retrograde translocation through the sec61 translocon in the ER and 
the binding of importin to the NLS sequence (Liao & Carpenter, 2007). The NLS123 
mutant not only showed lack of nuclear translocation but also ligand dependent or 
independent  activation.  This  is  because  the  EGFR  NLS  sequence  is  involved  in 
dimer  stabilisation  and  allosteric  conformational  change  (Jura  et  al,  2009).  The 
constitutive activation showed by the LNLS123 mutant suggested that the L858R 
mutation per se, within the kinase domain, is sufficient to determine a receptor mode 
of  activation  that  escapes  the  allosteric  conformational  change  requirement.  This 
explains  why  the  LNLS123  is  active  despite  harbouring  the  NLS  mutation  that 
rendered the NLS123 kinase dead.  
 
4.1.1 EGFR role in DNA repair 
Increased  EGFR  activation  has  been  strongly  associated  with  tumorigenesis  and 
cancer  progression  (Bublil  &  Yarden,  2007;  Fischer  et  al,  2003;  Lemmon  & 
Schlessinger, 2010). Although EGFR already promotes the activation of survival, 
growth  and  proliferation  signalling,  EGFR  inhibition  by  TKI  (e.g.  gefitinib  and 
erlotonib)  and  monoclonal  antibodies  (e.g.  cetuximab)  have  indicated  a  role  for 
EGFR in the modulation of DNA repair following chemotherapy and radiotherapy 
(Gazdar, 2009a; Wheeler et al). Several studies have demonstrated the association of 
EGFR with DNAPKcs, the central component of the NHEJ pathway involved in the 
repair of DNA strand breaks (Dittmann et al, 2008a; Dittmann et al, 2007; Friedmann 
et al, 2006; Hsu et al, 2009; Mahaney et al, 2009; Mukherjee et al; Rodemann et al, 
2007).  Nuclear EGFR is found to correlate with worse prognosis in a variety of 
human cancers such as breast, head and neck and ovarian (Galleges Ruiz et al, 2009; 
Hoshino  et  al,  2007;  Lo;  Lo,  2010).  Therefore,  understanding  the  relationship 
between sensitivity to cancer therapy and EGFR sub-cellular distribution is necessary 
to design novel therapeutic combination strategies. While the interaction between 
EGFR and DNAPKcs has been demonstrated in response to IR (Rodemann et al,  
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2007), little is known about the role of EGFR in the modulation of repair following 
drug (e.g. cisplatin) treatment (Hsu et al, 2009). Having characterised the nuclear 
import  and  the  activation  potential  of  the  different  constructs  the  relationship 
between nuclear translocation and the kinetics of DNA repair following treatment 
with cisplatin or IR were characterised. This was achieved by the use of the alkaline 
single cell gel electrophoresis (comet) assay which determined the formation and 
repair  of  DNA  strand  breaks  (both  single  and  double)  and  interstrand  crosslinks 
(ICLs) (Hartley et al, 1999). 
 
4.1.2 Cisplatin damage and repair 
Cisplatin can form intrastrand crosslinks, interstrand crosslinks (ICLs), DNA-protein 
crosslinks  and  monoadducts  with  DNA  (Nojima  et  al,  2005)  and  inhibition  of 
ribosomal RNA synthesis (Jordan & Carmo-Fonseca, 1998). Among all these lesions 
ICLs, although only 6-8% of the total lesions (Zdraveski et al, 2000), are considered 
to  be the main determinant  of toxicity of crosslinking agents. This  is due to  the 
difficulty to resolve the ICLs that can also result in blocked transcription and DNA 
replication and initiate apoptosis (Wang & Lippard, 2005). 
The comet assay is designed as a method to measure DNA strand breaks in single 
cells (Olive, 1999) and can be modified for the purpose of measuring interstrand 
crosslink formation and repair (Spanswick et al) as described in the Materials and 
Methods section. Cisplatin repair in this study refers to the unhooking of the ICLs as 
measured using the comet assay. 
 
4.1.3 IR damage and repair 
IR exposure gives rise to multiple forms of direct DNA lesions including damage to 
the bases, cleavage of the DNA backbone to form single strand breaks (SSBs) and 
double strand breaks (DSBs) which can occur when two SSBs are formed at opposite 
strands or up to 10-20 bases apart (De Bont & van Larebeke, 2004; Jeggo & Lavin, 
2009; Olive, 2009; Szumiel, 2008). Moreover, indirect damage due to ionisation, 
hydrated electrons and hydroxyl radicals, results in sugar derived product, additional 
single  and  double  strand  breaks  and  DNA-protein  crosslinking  (Ward,  1995). 
Exposure to one Gray of IR is known to produce 1000 SSBs and about 30 DSBs per 
diploid cell independently from the cell type (Jeggo, 2009). Unrepaired SSBs lead to 
blockage of DNA replication forks during S phase and possibly to the formation of  
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DSBs  (Mahaney  et  al,  2009)  Although  cells  have  two  non-competing  repair 
pathways, NHEJ and HR, responsible for the repair of DSBs, acute levels of SSBs 
may saturate these pathways leading to genetic instability or cell death (van Gent & 
van der Burg, 2007). Alternatively, high levels of SSBs may induce cell death by 
excessive  activation  of  the  SSB  sensor  protein  poly  (ADP-ribose)  polymerase1 
(PARP1)  whose  prolonged  activation  leads  to  depletion  of  NAD  and  ATP  and 
release  of  the  apoptosis-inducing  factor  AIF  from  mitochondria  (Hefferin  & 
Tomkinson, 2005).  DNA DSBs are considered the most lethal type of lesion. It has 
been shown that even 1 unrepaired DSB is sufficient to cause cell death (Jackson & 
Bartek, 2009).  
 
4.1.4 Constructs utilised in this study 
 The investigation of the involvement of EGFR in the modulation of DNA repair and 
the mechanism that mediates this modulation requires a careful and detailed analysis 
of the different aspects of EGFR biology. For this reason five additional constructs 
were added to this study in addition to those described in the previous chapter. These 
are three EGFR NLS sequence mutants, 1 kinase mutant and a somatic mutant found 
in Glioma (EGFRvIII). While the addition of the three NLS mutants aims at mapping 
the extent of EGFR nuclear translocation required for repair, both the kinase mutant 
and EGFRvIII are needed to decipher the role of kinase activation in both nuclear 
translocation and repair. 
 
4.1.5 CHAPTER AIMS: 
  Test  the  hypothesis  that  nuclear  localisation  is  required  for  the  repair  of 
cisplatin  or  IR  induced  damage  and  investigate  the  differential  repair 
modulation of all the mutants. 
  Investigate  the  relation  between  DNA  repair  modulation  and  intrinsic 
phosphorylation activity of the different transfected constructs. 
  Determine  the  involvement  of  DNAPKcs  in  the  repair  of  cisplatin-induced 
damage  
 
 
 
  
152 
 
4.2 RESULTS  
4.2.1 EGFR constructs utilised for the DNA repair assays 
The effect of both cisplatin and IR on EGFR expressing cell lines has been well 
described. However, the role and consequences of EGFR nuclear translocation and 
kinase activation in the repair of both ICLs and strand breaks have not been fully 
examined. To probe the differential EGFR modulation on DNA repair, the EGFR 
negative cell line, NIH3T3, was transfected with 10 different plasmids (wtEGFR, 
NLS123, L858R, LNLS123, EGFRvIII, VC, M1, M12, KMT or ∆NLS) and DNA 
repair was assessed via the alkaline comet assay. These contain mutations within the 
NLS sequence (NLS123, LNLS123, M1, M12, ∆NLS), the kinase domain (L858R, 
KMT) and the extracellular domain (EGFRvIII) (Fig 4.1). The M1 receptor bears the 
mutation  of  the  first  cluster  of  basic  amino  acids  of  the  NLS  sequence 
(RRRHIVRKRTLRR  into  AAAHIVRKRTLRR),  the  M12  receptor  bearing  the 
mutation of the first two clusters (RRRHIVRKRTLRR into AAAHIVAAATLRR), 
the  NLS having the NLS sequence deleted. KMT bears the mutation of the Lysine 
721 into an Alanine (K721/A) and the EGFRvIII bears the deletion of exons 2-7. 
These affect the receptor kinase activity rendering the mutants: kinase dead (KMT) 
or constitutively active (EGFRvIII) respectively. 
 
 
 
Figure  4.1:  Graphic representation of the EGFR constructs employed  in the 
study. 
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4.2.2 EGFR modulation of cisplatin-induced DNA damage repair. 
4.2.2.1 50 μM cisplatin forms sufficient ICLs to study repair 
kinetics over time 
Prior to investigating the repair of cisplatin adducts, the dose of cisplatin required to 
induce detectable DNA damage was calculated using a modification of the comet 
assay  as  previously  described  (Spanswick  et  al,  2002;  Spanswick  et  al).  Cells 
transfected with wtEGFR or VC were incubated with cisplatin at a dose up to 150 
μM for 1 hour in serum-free media. It has been previously shown that cisplatin ICL 
formation peaks 9 hours after treatment with cisplatin. For this reason the cells were 
examined 9 hours following the treatment to determine the level of ICLs formed 
following drug treatment (Fig 4.2). The analysis of the comet assay showed that there 
was no difference in the formation of the crosslinks between cells transfected with 
wtEGFR  or  VC  at  all  the  time  points.  Levels  of  ICL  formation,  sufficient  to 
investigate  repair  over  time,  were  already  detectable  following  50  μM  cisplatin. 
Higher  doses  (100-150  μM)  showed  a  plateau  effect  for  the  formation  of  ICLs, 
suggesting that 50 μM was the optimal dose to determine repair over time.  
Next, it was established whether the amount of damage inflicted by 50 μM cisplatin 
was reparable over a period of 48 hours in cell transfected with wtEGFR. Fig 4.3 
shows a representative result of the % decrease in tail moment over a period of 48 
hours in NIH3T3 cells transfected with wtEGFR following treatment with 50 μM 
cisplatin. The graph shows that ICLs start forming already at 1 hour and that the   
peak of ICLs is at 9 hours following treatment (71.7 +/-2.01%). The majority of the 
lesions are then resolved by 36 hours in wtEGFR expressing cells suggesting that the 
amount of ICLs formed is sufficient to investigate repair kinetics over a period of 48 
hours.  
154 
 
 
 
Figure 4.2: 50 μM cisplatin induces optimal levels of detectable DNA damage.                       
Wild type and vector control expressing NIH3T3 were treated with 10, 25, 50, 100, 
150 μM cisplatin 48 hour following transient transfection. Cells were then examined 
9  hours  following  the  treatment  to  determine  the  percentage  of  ICLs  a  major 
cytotoxic  lesion  produced  following  drug  treatment.  The  graph  shows  the  mean 
values from three independent experiments. Error bars represent standard deviation 
(SD). 
 
 
 
Figure  4.3:  50  μM  cisplatin  induces  damage  repairable  over  time.  Cells 
expressing  wtEGFR  were  treated  with  50  μM  cisplatin  over  48  hour  following 
transient transfection. Cells were then examined at different time points s following 
the treatment to determine the percentage decrease in tail moment as a measurement 
of  ICLS  unhooking.  The  graph  shows  the  mean  values  from  three  independent 
experiments. Error bars represent standard deviation (SD). 
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4.2.2.1.1 Transfection of the EGFR mutants does not affect 
the peak of crosslinks 
At this point, before evaluating the kinetics of repair of cisplatin induced ICLs, it was 
investigated whether the transfection of all the mutants in NIH3T3 cells could have 
an effect on the formation of ICLs following cisplatin treatment. Cells transfected 
with wtEGFR, NLS123, L858R, LNLS123, M1, M12, KMT,  NLS, EGFRvIII or 
VC were treated with 50 μM cisplatin for 1 hour and samples were obtained 9 hours 
following treatment. Fig 4.4 and table 4.1 show the peak of crosslink across all the 
transfected cell lines. There was no significant difference among the peaks of ICLs 
suggesting  that  the  transfection  of  different  EGFR  mutants  does  not  affect  the 
amounts ICLs formed at 9 hours. 
 
4.2.2.1.2  wtEGFR  and  EGFRvIII  completely  repair 
cisplatin crosslink 48 hours following treatment 
Having determined the optimal dose of cisplatin to use during the comet assay, and 
after establishing that the transfection of different mutants in NIH3T3 cells was not 
affecting the formation of the crosslinks, NIH3T3 cells were transfected with all the 
mutants described in Fig 4.1 and cells were treated with 50μM cisplatin, for 1 hour in 
serum free media.  Samples were then collected over a period of 48 hours to assess 
repair of ICLs. Since there was no alteration in the formation of ICL by cisplatin in 
cells  expressing  all  constructs  and  no  significant  difference  among  the  peak  of 
crosslinks, the data collected over 48 hours were plotted as percentage of peak of 
crosslink. Fig 4.5 shows the graphical comparison of the repair kinetics between each 
individual  construct  and  wtEGFR  transfected  cells.  Only  cells  transfected  with 
wtEGFR  and  EGFRvIII  showed  complete  repair  by  48  hours  following  cisplatin 
treatment.    The  repair  kinetics  of  these  transfected  cells  showed  significant 
differences  already  by  18  hours  following  treatment  establishing  three  different 
repair behaviours: greatly impaired repair (NLS123, LNLS123), intermediate repair 
(L858R, KMT,  NLS) and complete repair (wtEGFR, EGFRvIII,  M1  and M12), 
shown together in Fig 4.6.  
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Figure 4.4: Percentage decrease of tail moment, at the peak of ICLs among the 
different constructs. The graph shows the average peak of ICLs, 9 hours following 
treatment  with  cisplatin,  of  NIH3T3  cells  transfected  with  wtEGFR,  NLS123, 
L858R, LNLS123, VC, EGFRvIII, M1, M12, KMT and ΔNLS. The average and the 
standard deviation of the data collected from 3 independent experiments are shown 
in the Table below. 
 
 
 
Table 4.1: Values and statistical analysis of the peak of crosslink. The average 
value  from  3  independent  experiments,  the  standard  deviation  and  the  statistical 
significance expressed as a P value are shown in the table  
 
Unhooking  of  cisplatin–induced  ICL  was  60.14  ±  6.56  %  and  61.32  ±  2.65  % 
unhooking by 24 hours in cell expressing wtEGFR and EGFRvIII and 100% after 36 
hours in both cell lines. In contrast, cells expressing NLS123 and LNLS123 showed 
only 7.98 ± 1.76 % and 11.12 ± 2.59 % of unhooking by 18 hours and 26 ± 4.07% 
and 19.3 ± 4.8 % of unhooking at 48 hours.  The intermediate repair group showed 
19.23  ± 3.89 (L858R), 35.2  ± 6.87 % (KMT), 40.87  ± 8.37 % ( NLS) unhooking 
by 18 hours and 46.57 ± 2.13%  (L858R), 54.95 ± 2,56% (KMT) and 57.21 ± 9.72% 
( NLS) unhooking of ICLs by 48 hours following cisplatin treatment. M1 and M12  
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expressing cell lines showed 84.09 ± 4.87% and 97.41 ±2.73% unhooking of ICLs 
respectively at 48 hours following cisplatin treatment. All the numerical data are 
reported in Table 4.2, where the Statistical analysis by the 2 way ANOVA shows the 
average values of every single time point, the standard deviation and its statistical 
significance expressed as P value.  Statistical significance (P value < 0.01/0.001) was 
found at 48 hours time points and/or at earlier time points when the kinetics of cells 
expressing  wtEGFR  were  compared  to  the  kinetics  of  cells  expressing  NLS123, 
L858R, LNLS123, M1, M12, KMT,  NLS or VC. 
 
 
Figure 4.5: Effects of EGFR modulation in repair of ICLs. The modulation in 
repair of single mutants is compared to the modulation in repair by wtEGFR.  
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Figure 4.5: cont.  
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Figure 4.5: cont.  
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Fig 4.5: cont. 
 
 
 
Table 4.2: Statistical analysis of the cisplatin induced damage repair assay.  Tables 
show the average value of three independent experiments. P values obtained with the 2-way 
Anova statistical analysis represent the comparison between all the mutants and to wtEGFR 
transfected cells 
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4.2.3 Effects of gefitinib on cisplatin induced ICLs formation and repair 
The use of gefitinib in combination with cisplatin has shown to have a poor clinical 
outcome  in  tumours  presenting  EGFR  overexpression  and/or  secondary  acquired 
somatic mutations (Giaccone et al, 2004a; Normanno, 2005; Oliveras-Ferraros et al, 
2008). The effect of the single agent gefitinib on the EGFR modulation of cisplatin 
DNA  damage  repair  was  therefore  investigated.  NIH3T3  cells  transfected  with 
wtEGFR, NLS123, L858R, LNLS123 or VC were pre-treated with 2μM gefitinib for 
1hour prior to treatment with cisplatin as previously reported (Moasser et al, 2001). 
Following treatment of 50 μM cisplatin for 1 hour in serum free media containing 2 
μM gefitinib, cells were further incubated in media containing 2 μM gefitinib and 
samples were collected over a period of 48 hours. Fig 4.7 shows the percentage of 
peak of crosslinks results obtained from the analysis of the comet assay. There was 
no difference in the peak formation of the ICLs in all the mutants. Despite treatment 
with gefitinib showed inhibition of cisplatin unhooking in cells expressing wtEGFR 
(66.18 ± 8.88 % unhooking by 48 hours), there was a significant difference when 
compared to unhooking in NLS123 (35.88 ± 1.74 %), L858R (41.74 ± 9.38%) and 
LNLS123 (25.48 ± 6.92%) expressing cells (Table 4.3). Statistical significance was 
also found when the unhooking of cisplatin ICLs in wtEGFR expressing cells was 
compared to VC expressing cells with wtEGFR expressing cells showing 22.57 % 
less  unhooking  (Table  4.3).  Next,  the  results  of  the  cisplatin  unhooking  in  cells 
treated with gefitinib were compared to the unhooking of cells treated with cisplatin 
alone (Fig 4.8). Interestingly, only cells expressing wtEGFR treated with gefitinib 
showed significant differences at all the time points following peak of crosslinks 
(Table  4.4).  L858R  expressing  cells  showed  statistical  significance  at  18  hours 
(19.43  %  less  unhooking  in  gefitinib  treated  cells)  and  at  24  hours  (20.4%  less 
unhooking  in  gefitinib  treated  cells)  following  cisplatin  treatment.  There  was  no 
statistical  significant  difference  when  treatment  with  gefitinib  was  compared  to 
cisplatin alone in NLS123 or LNLS123 expressing cells (Table 4.4). Only the repair 
kinetics of wtEGFR transfected cells were impaired when cells were treated with 
cisplatin in combination with gefitinib.     
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Figure  4.7:  Effects  of  gefitinib  on  EGFR  modulation  in  repair  of  ICLs. 
Measurement of drug-induced DNA ICLs in NIH3T3 cells transfected with wtEGFR, 
NLS123,  L858R,  LNLS123,  and  Vector  control  pre-treated  with  2  μM  gefitinib 
followed by 1 hour 50μM cisplatin with 2 μM gefitinib. Error bars represent standard 
deviation. The graph shows the average value of two independent experiments. ICL 
formation is represented as a percentage decrease of the peak of crosslink. 
 
 
 
Table 4.3: Statistical analysis of cisplatin induced damage repair assay in cells 
treated  with  2μM  gefitinib.  Tables  show  the  average  value  of  2  independent 
experiments. P values obtained with the 2-way Anova statistical analysis represent 
the comparison between all the mutants to the wtEGFR transfected cells. 
  
164 
 
 
 
 
Figure  4.8:  ICLs  unhooking  comparison  between  transfected  cells  treated 
(dotted line) and untreated (complete line) NIH3T3 cells.  Error bars represent 
standard deviation. The graphs represent the single breakdown of the above shown 
comet assays. ICL formation is represented as a percentage decrease of the peak of 
crosslink. 
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Figure 4.8: cont. 
4.2.4 EGFR modulation of IR induced DNA damage repair 
4.2.4.1 IR dose response 
The  dose  of  IR  required  to  induce  detectable  DNA  damage  and  sufficient  to 
investigate its repair over time was determined by using the comet assay. NIH3T3 
cells transfected with wtEGFR or VC were treated with IR at a dose up to 30 Gy. 
Since  IR  produces  an  immediate  physical  lesion  to  the  DNA,  treated  cells  were 
examined after the termination of the exposure. Fig 4.9 shows the results of the dose 
response obtained from the comet assay. The amount of strand breaks produced is 
shown as the mean tail moment value of three independent experiments. The data 
suggest that 15 Gy is the dose necessary to produce sufficient DNA strand breaks to 
asses repair over time and that EGFR expression does not influence the quantity of 
detectable  DNA  damage  produced.  For  this  reason  the  kinetics  of  repair  will  be 
shown as a percentage decrease of tail moment.  
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Table 4.4: Statistical analysis of cisplatin induced damage repair assay in cells 
treated with2 μM gefitinib compared to cells untreated with gefitinib. Tables 
show  P  values  obtained  with  the  2  way  Anova  statistical  analysis  represent  the 
comparison between cell treated vs untreated with gefitinib but transfected with the 
same construct.  
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4.2.4.2 DNA repair kinetics following IR treatment 
Next, the effect of all the EGFR constructs (reported in Fig 4.1) on repair of stand 
breaks  induced  by  IR  was  investigated.  NIH3T3  cells  were  transfected  with 
wtEGFR, NLS123, L858R, LNLS123, M1, M12, KMT, ΔNLS, EGFRvIII or VC. 
Following 48 hours transfection, cells were treated with 15 Gy IR and repair of IR-
induced  DNA-SB  was  examined.  This  is  shown  as  percentage  of  tail  moment 
calculated from the tail moment detected immediately following irradiation, over a 
period of 4 hours. Fig 4.10 shows the difference in repair kinetics between wtEGFR 
and single construct transfected cells.  Following treatment with IR alone, repair of 
strand  breaks  was  rapid  in  all  the  cell  lines.  Table  4.5  shows  the  statistical 
comparison  between  single  constructs  and  wtEGFR  transfected  cells.  Significant 
differences  (P  value  <0.001)  in  repair  kinetics  between  wtEGFR  and  NLS123, 
L858R,  LNLS123,  M1,  M12,  KMT  or  NLS  were  found  already  at  30  minutes 
following  radiation  (Table  4.4).  The  decrease  of  tail  moment  was  100%  in  both 
wtEGFR  and  EGFRvIII-expressing  cell  lines  at  4  hours  following  treatment, 
indicating  repair  of  SB.  In  contrast,  at  4  hours,  cells  expressing  NLS123  and 
LNLS123 showed significant delay in repair of SBs with 22.48 ± 3.72 % and 24.94 ± 
1.45  %  of  unrepaired  SBs.  Intermediate  levels  of  repair  were  observed  for  cells 
expressing L858R (12.33 ±1.00 %), KMT (18.86±3.45%),  NLS (17.38±5.06 %), 
M1  (8.51±1.12%)  and  M12  (9.28±2.26%).  The  results  are  graphically  grouped 
together in Fig 4.11 where the kinetics of all mutants are shown on the same graph.  
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Figure 4.9: 15 Gy IR induces optimal levels of detectable DNA damage. NIH3T3 
cells transfected with wtEGFR or VC were treated with 1, 3, 10, 15, 30 Gy IR. Cells 
were collected immediately following irradiation to determine the tail moment. The 
graph  shows  the  average  values  from  three  independent  experiments.  Error  bars 
represent standard deviation. 
 
Figure 4.10: Effects of EGFR modulation on repair of Strand breaks. Repair of single 
mutants compared to repair by wtEGFR. 
  
169 
 
 
 
 
 
Figure 4.10: cont. 
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Figure 4.10: cont. 
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Figure 4.10: cont. 
 
 
 
 
Table  4.4:  Statistical  analysis  of  IR-induced  DNA  SB  repair  assay  in  cells 
treated  with  15  Gy  IR.  Tables  show  the  average  values  of  3  independent 
experiments. P values obtained with the 2 way Anova statistical analysis represent 
the comparison between all the mutants to the wtEGFR transfected cells. 
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4.2.5 Cisplatin induced EGFR-DNAPKcs binding 
Previous  studies  have  demonstrated  the  association  of  EGFR  and  DNAPKcs 
following  IR suggesting an intrinsic link between EGFR nuclear localisation and 
DNAPKcs association and activation (Dittmann et al, 2005a; Dittmann et al, 2008a; 
Golding et al, 2009; Rodemann et al, 2007). The timing of this association and its 
significance have not been described following cisplatin treatment, although already 
reported  following  cisplatin  treatment  (Hsu  et  al,  2009).  EGFR-DNAPKcs 
association    and  its  involvement  in  the  mechanism  of  cisplatin  repair  was 
investigated. Since the modulation in repair kinetics in wtEGFR expressing cells was 
already detectable at 18 hours following cisplatin treatment the association between 
EGFR and DNAPKcs was investigated over a period of 24 hours following cisplatin 
treatment.  NIH3T3  cells  were  transfected  with  wtEGFR  and  48  hour  following 
transfection  they  were  treated  with  50µM  cisplatin.  Cells  were  then  collected  at 
various  time  points  up  to  24  hours  following  treatment.  Protein  extracts  were 
immunoprecipitated using an anti-DNAPKcs monoclonal antibody and blotted with 
an anti-EGFR antibody. Fig 4.12 shows a time dependent association of EGFR and 
DNAPKcs with a 2.7-fold increase at 18 hours following cisplatin treatment.  
 
4.2.6  EGFR-DNAPKcs  binding  following  cisplatin  treatment  does  not 
correlate with EGFR activation  
Next  the  cisplatin-induced  activation  in  all  the  mutants  and  their  binding  with 
DNAPKcs  was  examined.  NIH3T3  cells  transfected  with  wtEGFR,  M1,  M12, 
NLS123,  L858R,  LNLS123,  KMT,  ΔNLS,  EGFRvIII,  or  VC  were  treated  with 
50µM cisplatin. Cells were then collected 18 hours following treatment and protein 
lysates  were  immunoprecipitated  with  anti  DNAPKcs  and  blotted  for  EGFR  and 
DNAPKcs. Fig 4.13 shows EGFR and DNAPKcs association in wtEGFR, M1, M12 
or EGFRvIII transfected cells. In contrast, L858R and LNLS123 transfected cells 
showed  reduced  EGFR-DNAPKcs  binding  whereas  NLS123,  KMT  or  ΔNLS 
transfected  cells  showed  no  binding.    The  previous  chapter  showed  that  EGFR 
nuclear  localisation  was  not  dependent  on  EGFR  phosphorylation.  Therefore  the 
correlation  between  EGFR  phosphorylation  and  EGFR-DNAPKcs  binding  was 
ivestigated.  Cells transfected with wtEGFR, M1, M12, NLS123, L858R, LNLS123, 
KMT  or  ΔNLS  were  treated  with  cisplatin  for  one  hour  and  cell  lysates  were 
immunoprecipitated  with  EGFR  and  blotted  with  PY20  and  EGFR.  In  Fig  4.14,  
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wtEGFR,  M1,  M12,  EGFRvIII  showed  phosphorylation  activation  following 
cisplatin  treatment,  L858R  and  LNLS123  transfected  cells  showed  constitutive 
tyrosine phosphorylation. NLS123, KMT, ΔNLS transfected cells showed lack of 
kinase activation. There was no correlation between EGFR activation and EGFR-
DNAPKcs  binding  as  different  constitutively  active  mutants  showed  pronounced 
(EGFRvIII) or reduced (L858R, LNLS123) association with DNAPKcs.  
 
Figure  4.12:  DNAPKcs-EGFR  association  over  time.  wtEGFR  Transfected 
NIH3T3 cells were treated with 50μM cisplatin for 1 hour in serum free media. Cells 
were then lysed at 1, 9, 12, 15, 18, 24, hours following treatment. 750μg of protein 
lysate were immunoprecipitated using anti DNAPKcs and blotted with anti EGFR 
and anti DNAPKcs. EGFR pull down was quantified by 2D densitometry analysis 
and shown as a fold binding compared to the untreated control. Mouse unrelated 
antibody (M IGg) was used as negative control. 
 
 
 
 
Figure 4.13: DNAPKcs-EGFR association. NIH3T3 cells were transfected with all 
the mutants reported in Fig 4.1. 48 hours following transfection cells were treated 
with 50μM cisplatin for 1 hour in serum free media. Cells were then lysed 18 hours 
following  treatment.  750μg  of  protein  lysate  were  immunoprecipitated  using  anti 
DNAPKcs and blotted with anti EGFR and anti DNAPKcs.  
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 Figure 4.14: EGFR mutants’ activation. NIH3T3 cells were transfected with all 
the mutants reported in Fig 4.1. 48 hours following transfection cells were treated 
with  50μM  cisplatin  for  1  hour  in  serum  free  media.  Cells  were  then  lysed 
immediately following treatment. 750μg of protein lysate were immunoprecipitated 
using anti EGFR and blotted with anti PY20 and anti EGFR. 
 
4.2.7 EGFR and DNAPKcs cellular localisation following IR or cisplatin 
Next, the cellular localisation of both EGFR and DNAPKcs following cisplatin (Fig 
4.15 A-B) or IR (Fig 4.16 A-B) was investigated to determine whether the role of 
EGFR nuclear translocation in the repair of SB or ICL DNA damage was related also 
to  and the  EGFR-DNAPKcs  binding. Cells  transfected with  wtEGFR, M1,  M12, 
NLS123, L858R, LNLS123, KMT, ΔNLS, EGFRvIII, or VC were either fixed 18 
hours following treatment with 50 µM cisplatin or serum starved for 24 hours and 
then  fixed  20  minutes  following  4  Gy  IR.  Fig  4.15  and  4.16  show  the 
immunofluorescence results obtained via confocal analysis. Cells transfected with 
wtEGFR,  M1,  M12  and  EGFRvIII  showed  EGFR  nuclear  expression  following 
cisplatin or IR. DNAPKcs showed similar pattern of expression in cells transfected 
with these constructs. In wtEGFR and EGFRvIII transfected cells, EGFR was largely 
expressed  in  the  nucleus  following  cisplatin  or  IR.  In  contrast  M1  and  M12 
transfected cells showed reduced levels of EGFR nuclear expression. 
L858R,  KMT  and  ΔNLS  transfected  NIH3T3  showed  only  membrane/cytosolic 
EGFR localisation following cisplatin or IR. DNAPKcs nuclear expression in L858R 
cells was reduced compared to wtEGFR and EGFRvIII transfected cells following 
cisplatin or IR. In contrast, NLS123 and LNLS123 transfected cells showed lack of 
both DNAPKcs and EGFR nuclear expression. 
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4.3 DISCUSSION 
4.3.1  The  NLS  sequence  is  required  for  nuclear  translocation  and 
receptor activation 
The data presented in Chapter 3 have confirmed the previously reported EGF and IR 
induced EGFR nuclear translocation and investigated the NLS123 mutation of the 
EGFR NLS sequence. The basic Arginine amino acids contained in the NLS/p13+ 
peptide sequence of the EGFR JX domain are necessary to achieve a conformational 
change  that  seems  to  be  a  prerequisite  to  achieve  receptor  activation.  Upon  any 
activating stimulus, the mutant receptors fail to achieve a conformational change that 
not only prevents activation but also stops the protein from binding to the importin 
machinery and achieve nuclear translocation. The NLS123 mutation has shown two 
effects in a wtEGFR background. Firstly it inhibits the protein translocation to the 
nucleus and secondly it interferes with EGFR phosphorylation, negatively affecting 
its downstream signalling pathways. This chapter provides evidence for an EGFR 
role  in  the  modulation  of  DNA  repair  following  cisplatin  or  IR  induced  DNA 
damage. The data show DNA repair kinetics modulated by the expression of EGFR 
and also by its capability to translocate to the nucleus. Receptor activation and kinase 
activity do not seem to be central in this modulation. It appears that binding and the 
similar localisation pattern with DNAPKcs within the nuclear compartment may be 
responsible for the enhanced repair kinetics. 
 
4.3.1.2 EGFR modulates the repair of cisplatin-induced ICLs 
4.3.1.2.1 DNA repair of cisplatin lesions 
The effects of cisplatin and the repair pathways that may be involved in the repair of 
cisplatin damage are still debated and the literature emphasises that there is more 
than one pathway at work (Hlavin et al, 2010a; Martin et al, 2008; Wang & Lippard, 
2005). It is, in fact, established that cisplatin not only binds to DNA but also to many 
cellular  components  that  have  soft  nucleophilic  sites  such  as  cytoskeletal 
microfilaments, RNA, proteins. Only 5-10% of covalently bound associated cisplatin 
is  found  in  the  genomic  DNA  whereas  75-85%  of  the  drug  binds  to  proteins 
suggesting that the toxicity of this drug is also mediated by activation of specific 
signalling pathways that ultimately leads to cell death (Zdraveski et al, 2000).   
Although there is evidence suggesting a strong effect on DNA replication it is not 
completely clear whether replication may be one of the consequences rather than the  
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reason of the lethality of the treatment (Zorbas and Keppler 2005).This is because in 
cycling cells the persistence of ICLs may also induce single and double  DNA strand 
breaks (Smeaton et al, 2008; Smeaton et al, 2009).  Therefore as a result, the cell 
machinery  blocks  replication  and  transcription  allowing  sufficient  time  for  DNA 
repair  mechanisms  to  resolve  the  crosslinks  (Nojima  et  al,  2005).  The  pathway 
responsible for this cellular arrest is not completely characterised but EGFR seems to 
be involved in the mechanism (Ceppi et al, 2006; Chen et al, 2000; Hiraishi et al, 
2008; Hsu et al, 2009; Kim et al, 2009b; Klass et al, 2009; Michaelis et al, 2008; 
Oliveras-Ferraros et al, 2008; Yoshida et al, 2008). 
Because of the variety of DNA damage that arises from cross-linking agents, there 
are many pathways that are activated to repair these lesions. Their concerted activity 
is a key element to achieve complete DNA repair. Cross-links are well known to be 
repaired  by  Nucleotide  excision  repair  (NER)  and  post  replication  repair  (PRR) 
(Clingen et al, 2007; Clingen et al, 2005; De Silva et al, 2002; Hartley et al, 2004; 
McHugh  et  al,  2001).  Cisplatin  adducts  are  detected  by  the  NER  components 
Xpx/Hr23B  and  XPA.  These  then  recruit  the  endonucleases  Ercc1-Xpf  and  Xpg 
which are the catalytic NER proteins responsible for the dual incision process. The 
strand affected by the crosslink is incised 5‟ to the lesion by ERCC1-Xpf and 3‟to the 
lesion by Xpg. Once the lesion is removed the gap is filled by repair synthesis.  
In  presence  of  a  stalled  replication  machinery  at  the  site  of  the  lesion,  both 
Translesion DNA synthesis (TLS) and HR are required to help restart replication. 
TLS fills the gap via RAD6/ RAD18 and specialised polymerases such as Polε, Polκ 
and Polδ complete repair. HR fills the gap left by the excised lesion by copying the 
other  intact  sister  DNA  as  a  template.  HR  could  also  be  required  to  repair  the 
induced  DSB  created  as  an  indirect  consequence  of  crosslinked  DNA  during 
replication. NHEJ can also be employed to relegate the strands broken as a result of 
the  stalled  replication  machinery  (Nojima  et  al.  2005c;  Kartalou  and  Essigmann 
2001; Cepeda et al. 2007). Some studies have shown that upon defective HR and 
TLS, mammalian cells seemed to be hypersensitive to crosslinking agents suggesting 
a minor role of NER (Nojima et al. 2005b), on the other hand there are some other 
studies that have clearly shown that upon inefficiency of NER components, cells are 
hypersensitive to cisplatin adducts (Nojima et al. 2005a; De, I et al. 2002; De, I et al. 
2000).   
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4.3.1.2.2  Unhooking  is  the  major  determinant  in 
interstrand crosslink repair 
The ability of cisplatin to form covalent linkages between two strands of the double 
helix is without any doubt the basis for its high cellular cytotoxicity (Malinge et al, 
1999). If left unrepaired, interstrand crosslinks prevent, virtually, all aspect of DNA 
metabolism,  such  as  replication,  transcription  and  recombination  (Hlavin  et  al, 
2010b).  The  capability  of  linking  both  the  DNA  strands  renders  bifunctional 
crosslinking  agents  the  most  genotoxic  and  mutagenic  of  compounds.  This  is, 
perhaps,  the  reason  why  their  removal  is  the  most  complicated  of  DNA  repair 
processes (Wang & Lippard, 2005). ICLs repair takes place in two ways. During the 
first, also called recombination-independent, the lesion is excised (unhooked) on one 
strand of the helix and the remaining gap is filled by TLS. This process converts the 
crosslink into a mono-adduct which is, subsequently, resolved by a second cycle of 
excision repair. In bacteria this process is carried out by NER and Pol II, however it 
remains unclear in mammalian cells. Although NER has been shown to be a major 
component, this repair mechanism seems to be clearly minor in cycling mammalian 
cells; however, in differentiated non-replicating cells it may represent the only way 
for the removal of ICLs. The second repair mode begins with the excision of the 
crosslinks and is followed by homologous recombination. This second pathway takes 
place during the S phase and it is the predominant pathway in cycling mammalian 
cells. Despite the different modality of DNA synthesis of these two systems, the 
central  step  in  the  repair  of  crosslinks  is  still  the  initial  processing  /unhooking 
(Hlavin et al, 2010a; Hlavin et al, 2010b; McCabe et al, 2009; Muniandy et al, 2010; 
Shrivastav  et  al,  2009;  Smeaton  et  al,  2009;  Tornaletti,  2009;  Wang  &  Lippard, 
2005).  The  context  in  which  the  ICL  is  recognised  induces  the  recruitment  of 
different repair proteins rendering this step incredibly complex.  
 
 
4.3.1.2.3 Unhooking requires  different protein complexes 
often dependent on the type of bifunctional alkylator  
Although many proteins have been implicated the precise mechanism remains to be 
elucidated. Cycling cells treated with crosslinking reagents accumulate replication 
fork induced-breaks consisting in a DSB on one end, and a double stranded DNA 
cross-linked with a single strand in three stranded structure on the other. Different  
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from E. coli and S. cervisiae, ICL processing in mammalian cells only requires some 
of the protein involved in NER.  XPF-ERCC1 are structure specific endonucleases 
capable of making 5‟ incision at the junction between double stranded DNA and a 3‟ 
single stranded region (Clingen et al, 2005). Cells deficient in XPF-ERCC1 show 
only 15% unhooking of nitrogen mustards (NH2) induced ICLs (assessed by the 
Comet assay). Other NER components do not seem to be required in the unhooking 
of NH2 ICLs. In contrast, little or no unhooking of cisplatin induced ICLs has been 
shown not only in cells deficient in XPF-ERCC1 but also in XPD, XPB or XPG 
deficient cells implicating all these NER proteins in the unhooking step of cisplatin 
ICLs (De Silva et al, 2000; McCabe et al, 2009). Interestingly, although all impaired 
in  the  unhooking,  only  cells  deficient  in  XPF-ERCC1  have  higher  cisplatin 
sensitivity (37-40 fold more sensitive than their isogenic) compared to the other NER 
mutant  cells  (1.3-3.1  fold  more  sensitive  than  their  parental  line)  (Hlavin  et  al, 
2010a). In addition the observation that XRCC2 and XRCC3 deficient cells are also 
highly sensitive to cisplatin treatment, suggests that, as these two proteins, also XPF-
ERCC1  may  be  (additionally)  involved  in  recombinational  repair  (or  DNA  re-
sysnthesis to fill the gap left by the DNA incision) (De Silva et al, 2002; Smeaton et 
al, 2009). It is therefore unclear whether the inhibition of unhooking observed in 
cells deficient in XPF-ERCC1 via the comet assay is actually the product of failed 
recombination intermediates that result in DNA migrating with the similar retarded 
mobility as cross-linked DNA (Fisher et al, 2008). Smeaton et al., have also shown 
NER independent 5‟ incision, unaffected by the absence of ERCC1-XPF suggesting 
alternative contributions of these proteins to the unhooking step. This was further 
confirmed by the finding that the ERCC1-XPF does not function alone and it has 
been  found  associated  with  the  SLX4  protein  that  acts  as  a  scaffolding  for  this 
complex as well as for two other nucleases: MUS81-EME1 and SLX1.  
Cell  free  extracts  and  purified  protein  experiments  have  also  shown  contrasting 
results (Hlavin et al, 2010a; Smeaton et al, 2008; Smeaton et al, 2009). Bessho et al. 
have shown that the NER factors XPA, RPA, TFIIH XPC, XPG, ERCC1-XPF, were 
necessary and sufficient for the incision step and also that cells employ the incision 
step to relieve the DNA duplex from the distortion at either sides of the ICLs rather 
than removing the ICLs following its recognition (Bessho et al, 1997). Another study 
showed the requirement of RPA for both incision (unhooking) and re-synthesis and 
the essential role of PCNA for DNA synthesis and incision. The same group has also  
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shown  the  involvement  of  the  complex  containing  the  Pso4  pre  mRNA  splicing 
factor and the Werner Syndorme (WS) helicase activity (stimulated by BRAC1) in 
the  initial  ICL  processing  (Cheng  et  al,  2006).  Recently  there  has  been  some 
evidence of the involvement of Fanconi Anemia (FA) complex in the unhooking of 
cisplatin  ICLs.  Although  still  not  fully  understood,  it  seems  that  FA  complex 
recognises stalled replication forks created by ICLs, recruits protein complexes to 
this site and induces remodelling of the replication fork allowing repair to proceed. 
The role of FA proteins in unhooking is controversial. Although cells deficient in 
FANCA,  B, C, D2,  F and G or treated with  antibodies against FANCA showed 
reduced incision, the suppression is generally not complete with the 3‟ incision being 
more resistant. Many other reports have shown partial or no requirement of these 
proteins (McCabe et al, 2009; McHugh et al, 2001; Muniandy et al, 2010; Nojima et 
al, 2005).  
 
4.3.1.2.4 EGFR involvement in Cisplatin repair 
The  role  of  EGFR  in  the  response  to  cisplatin  treatment  was  firstly  reported  by 
Benhar M et al. Genotoxic stress induced by cisplatin activates DNA damage signals 
that culminate in EGFR autophosphorylation in a ligand independent mechanism. 
While initially it was proposed that EGFR activation induces downstream signalling 
responsible for cellular death, different groups have shown the contribution of EGFR 
in  the  repair  of  cisplatin  lesions  (Dittmann  et  al,  2005a;  Friedmann  et  al,  2004; 
Friedmann et al, 2006; Oliveras-Ferraros et al, 2008).  Recently, a study by Hsu et 
al.,  has  suggested that  nuclear  EGFR is  involved in  the repair of cisplatin  DNA 
damage (Hsu et al, 2009). The study looked at the phosphorylation of H2AX as a 
marker of DNA damage and of the repair of DSBs. Although their results pointed 
towards an involvement of nuclear EGFR in cisplatin toxicity, the phosphorylation of 
H2AX was determined only 12 hours following treatment (cisplatin crosslinks peak 
at nine hours following treatment) and repair of DSBs is not a good marker to asses 
the repair kinetics of cisplatin induced damage as DSBs are not directly caused by 
cisplatin.  
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4.3.1.3  EGFR  constructs  that  translocate  to  the  nucleus  repair 
cisplatin lesions 
 This  study  confirms  cisplatin-induced  EGFR  phosphorylation,  shows  enhanced 
repair kinetics in cells expressing EGFR constructs undergoing nuclear translocation 
and suggests that this  mechanism is mediated by EGFR binding with DNAPKcs.   
Three  distinctive  repair  behaviours:  complete  repair,  intermediate  inhibition  and 
highest inhibition of repair have been observed. Cells transfected with wtEGFR or 
EGFRvIII show complete repair both by 36 hours following cisplatin. Our data have 
demonstrated  that  both  wtEGFR  and  EGFRvIII  not  only  undergo  nuclear 
translocation but that they also bind DNAPKcs following cisplatin. In addition the 
confocal analysis of wtEGFR and EGFRvIII expressing cells shows similar EGFR 
and  DNAPKcs  localisation  pattern  in  the  nucleus  following  cisplatin  treatment.  
Cells that showed intermediate repair inhibition (L858R, KMT,  NLS) and highest 
inhibition  of  repair  (NLS123,  LNLS123)  correlated  to  impaired  EGFR  nuclear 
translocation. 
 
4.3.2 DNAPKcs involvement in the repair of cisplatin lesions 
The matter of whether DNAPKcs promotes, amplifies, transmits stress signals, has 
been largely debated. The initial studies that looked at the involvement of DNAPKcs 
in  the  repair  of  cisplatin  damage  showed  that  cells  deficient  in  DNAPKcs  were 
hypersensitive  to  cisplatin  treatment  and  that  in  the  parental  cell  lines  although 
showing quicker repair kinetics, DNAPKcs was not found at the site of the DNA 
lesion (Boeckman et al, 2005; Turchi et al, 1999; Turchi et al, 2000; Turchi et al, 
1996). Subsequently it was reported that cisplatin adducts reduce the rate at which 
Ku,  the  subunit  of  the  DNA-PK  heterotrimeric  complex,  slides  along  the  DNA 
duplex blocking its translocation from the DNA terminus (Pawelczak et al, 2005; 
Turchi et al, 2000). This resulted in a reduced association of Ku to DNAPKcs and 
also in the formation of inactive kinase complexes that are unable to resolve DNA 
breaks suggesting that cisplatin could be used to pre-sensitise cells to radiotherapy 
treatments (Turchi et al, 2000). However, in 2004 Glazer et al. showed that cells 
deficient  in  Ku80  and  DNAPKcs  were  actually  resistant  to  cisplatin  treatment 
compared to the wild type but that such difference is only marked when cells were 
treated at high confluence (Jensen & Glazer, 2004). Moreover the authors showed 
that following cisplatin treatment DNA-PK trimeric complexes mediate death signals  
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within damaged cells via cell to cell contact through gap junction (Jensen & Glazer, 
2004; Zorbas & Keppler, 2005). Subsequently, Shao et al. 2008 showed that high 
levels  of  DNAPKcs/Ku80  kinase  activity  in  gliomas  correlates  with  cisplatin 
resistance suggesting that activation of this trimeric complex could be utilised to 
screen for patients that would benefit from cisplatin treatment (Shao et al, 2008). 
 
4.3.3 EGFR modulation of DNA repair following IR 
The involvement of EGFR in the repair of IR-induced damage has been extensively 
reviewed in the introduction section. The characterised nuclear interaction of EGFR 
with DNAPKcs following IR is responsible for the DNA repair and resistance to IR 
treatment. Similarly, this study shows that cells expressing wtEGFR and EGFRvIII 
have completely repaired IR-induced SBs by 4 hours following treatment and this 
also  correlates  with  EGFR  nuclear  translocation  and  similar  DNAPKcs  nuclear 
localisation pattern. EGFRvIII expressing cell line shows the highest rate of DNA SB 
repair (significantly higher to wtEGFR) suggesting that cancer cell expressing this 
mutant may present a more efficient DNA repair mechanism and therefore a higher 
resistance potential to IR. 
 
4.3.3.1 EGFR modulation of SSBs and DSBs is shown at different 
time points 
The  differences  in  percentage  tail  moment  among  the  different  transfectants  are 
smaller compared to the distinct patterns observed following cisplatin treatment. The 
type of damage conferred and the different repair pathways involved explain the 
significance of these differences. DNA SBs are formed immediately following IR 
treatment and therefore repair will act promptly upon their recognition. While SSBs 
are quickly repaired by the DNA repair machinery, the more complex double strand 
breaks  will  require  a  longer  time.  Therefore  the  differences  observed  at  4  hours 
following IR treatment represent the impairment of DSBs repair whereas the very 
early time points show the different kinetics in the repair of single strand breaks. The 
alkaline  comet  assay  does  not  distinguish  between  the  single  and  double  strand 
breaks therefore it is unknown whether the percentage decrease in tail moment is due 
uniquely to inhibition of DSBs or to the accumulation of unrepaired SSBs and DSBs. 
This suggests that another DNA repair component, rather than DNAPKcs, involved 
in the EGFR modulation of IR induced repair cannot be excluded. Considering the  
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high biological significance and the great lethality of even one DSB the differences 
in percentage decrease of tail moment following IR among the mutants, although 
rather  small  numerically,  have  been  still  classified  using  the  three  categories 
(complete repair, intermediate inhibition and highest inhibition of repair) as for the 
cisplatin comet assay result.  
 
4.3.4 The window of molecular intervention to determine DNA repair 
The cisplatin comet assay also shows that the % unhooking obtained at the 18-hour 
time point could be very important to predict the overall repair response.  Less than 
50% of the unhooking at 18 hours will indicate that it is unlikely the ICLs will be 
successfully resolved within the 48 hours. This suggests that the binding between 
DNAPKcs and EGFR is only involved in the resolution of 50% of the unhooking 
however the immunoprecipitation analysis shows that the EGFR-DNAPKcs binding 
is  progressive  overtime  therefore  the  earlier  unhooking  may  still  be  due  to  this 
complex.    Similarly,  the  reduction  of  tail  moment  at  30  minutes  following  IR 
treatment predicts clearly the rate of repair. More than 60% reduction of tail moment 
will result in complete repair within the following 4 hours. These data suggest that 
the  initial  18  hours  following  cisplatin  treatment  and  30  minutes  following  IR 
treatment could be utilised to predict the overall repair kinetics following therapy 
 
4.3.5  EGFR  nuclear  localisation  expression  does  not  quantitatively 
determine modulation of DNA repair  
The IF analysis shows that despite the mutation in the NLS sequence, the nuclear 
translocation of both M1 and M12 show is only decreased. This, together with their 
ability to repair (shown in the comet assays), suggests that the amount of EGFR 
nuclear expression is not in linear relation with the repair kinetics. Even a small 
percentage of EGFR nuclear translocation results in sufficient repair. The difference 
in  nuclear  translocation  as  compared  with  wtEGFR  and  EGFRvIII,  interestingly, 
suggests that the induction of EGFR nuclear expression following IR and cisplatin 
may not only be required for DNA purposes but also to exert some other biological 
functions.  In  addition,  the  comparison  between  the  levels  of  M1/DNAPKcs, 
M12/DNAPKcs binding in relation to the levels of M1 and M12 nuclear expression 
and the levels of wtEGFR/DNAPKcs binding in relation to  its nuclear expression, 
suggests a role for EGFR independent of DNAPKcs.  
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4.3.6 Kinase activity does not determine nuclear expression and it is not 
central to repair 
KMT, L858R and ΔNLS show very similar intermediate levels of repair however 
their structural characteristics are quite different. The kinase dead mutant KMT bears 
the mutation K721A which is known to modify the kinase domain conformation 
hindering both dimerisation and receptor activation. The ΔNLS mutant lacks entirely 
the NLS sequence and in accordance to the allosteric model, (an EGFR receptor 
molecule lacking the p13+ peptide is unable of dimerise and activate) this receptor is 
kinase dead. Both these two mutants show impaired EGFR nuclear localisation.  On 
the other hand, L858R bears the somatically acquired mutation of the Leucine 858 
into an Arginine which renders the mutant 50 fold more active; 10-100 fold more 
sensitive to gefitinib and binds to gefitinib 20 times more tightly. In the inactive 
conformation Leucine 858 is exposed in the helical turn of the activation segment. 
Here it makes non-polar contact with the nearby Phenialanine 723 and the glycine-
rich  loop.  Substitution  with  the  positively  charged  amino  acid  Arginine  is  not 
compatible with the inactive conformation but is with the active conformation. This 
produces a lower affinity for ATP but higher affinity for TKI (Dixit & Verkhivker, 
2009; Fassina et al, 2009). Moreover it has been shown that due to this mutation the 
residue  Tyrosine  845  does  not  require  SRC  phosphorylation  but  undergoes 
constitutive autophosphorylation (Fu et al, 2008; Yang et al, 2008). Expression of the 
L858R  mutant  also  resulted  in  impaired  nuclear  expression  despite  constitutive 
kinase activity (Das et al, 2007). This resulted in reduction of DNA strand break 
repair which is consistent with the observation that non-small cell lung cancer lines 
expressing L858R show increased sensitivity to IR and reduced nuclear expression. 
Moreover, the difference in repair between cells expressing L858R (kinase active but 
with impaired nuclear localization) and EGFRvIII (kinase active and expressed in the 
nucleus)  suggests  that,  as  a  consequence  of  the  lack  of  allosteric  activation,  the 
impaired nuclear EGFR accumulation and not kinase activity per se determines the 
reduced DNA repair in these models.  
The confocal imaging shows that L858R, KMT or  NLS transfected cells still induce 
nuclear DNAPKcs following cisplatin and IR suggesting the presence of a backup 
signalling  pathway  that  triggers  some  DNAPKcs  nuclear  accumulation  however 
insufficient to determine complete repair. It is unknown whether the KMT mutant  
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undergoes  a  conformational  change  and  therefore  whether  its  lack  of  nuclear 
localisation is due to a sterically hindered NLS sequence or to an impaired kinase 
activation.  Previous  data  have  shown  that  inhibition  of  EGFR  kinase  activity  is 
sufficient  to  inhibit  the  receptor  nuclear  translocation  suggesting  that  despite  an 
intact  NLS  sequence  the  kinase  activity  is  also  a  requirement  for  nuclear 
translocation.  Our  data  have  shown  that  nuclear  accumulation  is  the  absolute 
requirement for efficient repair as kinase activity without nuclear accumulation can 
only account for intermediate levels of repair.  
 
4.3.7 Maximal gefitinib inhibition of repair is shown only when EGFR 
translocates to the nucleus 
The results obtained by the gefitinib treated cells following cisplatin suggest that 
nuclear  localisation  is  central  for  the  modulation  of  cisplatin  repair  modulation. 
Gefitinib showed maximal inhibition only in wtEGFR transfected cells whereas it 
had  no  significant  effect  on  cells  expressing  NLS123  or  LNLS123.  Although 
wtEGFR cell treated with gefitinib showed significant inhibition compared to VC 
transfected  cells  (which  do  not  express  EGFR),  the  inhibition  of  repair  was  still 
significantly  lower  compared  to  cells  with  impaired  EGFR  nuclear  translocation. 
Importantly, the intermediate levels of repair shown by wtEGFR expressing cells, 
treated with  gefitinib, suggests that whilst not  sufficient to determine a complete 
inhibition of repair, inhibition of EGFR kinase activity has a role in repair, however 
different from nuclear translocation.  
The increased sensitivity shown in L858R transfected cells reflects the characteristic 
of this mutant to have a higher affinity to 4-anilinoquinazoline compounds such as 
gefitinib. Significant inhibition of repair was found only between 18 and 24 hours 
following cisplatin treatment. There was no significant difference in gefitinib treated 
cells  at  48  hours.  The  effect  of  the  inhibitor  on  the  receptor  activation  was  not 
determined therefore it  cannot  be concluded that  the higher inhibition  is  directly 
determined  by  the  peak  of  gefitinib-induced  impairment  of  kinase  activation. 
Interestingly, the time frame coincides with EGFR-DNAPKcs nuclear association 
shown in cells where EGFR translocates to the nucleus. It has been reported that 
gefitinib treatment induces cytosolic accumulation of DNAPKcs (Friedmann et al, 
2004). The possibility that repair inhibition observed in L858R cells is due to other  
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factors  rather  than  to  an  impaired  kinase  activity  cannot  be  excluded.  Future 
experiments will answer these important questions.  
4.3.8 Gefitinib binds to EGFR active conformation 
The necessity of a conformational change to allow recognition of the NLS sequence 
for nuclear translocation has been previously discussed. The impaired EGFR nuclear 
localisation has been explained as a result of an inactive conformation (NLS123) due 
to the lack of a dimer-dimer interface that initiates the allosteric mechanism and to a 
kinase  mutation  that  achieves  active  conformation  without  requiring  the 
conformational change (L858R). It has been shown that gefitinib binds only EGFR 
molecules in an active conformation. In line with this evidence, L858R and wtEGFR 
show  gefitinib-induced  inhibition  of  DNA  repair.  The  lack  of  gefitinib-induced 
inhibition,  in  NLS123  cells,  adds  more  evidence  towards  the  argument  that  the 
NLS123 mutation impedes the allosteric conformational change necessary to achieve 
an  active  conformation.  The  fact  that  gefitinib  treatment  has  shown  no  effect  in 
LNS123 cells suggests that the mutation of all the arginines within the NLS sequence 
may impair the active conformation that the L858R receptor obtains via the arginine 
substitution at position 858. This underlines the importance of this stretch of amino 
acid and the necessity for further experiments to determine the correlation between 
the induction of impaired active conformation and DNA repair.  
 
4.3.9 The NLS sequence is a target for molecular intervention 
The NLS mutation (AAAHIVAKATLAA) contributed to an even greater delay of 
repair.  The NLS123 mutant showed not only inhibition of nuclear translocation, 
abolished  kinase  activation  and  impaired  DNAPKcs  binding  but  also  lack  of 
DNAPKcs  nuclear  accumulation.  The  LNLS123  showed  impaired  EGFR  nuclear 
accumulation  and  DNAPKcs  binding,  mirrored  by  the  inhibition  of  DNAPKcs 
nuclear translocation maintaining, however, the receptor constitutive activation. The 
mutation  of  the  three  Arginine  cores  of  the  NLS  sequence  may  have  caused  a 
structural change to the receptor obstructing the binding of other proteins and their 
trans-phosphorylation which results in the lack of DNAPKcs nuclear accumulation. 
A  recent  study  has  shown  that  targeting  EGFR  NLS  sequence  by  a  peptide 
corresponding to phosphorylated NLS resulted in abolished nuclear EGFR, reduced 
radiation-induced  activation  of  DNAPK  and  reduced  survival  following  IR 
(Dittmann et al, 2010a).  
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4.3.10 DNAPKcs subcellular distribution 
These  data  clearly  show  that  DNAPKcs  is  not  only  localised  into  the  nucleus 
supporting other published data on the cytosolic functions of DNAPKcs. Moreover, 
in our EGFR overexpressing cellular system, DNAPKcs mirrors the EGFR cellular 
localisation suggesting that the behaviour of these two proteins is highly linked. In 
fact the inhibition of the nuclear translocation of the receptor is sufficient to mediate 
decreased DNAPKcs nuclear accumulation following cisplatin and IR. Previous data 
have shown that EGFR inhibition of gefitinib induce DNAPKcs accumulation in the 
cytosol (Friedmann et al, 2006). Although the gefitinib dose used in that study was 
greater the effects on EGFR kinase activity are comparable to those obtained with the 
NLS123 mutant. The statement that EGFR cellular localisation influences DNAPKcs 
subcellular distribution can be justified if one accepts the idea of EGFR being a 
kinase for DNAPKcs. 
 
4.3.11 Conclusions 
This chapter shows that nuclear EGFR plays an important role in modulating the 
repair of DNA damage caused by cisplatin and IR. Transfecting cells with wtEGFR 
and EGFRvIII showed an increased efficiency of the repair of DNA lesions, whereas 
the transfection of EGFR-NLS mutants  demonstrated an impairment of DNA repair. 
Following cisplatin treatment there was a time dependent association of EGFR and 
DNAPKcs as assessed by immunoprecipitation assays. Confocal microscopy in cells 
transfected with wtEGFR or EGFRvIII showed similar localisation pattern  of EGFR 
and DNAPKcs in the nucleus whereas the two proteins were exclusively detectable 
in the cytoplasm in cells transfected with EGFR NLS123 mutants. These results are 
in keeping with the observation that inhibitors of EGFR can inhibit DNA repair and 
demonstrates the importance of EGFR nuclear expression in this process. 
It now needs to be demonstrated that both cisplatin and IR stimulate the formation of 
EGFR  and  DNAPKcs  complex  and  therefore  as  a  consequence  of  their  physical 
interaction DNAPKcs  undergoes  a kinase modulation which is  mediated only by 
nuclear EGFR.  
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CHAPTER 5:  
THE MECHANISM OF EGFR 
MODULATION OF DNA REPAIR 
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5.1 INTRODUCTION 
5.1.1 The role of EGFR nuclear translocation in the binding to DNAPKcs 
EGFR modulation of DNA repair has been described in many reports with regards to 
the binding with DNAPKcs following IR. Although this interaction has been greatly 
discussed and characterised in the literature, there is no clear understanding as to 
whether  EGFR  nuclear  expression  is  sufficient  and  necessary  to  determine  this 
binding. The previous chapter has  shown how  EGFR can modulate  ICL  and SB 
repair. EGFR kinase activity and nuclear localization, despite appearing to rely both 
on the receptor active conformation, have distinct, non-mutually exclusive, roles in 
the repair of DNA damage.  
Inhibition of EGFR (or other ERBB family receptors) kinase activity can either be 
achieved by TKI or by antibodies that impair the ligand binding to the receptor. 
When  wtEGFR  transfected  cells  were  treated  with  gefitinib  in  combination  with 
cisplatin the resulting effect on the DNA repair kinetics were similar to the behaviour 
of the KMT mutant. Cell expressing this kinase dead mutant showed impaired EGFR 
nuclear translocation and intermediate levels of ICL or SB repair.  Our data have also 
shown  that  induced  inhibition  of  EGFR  nuclear  translocation  via  the  NLS123 
mutation resulted in a consequent impaired kinase activity. However cells transfected 
with  the  NLS123  showed  complete  inhibition  of  repair  suggesting  that  different 
targeting clearly has a more dramatic effect. 
Confocal microscopy analysis suggested that mutation in the EGFR NLS sequence 
inhibits DNAPKcs nuclear localization without establishing a physical interaction. 
The question as to whether EGFR-DNAPKcs association takes place exclusively in 
the nucleus and whether EGFR kinase activity or nuclear translocation per se can 
induce this association remain unclear.  The suggestion that EGFR acts as a kinase 
for  DNAPKcs  would  explain  DNAPKcs  cytosolic  localisation  in  presence  of  an 
EGFR  NLS  mutant.  EGFR-DNAPKcs  binding  inhibition  could  interfere  with 
DNAPKcs activation resulting in a DNAPKcs accumulation in the cytosol.  
 
5.1.2 EGFR nuclear localisation and DNAPKcs kinase activity   
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Previous reports have shown a correlation between direct inhibition of EGFR kinase 
activity and consequent inhibition of DNA-PK kinase activity suggesting a relation 
between  EGFR  kinase  activity  and  DNAPKcs.  EGFR  kinase  inhibition  by  TKI 
(gefitinib) or mAB (cetuximab) have shown inhibition of DNA-PK kinase activity, 
DNAPKcs  cytosolic  accumulation  and  delayed  repair  (Dittmann  et  al,  2008a; 
Dittmann et al, 2005b; Friedmann et al, 2006; Golding et al, 2009). Recent reports 
have also shown a function for cytosolic DNAPKcs in apoptosis, activation of AKT 
and in cell-cell communication (Achanta et al, 2001; Gurley et al, 2009; Lu et al, 
2006; Shi et al, 2009; Toulany et al, 2008b). Here it has been shown that inhibition of 
EGFR  nuclear  translocation  via  the  NLS123  mutation  also  indirectly  inhibits 
DNAPKcs nuclear accumulation following cisplatin and IR induced damage. This 
raised  many  questions  on  the  induction  of  EGFR-DNAPKcs  association  and  its 
consequences including whether this binding takes place exclusively in the nucleus, 
whether  it  is  EGFR  nuclear  translocation,  the  treatments  or  EGFR  allosteric 
conformational  change  that  induce  EGFR-DNAPKcs  association  and  whether  the 
complex can modulate DNAPK kinase activity.  These are all central to decipher the 
mechanism that links EGFR with DNAPKcs and DNA repair, to provide substantial 
evidence to establish that nuclear EGFR is required for repair of cisplatin and IR 
induced DNA damage and that repair is mediated via binding to DNAPKcs. 
 
5.1.3 Stable expression of EGFR constructs  
The  transient  over-expression  of  the  wtEGFR  or  other  EGFR  mutants  has  been 
utilised to determine the effect of EGFR on repair. In this chapter wtEGFR, NLS123, 
L858R,  LNLS123,  EGFRvIII  were  stably  expressed  in  NIH3T3  cells  and  the 
mechanism  of  EGFR  modulation  of  DNA  repair  was  investigated.  This  allowed 
homogeneous EGFR- expressing populations of cells to be examined. The constructs 
within  the  stable  transfectants  represent,  more  significantly,  the  different  DNA 
damage repair behaviours discussed in chapter 3 while presenting different EGFR 
characteristics in terms of nuclear translocation, kinase activation, and DNAPKcs 
binding. 
 
5.1.4 Cisplatin cytotoxicity and survival 
As detailed in the introduction chapter, cisplatin has been used in the clinic for over 
30 years in the treatment of testicular, head and neck, cervix, ovary and lung cancer.  
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However, clinical responses to cisplatin are variable and there is substantial evidence 
suggesting that EGFR over-expression, as well as its nuclear expression, are major 
determinants  of  cisplatin-acquired  resistance  (Benhar  et  al,  2002;  Eckstein  et  al, 
2008; Wernyj & Morin, 2004; Winograd-Katz & Levitzki, 2006; Wynne et al, 2007). 
The general consensus is that the variety of platinum adducts underlie most of the 
cytotoxic effects of this drug (Malinge et al, 1999; Wang & Lippard, 2005). Besides 
EGFR,  cisplatin  activates  a  variety  of  cellular  protein  that  exerts  many  crucial 
cellular functions such as p53, p73, c-abl, hence predicting signalling responses to 
cisplatin has been a challenge for many years (Boeckman et al, 2005; Laachi et al, 
2009;  Nojima  et  al,  2005;  Patrick  et  al,  2008;  Turchi,  2006;  Wang  et  al,  2005; 
Winograd-Katz & Levitzki, 2006). It remains to elucidate the consequences of such 
high inhibition of repair in terms of survival. This is essential to assess the potential 
benefits of targeting EGFR nuclear localisation for therapeutic purposes. 
 
5.1.4 Aims of this chapter: 
  Investigate the induction of EGFR-DNAPKcs binding  
  Determine the role of EGFR kinase activity in the binding with DNAPKcs.  
  Determine  the  role  of  EGFR  cellular  localisation  in  relation  to  DNAPKcs 
cellular distribution.   
  Identify  the  cellular  compartment  where  EGFR-DNAPKcs  association  takes 
place. 
  Study  the  consequence  of  EGFR-DNAPKcs  association  in  terms  of  DNAPK 
kinase activity. 
  Determine  the  survival  of  exponentially  growing  wtEGFR,  NLS123,  L858R, 
LNLS123, EGFRvIII or VC expressing cells following cisplatin treatment. 
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5.2 RESULTS 
5.2.1  wtEGFR  and  EGFRvIII  are  expressed  in  the  nucleus  18  hours 
following cisplatin treatment 
In the previous chapter, confocal microscopy showed EGFR nuclear expression 18 
hours  following  cisplatin  treatment.  Although  immunofluorescence  is  the  most 
reliable technique to determine the cellular localisation of any protein, wtEGFR and 
EGFRvIII  nuclear  translocation  was  confirmed  by  cellular  fractionation.  Cells 
expressing wtEGFR, EGFRvIII, NLS123 or VC were treated with 50μM cisplatin for 
one  hour  in  serum-free  media  and  cytosolic  and  nuclear  compartments  were 
separated 18 hours following cisplatin treatment (Fig 5.1). Densitometric analysis 
showed a 2.35-fold increase in EGFR nuclear expression in wtEGFR expressing cells 
and 3.28-fold increase in EGFRvIII expressing cells. EGFR nuclear translocation 
was impaired in NLS123 expressing cells. Fig 5.2 shows the graphical representation 
of the densitometric analysis 
 
5.2.2 Ionising radiation or cisplatin induce EGFR-DNAPKcs binding 
The timing of EGFR nuclear translocation following cisplatin was chosen according 
to  the  peak  of  EGFR-DNAPKcs  binding  following  cisplatin.  Interestingly,  it  has 
been shown that IR-induced EGFR-DNAPKcs binding also coincides with the time 
of IR-induced EGFR nuclear translocation (Das et al, 2007; Dittmann et al, 2008a). 
Although  the  formation  of  the  EGFR-  DNAPKcs  complex  and  EGFR  nuclear 
expression have always been related in the literature there is no clear understanding 
as  to  whether  EGFR-DNAPKcs  binding  is  a  consequence  of  EGFR  nuclear  
expression.  Therefore  the  induction  of  this  complex  formation  was  invetsigated. 
Cells  stably  expressing  wtEGFR,  NLS123,  L858R,  LNLS123  or  EGFRvIII  were 
treated with 4 Gy IR or 50µM cisplatin or 100 ng EGF and samples were collected at 
the appropriate timing showing EGFR nuclear translocation. Cellular extracts were 
then  immunoprecipitated  using  an  anti-EGFR  antibody  and  blotted  with  anti-
DNAPKcs. The addition of the EGF treatment was necessary to determine whether 
the EGFR-DNAPKcs association is induced by nuclear translocation per se, by the 
induction of the allosteric conformational change that exposes the NLS sequence, or 
by the treatment. Fig 5.3 shows the western blot analysis of the EGFR pull-down  
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lysates  blotted  with  anti-DNAPKcs.  Cells  expressing  wtEGFR  and  EGFRvIII 
showed  EGFR  association  with  DNAPKcs  only  following  treatment  with  IR  or 
cisplatin.  Cells  expressing  NLS123,  L858R  and  LNLS123  showed  no  interaction 
between  the  mutant  EGFR  and  DNAPKcs.  This  confirmed  the  results  of  the 
reciprocal DNAPKcs pull-down following cisplatin treatment shown in the previous 
chapter.  EGF  induction  of  EGFR  nuclear  translocation  did  not  induce  EGFR-
DNAPKcs binding suggesting that the type of treatment induces EGFR-DNAPKcs 
binding. Since cisplatin, IR and EGF are potent activators of EGFR kinase activity, 
EGFR  phosphorylation  activation  in  relation  to  EGFR-DNAPKcs  complex 
formationwas  investigated.  Fig  5.3  shows  the  analysis  of  the  EGFR-  pull  down 
lysates  blotted  with  the  pan-phosphotyrosine  PY20  antibody.  Cells  expressing 
wtEGFR  showed  maximal  activation  of  the  receptor  following  EGF  treatment. 
Intermediate levels of activation were detected following  IR or cisplatin.  L858R, 
LNLS123 and EGFRvIII  expressing cells  showed a constitutive activation  of the 
receptor whereas NLS123 showed no receptor activation. Despite maximal EGFR 
activation  being  achieved  in  wtEGFR  expressing  cells  following  EGF  treatment, 
there was no correspondent EGFR-DNAPKcs binding. Kinase activity is therefore 
not sufficient to determine EGFR-DNAPKcs binding. This association is triggered 
by cisplatin or IR and not by the EGFR nuclear translocation per se.  
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Figure 5.1:  Cisplatin induces  EGFR nuclear translocation.  EGFR-null murine 
NIH3T3  cells  were  transfected  with  wtEGFR  (wt),  EGFRvIII  (viii),  M123,  and 
vector control (VC). Cells were treated with 50μM cisplatin for one hour and nuclear 
extracts were obtained 18 hours following treatment. Nuclear extracts are prepared 
according to the Active Motif Nuclear extract kit and loaded relative to the cytosolic 
extracts and blotted with antibodies to EGFR or Calnexin or Lamin A/C. Numbers 
(black) represent fold increase compared to untreated, (blue) EGFR/Calnexin density 
ratio, (red) fold increase of nuclear EGFR once density of cytosolic contamination 
was substracted (blue underlined). 
 
 
Figure  5.2:    Cisplatin  induces  EGFR  nuclear  translocation.  EGFR  cellular 
distribution is shown in the graph. The bars show the graphical representation of the 
densitometric analysis of Fig 5.1. 
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 5.2.3 Mutant EGFR associates with the heat shock protein 90 chaperone 
The association of heat shock proteins (Hsps) to protein kinases has been shown in 
several reports (Citri et al, 2006; Pashtan et al, 2008; Sawai et al, 2008). Hsps are 
molecular chaperones whose expression increases in response to metabolic insults. 
Their most acknowledge function is to assist protein synthesis and folding (Young et 
al,  2001).  In  addition  they  have  been  shown  to  participate  in  protein  assembly, 
secretion and trafficking and regulation of transcription factors (Citri et al, 2006). 
While Hsp70 have been shown to be involved in the nuclear translocation of EGFR 
(Liao & Carpenter, 2007), Hsp90 has been often shown to  associate with EGFR 
somatic  mutants.  Previous  reports  have  demonstrated  that  EGFRs  harbouring 
mutation within the kinase domain require the Hsp90 chaperone for conformational 
maturation and stability. In fact, the inhibition of Hsp90 has been often associated 
with reduced expression of EGFR mutants and consequent sensitivity to treatment 
(Sawai et al, 2008). The cellular requirement for EGFR mutants to achieve post-
translational  maturity  and  proper  folding  induces  HSp90  association  with  EGFR 
kinase mutants (Lavictoire et al, 2003). Since the NLS123 mutation interferes with 
EGFR allosteric conformation, the Hsp90-EGFR association in wtEGFR, NLS123, 
L858R, LNLS123, EGFRvIII or VC expressing cells was inevstigated to understand 
the relationship between HsP90, EGFR nuclear localisation and EGFR-DNAPKcs 
binding. Therefore, the EGFR pull-down samples were also blotted with anti-HSP90 
antibody. Fig 5.3 shows the results of the western blot analysis. While,  wtEGFR 
showed  association  with  HSP90  only  following  cisplatin  treatment,  in  contrast 
EGFRvIII  expressing  cell  lines  showed  impaired  association  between  EGFR  and 
Hsp90.  L858R, LNLS123 and NLS123expressing cells showed constitutive levels of 
association between EGFR and HSP90 following IR, cisplatin or EGF treatment, 
although weaker following IR treatment in L858R and NLS123  expressing cells (Fig 
5.3).   
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Figure  5.3:  EGFR  activation  and  binding  to  DNAPKcs  and  Hsp90.  Stable 
NIH3T3  cells  expressing  wtEGFR,  NLS123,  L858R,  LNLS123,  EGFRvIII,  and 
Vector control were treated with 50μM cisplatin or 4 G IR, or treated with 100ng/ml 
EGF as described in the materials and methods. 1.5mg of protein lysate was then 
immunoprecipitated  using  anti-EGFR  monoclonal  antibody  and  blotted  with  anti 
DNAPKcs, anti-PY20, anti-EGFR and anti-HSP90. 
 
 
5.2.4  DNAPKcs and EGFR localise in the same cellular compartment 
following IR or cisplatin 
Having established the levels of association between EGFR and DNAPKcs following 
either cisplatin or IR treatment, their cellular localisation by confocal microscopy 
following IR (Fig 5.4) or cisplatin (Fig 5.5) treatment was also validated in the stably 
transfected lines.  Cells expressing wtEGFR, NLS123, L858R, LNLS123, EGFRvIII 
or VC were either fixed 18 hours following treatment with 50 µM cisplatin or serum  
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starved for 24 hours and then fixed 20 minutes following 4 Gy IR. Fig 5.4 and 5.5 
show  the  immunofluorescence  results  obtained  via  confocal  analysis.  Cells 
expressing wtEGFR and EGFRvIII showed nuclear expression of both EGFR and 
DNAPKcs following IR or cisplatin treatment. In contrast, L858R-expressing cells 
showed impaired EGFR nuclear localisation following either treatment.  This  was 
associated with diminished expression of DNAPKcs within the nucleus. Expression 
of  EGFR  and  DNAPKcs  was  exclusively  cytosolic  in  NLS123  and  LNLS123 
expressing cell lines following either IR or cisplatin treatment (Fig 5.4 and 5.5). 
Inhibition of EGFR nuclear translocation impaired DNAPKcs nuclear translocation, 
confirming the results obtained in Chapter 4 with the transiently transfected cells.  
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5.2.5  EGFR  and  DNAPKcs  association  following  cisplatin  or  IR 
treatment  
The time dependent association between EGFR and DNAPKcs showed a progressive 
formation  of  this  complex  following  cisplatin  treatment.  EGFR  is  mainly  a 
membrane/cytosolic protein, while DNAPKcs is principally found in the nucleus. 
Despite nuclear translocation and protein function, the most abundantly expressed 
nuclear protein will localise into the cytosol to  be degraded.  Although  previous 
reports have shown DNAPKcs cytosolic accumulation following EGFR inhibition by 
gefitinib(Friedmann et al, 2006),  the majority of the published data has investigated 
this complex formation almost exclusively in nuclear extracts (Dittmann et al, 2005a; 
Dittmann et al, 2008a; Dittmann et al, 2005b; Dittmann et al, 2007; Golding et al, 
2009; Hsu et al, 2009; Mahaney et al, 2009). DNAPKcs has been shown to have 
diverse roles in the cytosol (discussed later). Our cellular fractionations have never 
achieved  a  nuclear  fraction  free  from  any  cytosolic  contamination,  limiting  the 
possibility  to  investigate  EGFR-DNAPKcs  association  using  fractionated  cellular 
extracts. For this reason the cellular distribution of the EGFR-DNAPKcs complex 
formation  via  the  proximity  ligation  assay  was  investigated.  This  assay  allows 
fluorescent visualisation of the interaction between two proteins in fixed cells by 
labelling the secondary antibodies, used for the recognition of the protein involved in 
a complex, with two complementary oligos. Oligos from one secondary antibody will 
ligate only with oligos labelling the secondary antibody from different species (since 
they have been purposely made complementary) and within the proximity of 30nm. 
Ligation between two oligoes labelling the secondary antibody from the same species 
is therefore impossible. Therefore the formation of circular DNA molecule will be 
achievable only when two proteins are labelled by two secondary antibodies from 
different species and within the distance of 30nm. This is the distance recognised to 
be  sufficient  to  determine  physical  interaction  between  two  molecules.    Before 
assessing  the  EGFR-DNAPKcs  complex  distribution  in  the  NIH3T3  cells  stably 
expressing  wtEGFR  or  EGFR  mutants,  the  assay  and  the  antibody  concentration 
required to prevent saturation were tested on A549 cells over expressing EGFR and 
DNAPKcs.  Primary  antibody  concentration  titration  (1:50  -  1:150)  was  used  to 
determine the most sensitive antibody concentration in cells treated with IR. Fig 5.6 
shows the results of the confocal analysis of A549 cells blocked with anti-Rabbit 
EGFR antibody and anti-Mouse DNAPKcs and labelled using the proximity ligation  
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assay. Each interaction is represented via a single red fluorescent dot.   There was a 
clear accumulation of red dots in the nuclei of A549 cells following treatment with 
IR  at  all  the  antibody  dilutions.  This  confirmed  the  previously  described  EGFR-
DNAPKcs  association  and  established  the  optimal  concentration  of  primary 
antibodies to use in wtEGFR, NLS123, EGFRvIII or VC expressing cells. Fig 5.6 
shows  that  higher  antibody  dilutions  (1:75,  1:100  and  1:150)  produced  less 
sensitivity in detecting nuclear complexes maintaining a discreet level of background 
complexes (serum starved) while the lower antibody dilution (1:50) showed a clear 
increase in nuclear fluorescent dots following IR treatment.  
Next cells stably expressing wtEGFR, NLS123, EGFRvIII or VC were examined. 
Cells were treated with 50µM cisplatin or 4 Gy IR and then fixed 18 hours following 
treatment  with  cisplatin or 20 minutes following  IR. Fig 5.7 shows the confocal 
analysis of the stable cells blocked with 1:50 anti-Rabbit EGFR antibody and 1:50 
anti-Mouse  DNAPKcs  and  labelled  using  the  proximity  ligation  assay.  In  cells 
expressing vector or NLS123 constructs no interaction was detectable. In contrast, 
cells  expressing  wtEGFR  or  EGFRvIII  showed  interaction  between  EGFR  and 
DNAPKcs following either IR or cisplatin. The pattern of interaction suggests that 
EGFR-DNAPKcs complex formation takes place both in the nucleus and cytoplasm.  
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Figure  5.6:  EGFR-DNAPKcs  complex  cellular  localization.  A549  cells  were 
treated with 4 Gy IR and then fixed with 4%PFA 20 minutes follwowing radiation. 
Cells were then immuno blocked with anti-rabbit EGFR and anti-mouse DNAPKcs 
Dilution of the two antibodies are indicated (1:50-1:150). Interacting complexes were 
then visulised  via the duo link proximity assay. Each red spot represent a single 
interaction.  
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Figure 5.6 cont.  
 
 
  
208 
 
 
 
Figure 5.7: EGFR-DNAPKcs complex cellular localization. Stable NIH3T3 cells 
expressing wtEGFR, NLS123, EGFRvIII and Vector control were treated with 50μM 
cisplatin  for one hour in serum free media  and then fixed with 4%PFA 18 hours 
following treatment or 4 Gy and then fixed with 4%PFA 20 minutes follwowing 
radiation. Cells were then immuno blocked with anti-rabbit EGFR and anti-mouse 
DNAPKcs. Interacting complexes were then visulised  via the duo link proximity 
assay. Each red spot represent a single interaction.  
 
5.2.6 EGFR modulation of DNA-PK activity 
Previous reports have shown that the association of EGFR and DNAPKcs stimulates 
DNA-PK kinase activity. The experiments detailed above demonstrated that EGFR 
kinase activity alone is not sufficient to determine EGFR-DNAPKcs association and 
that cisplatin or IR treatment was required to induce this complex formation. This is 
suggesting that cisplatin and IR may be responsible for DNAPKcs activation which 
would  then  allow  binding.  The  modulation  of  repair  observed  during  the  study, 
however, suggests that treatment  alone and putative activation of DNAPK is  not 
sufficient to achieve complete repair (shown by the VC-expressing cells). Therefore  
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the  effect  of  EGFR-DNAPKcs  binding  on  the  alteration  of  functional  enzyme 
activity was investigated via the SignaTECT DNA-Dependent Protein Kinase Assay 
System.  This assay utilises SAM
2TM Biotin Capture Membrane and overcomes the 
problem of non specific substrate binding by using a byotinylated DNA-PK p53-
derived peptide substrate. The dose and the time to investigate the kinase activity 
were chosen according to the EGFR-DNAPKcs time of binding following IR (4 Gy, 
20 minutes) or cisplatin (50 μM cisplatin, 18 hours). EGF induction of EGFR (100 
ng/ml, 1 hour) was utilised to determine whether EGFR kinase activation per se were 
responsible for the effects on DNA-PK kinase activity.  
Fig 5.8 shows the results of the DNA-PK kinase assay performed on extracts from 
cells  expressing  wtEGFR,  NLS123,  L858R,  LNLS123,  EGFRvIII  or  VC.  Single 
treatment controls were used to determine the percentage change in DNA-PK kinase 
activity.    As  compared  with  EGFR-negative  cells  transfected  with  VC,  cells 
expressing wtEGFR showed a 27.5 ± 7.22% increase in DNA-PK activity following 
IR (4Gy) and 37.52 ± 4.01 % increase following 50µM cisplatin treatment for 1 hour 
(Fig  5.7).  Similarly,  in  cells  expressing  EGFRvIII  there  was  32.42  ±  16.58  % 
increase of DNAPK activity following IR and 26.6 ± 8.49% increase following the 
cisplatin treatment. In contrast, no significant change in DNA-PK activity compared 
to controls was found in L858R and LNLS123 expressing cell lines following IR (-
5.29  ±  8.27%  and  2.72  ±  7.06%)  or  cisplatin  treatment  (9.04  ±3.46%  and  2.25 
±6.07%).  Results  are  summarised  in  Table  5.1.  Only  cells  expressing  NLS123 
showed  a  clear  decrease  in  DNA-PK  kinase  activity  compared  to  control.  EGF 
treatment  showed  no  statistical  change  in  kinase  activity  suggesting  that  EGFR 
binding to DNAPKcs has a more significant role in determining DNA-PK kinase 
activity following cisplatin or IR. 
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Figure 5.8: EGFR modulation of DNA-PK kinase activity. Stable NIH3T3 cells 
expressing  wtEGFR,  NLS123,  L858R,  LNLS123  or  EGFRvIII  were  treated  with 
50μM cisplatin  for one hour or 4 Gy or 100ng/ml EGF in serum free media. 18 
hours following the treatment with cisplatin, 20 minutes following the treatment with 
IR and at the end of the EGF incubation cells were lsysed and samples prepared for 
the DNA-PK Kinase assay. The graph shows the percentage change in DNA-PK 
activity following each treatment compared to untreated.  
 
Table 5.1: The table shows numerical values and statistical significance from the 
DNAPK kinase assay. 
 
5.2.7 EGFR modulation of cellular survival 
The  DNA  repair  abilities  observed  in  the  cells  expressing  wtEGFR,  somatic 
mutations and NLS mutations  have underlined substantial differences in their repair 
kinetics following cisplatin and IR. The comet assay data, showed in result Chapter 
4,  suggested  significant  differences  in  the  mechanism  utlised  by  these  cells  to 
respond  and  repair  the  cisplatin  and  IR-induced  DNA  damage.  To  investigate 
whether the EGFR induced modulation of DNA repair  has an effect on survival, 
wtEGFR,  NLS123,  L858R,  LNLS123,  EGFRvIII  or  VC  expressing  cells  were 
treated with  cisplatin and  survival was  assesed via the MTT assay. Cells were 
plated at a concentration that allows them to grow exponentially (2.5x10
4/ml) and 
then treated with 50μM cisplatin for one hour in serum free media. Survival was 
assessed via the MTT assay over a period of 72 hours Fig 5.9 shows the percentage  
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decrease in survival of each stable cell line as  compared to their daily untreated 
control. The graph shows wtEGFR expressing cells comapred to single each cell line 
expressing different constructs.  Cells expressing wtEGFR and EGFRvIII showed 
61.99 ± 5.02  and 62.33 ± 6.82 %  survival. L858R expressing cells showed 42.26 ± 
1 % survival,  statistically  significant  when compared to  the  wtEGFR  % survival 
(P<0.01). NLS123 and LNLS123 showed  37.44 ± 2.26 and 33.76 ± 6.49 % survival, 
with high statistical significance when compared to wtEGFR %  survival (P value < 
0.001).  Details  of  statistical  analysis  is  reported  in  Table  5.2.  These  data  are 
graphically grouped in Fig 5.10. Fig 5.11 shows only the survival 72 hours following 
cisplatin expressed as % survival.  
 
 
Figure  5.9:  Cisplatin  effects  on  cellular  survival.  Cells  expressing  wtEGFR, 
NLS123, L858R, LNLS123, EGFRvIII or VC were plated at 2.5 x10
4/ml. Then cells 
were  treated  with  50μM  cisplatin  for  one  hour  in  serum  free  media  and  then 
incubated over a period of 72 hours. Survival  was assessed at 24 hours, 48 hours and 
72  hours  following  cisplatin  treatment.  %  decrease  survival  was  calculated  by 
comparing individually untreated cell lines with corresponding cisplatin treated. The 
graph shows mean % decrase survival of 3 independent experiments. The Fig shows 
comparison with wtEGFR expressing cells.  
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Figure 5.9: cont.  
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Table 6.1: Statistical analysis of the  cisplatin effects on cellular survival. Table  
shows the average of three individual experiments, standard deviation (S.D.) of each 
individual cell line. All the cell lines were considered individually and compared to 
the wtEGFR expressing cell percentage of survival. P values were calculated using 
the 2 way ANOVA analysis and the Bonferroni post test. Difference were considered 
significant only for a P value < 0.01. 
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Figure 5.10: Percentage decrease survival following cisplatin treatment. The 
graph shows the  effect of cisplatin on survival in all the cell lines grouped together 
 
 
 
Figure 5.11: Percenatge survival following cisplatin treatment. The graph shows 
survival of  all the cells lines 72 hours following cisplatin treatment Stars indicate 
statistical significance ( =P value <0.01,  = P value <0.001) 
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5.3 DISCUSSION 
 
5.3.1 IR or cisplatin induces EGFR-DNAPKcs association 
The association between EGFR and DNAPKcs has been shown in several reports 
however its induction has been controversial. The first study that shed light on this 
interaction demonstrated in fact that cetuximab inhibition of EGFR induced EGFR 
and DNAPKcs association resulting in a down-regulation of the DNA-PK kinase 
activity that impaired DNA repair (Bandyopadhyay et al, 1998).  In contrast, multiple 
lines of evidence have since shown that EGFR is a major determinant of radiation-
response  and  that  this  radio-protective  function  is  exerted  via  its  ability  to  bind 
DNAPKcs and mediate DNA repair (Dittmann et al, 2005a; Dittmann et al, 2007; 
Rodemann et al, 2007). These studies also demonstrated that EGFR inhibition via 
mAB or TKI treatment inhibits EGFR nuclear translocation and also association with 
DNAPKcs rendering cells sensitive to radiotherapy (Baumann et al, 2007; Das et al, 
2007; Dittmann et al, 2008a; Nyati et al, 2006; Rodemann & Blaese, 2007; Toulany 
et al, 2005; Wanner et al, 2008). This study has shown that EGF, IR and cisplatin 
mediated EGFR nuclear translocation however only treatment with IR and cisplatin 
induce  EGFR-DNAPKcs  binding.  Nuclear  expression  per  se  is  therefore  not 
sufficient to mediate this association suggesting that EGFR-DNAPKcs binding is 
specifically  induced  in  response  to  DNA  damage  confirming  the  involvement  of 
EGFR in modulation of DNA repair. As highlighted in the Introduction Chapter the 
role  of  EGFR  nuclear  expression  is  not  uniquely  related  to  DNA  repair.  EGFR 
stimulation by ligand has been shown to modulate gene expression and contribute to 
a variety of important transcription related cellular mechanisms such as proliferation 
(cyclinD1 expression) or oxidative stress (iNos expression) (Lo et al, 2005a; Wang & 
Hung,  2009).  This  highlights  the  complexity  of  EGFR  nuclear  localisation 
mechanism and its modularity to different inputs. Although, the molecular targeting 
of the pathway involved in EGFR nuclear translocation can still represent a good 
candidate for molecular intervention, these results have shown that EGFR nuclear 
translocation is not directly responsible for the binding with DNAPKcs. 
 
5.3.2 wtEGFR and EGFRvIII associate to DNAPKcs 
Despite the great number of reports discussing EGFR-DNAPKcs association and the 
lack of this complex formation in cells expressing L858R, the criteria necessary for  
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this binding and the EGFR characteristics required to allow this association have not 
been described. In this study there is not sufficient data to outline the mechanism that 
leads to this complex formation, however, the analysis of these results have lead to a 
few hypotheses. 
While the nuclear expression of wtEGFR has been shown in several reports, nuclear 
expression  of  EGFRvIII  has  been  controversial  in  the  literature.  EGFRvIII  and 
STAT3  localisation  within  the  nucleus  was  demonstrated  in  some  studies  (de  la 
Iglesia et al, 2008), whereas other studies have reported lack of nuclear expression in 
glioma models (Mukherjee et al, 2009). The understanding that EGFRvIII, following 
internalisation, is recycled rather then sent to the lysosomal compartment supports 
the  EGFR  nuclear  localisation  mechanism.    As  previously  discussed  the  nuclear 
translocation  can  take  place  only  if  the  receptor  escapes  degradation.  This  study 
confirms that wtEGFR and EGFRvIII are expressed in the nucleus and also shows 
that they bind to DNAPKcs following cisplatin or IR treatment.  If originally the 
constitutive  activation  may  have  been  accounted  as  a  determinant  of  EGFR-
DNAPKcs binding, the hypothesis is now excluded since EGFR-DNAPKcs binding 
takes place only following cisplatin or IR treatment, despite constitutive activation 
throughout the conditions (EGFRvIII, L858R, LNLS123) and EGF-induced EGFR 
phosphorylation. Another hypothesis was that cisplatin or IR   may induce EGFR 
phosphorylation  on  specific  residues  that  favour  EGFR-DNAPKcs  interaction. 
Although  this  could  be  valid  for  wtEGFR  receptor,  the  EGFRvIII  constitutive 
activation suggests that EGFR-DNAPKcs binding is not determined by a specific 
phosphorylation event or by the up-regulation of the kinase activity of the receptor. 
Moreover, the lack of EGFR-DNAPKcs binding shown in L858R expressing cells 
only  confirms  that  EGFR  kinase  activation  is  not  central  to  determine  EGFR-
DNAPKcs binding. The previous chapters has already suggested that the impaired 
EGFR nuclear translocation in L858R-expressing cells is probably due to a lack of 
conformational change that does not expose the NLS for recognition. EGFRvIII is 
always  in  a  dimerised  active  conformation  suggesting  that,  differently  from  the 
L858R mutant, EGFRvIII constitutive activation is a consequence of a constitutive, 
structural,  and  active  allosteric  conformation.  Recently,  it  has  been  shown  that 
induced phosphorylation by peptide targeting of the residue T654 within the EGFR 
NLS sequence results in EGFR phosphorylated NLS which abolishes EGFR nuclear 
localisation and DNAPK activation inhibiting repair of IR induced-DNA damage  
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(Huang  et  al,  1997;  Li  et  al,  2004).  These  results  suggest  that  IR  or  cisplatin 
treatment may either induce the activation of a secondary molecule that prevents 
T654  EGFR  phosphorylation  or  induce  an  EGFR  conformational  change  that 
prevents this phosphorylation event and favours DNAPKcs-EGFR association. 
 
5.3.3 EGFR-Hsp90 binding 
HSP90 is one of the most abundant proteins in the cell. It is widely involved in 
biogenesis, stability and activity of its binding partners also called client proteins. It 
participates in the maturation of nascent proteins and in the regulation of signalling 
events as it is often found bound to a protein effector domain (e.g.: hormone binding 
domain or kinase domain) (Young et al, 2001). In many cases Hsp90 binding is 
characterised by repeated cycles of low affinity binding and release (Lavictoire et al, 
2003). The literature suggests that Hsp90, rather than recognising specific motifs, 
binds to features that are common to unstable proteins, such as unveiled hydrophobic 
patches, gaining a higher level of affinity to the client protein via co-chaperones such 
as  CDC37  (Prince  &  Matts,  2005).  Pharmacological  inhibition  of  Hsp90,  via 
ansamycin  antibiotics  such  as  Geldanamycin,  results  in  the  degradation  of  client 
proteins showing that this chaperone is involved in protein stability (Sawai et al, 
2008).  As  with  other  Hsps,  it  responds  to  stressful  conditions  (mainly  metabolic 
insults)  by  assuring  stability  of  key  proteins  and  preventing  their  degradation.   
Hsp90 functions have been exploited by molecular intervention to target the over-
expression of proteins that are involved in tumorigenesis such as EGFR and Her2 
(Citri et al, 2004b; Yang et al, 2006). While EGFR requires Hsp90 for the maturation 
of  nascent  protein,  but  becomes  independent  of  it  once  matured,  Her2  stability 
depends  on  Hsp90  binding  (Citri  et  al,  2004a).    Wild  type  EGFR  is  quickly 
internalised following ligand activation and ubiquitinated by Cbl. In addition Cbl 
also promotes EGFR internalisation via its interaction with CIN85, which interacts 
with endophilins, the regulatory component of the clathrin coated pits. Recognition 
and  internalisation  of  active  EGFR  by  the  Cin85/Cbl  complex  is  necessary  to 
regulate  the  distribution  of  the  receptor  and  also  its  signal  input.  EGFR  somatic 
mutations in NSCLC such as L858R have been shown to escape the ligand induced 
receptor  down-regulation  and  present  a  strong  association  with  Hsp90  and 
unphosphorylated Cbl. This impairs the Cbl mediated recruitment of CIN85 to the 
endocytic  complex  preventing  the  receptor  degradation  (Sawai  et  al,  2008;  
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Shimamura et al, 2005; Yang et al, 2006).  The data showed in Fig 5.3 confirmed the 
binding between Hsp90 and L858R however IR treatment seemed to weaken this 
interaction.  Similarly,  NLS123  expressing  cells  showed  the  same  pattern  of 
interaction. This confirms the previously discussed data suggesting that the NLS123 
mutation destabilises the receptor conformation. This semi-constitutive association 
with  Hsp90  seems  to  be  a  signature  for  EGFR  conformational  instability.  It  is 
difficult to determine whether the weaker association shown following IR is due to 
timing or indicates receptor degradation. Future experiments will be able to shed 
more light on this open question.  
Interestingly, LNLS123 expressing cells do not show weakening of the association 
following IR treatment; in contrast the Hsp90 binding does not seem to be modulated 
by any particular treatment suggesting a mechanism of interaction that may involve 
both  conformational  change  and  receptor  activation.    It  has  been  shown  that 
mutations that occur within or near the M5 loop region ( C- 4 region) of the EGFR 
protein, are likely to favour the binding with Hsp90 by affecting the conformation of 
this  loop  or  altering  the  conformation  of  other  parts  of  the  kinase  domain  that 
interacts with Hsp90. All the mutations that expose the kinase domain to structural 
stresses require the chaperone stabilisation and, as a consequence, Hsp90 clients will 
boast an overall positive or neutral charge within the binding region. In contrast, 
proteins  that  do  not  require  chaperone  regulation  will  normally  bear  an  overall 
negative charge (Citri et al, 2006). The change of all the arginine residues within the 
NLS sequence into alanines changes the positive signal of that stretch of amino acid 
into a neutral signal; therefore the change in charge is not the determinant factor. 
However, as shown in the previous chapter, the NLS123 mutation is altering the 
conformational  change  of  the  receptor  impeding  the  allosteric  activation  and  the 
dimer interface formation. Therefore, the structural stress imposed on the receptor 
may be responsible for the Hsp90 binding to the NLS123 mutant. The impact of the 
NLS123 mutation on protein stability is also shown by the LNLS123 mutant that 
shows higher binding affinity with Hsp90 as compared to the L858R.  
It is difficult to comment on the interaction observed between Hsp90 and wtEGFR 
following cisplatin treatment. Although, the literature suggests mainly that Hsp90 
binding confers stability to the client protein, the main role of heat shock proteins is 
to  respond  to  cellular  shocks  favouring  survival.    Cisplatin-induced  binding  of 
wtEGFR  to  Hsp90  could  prevent  EGFR  degradation  and  maintain  a  constitutive  
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function required in the response to cisplatin treatment. A very recent study showed 
dependence of wtEGFR and EGFRvIII on Hsp90 binding (Pines et al) . It is clear 
from  Fig  5.3  that,  although  greatly  weaker  compared  to  the  other  mutants,  both 
wtEGFR and EGFRvIII show association with Hsp90. Future studies will determine 
the relevance of this dependence and its degree in the context of DNA repair. 
 
5.3.4 DNAPKcs subcellular localisation in response to IR or cisplatin is 
influenced by EGFR subcellular distribution. 
In line with previous published evidence, this study shows EGFR and DNAPKcs 
association. The confocal analysis of the stable cells expressing constructs confirms 
the  results  shown  in  the  previous  chapter.  Only  wtEGFR  and  EGFRvIII  are 
expressed  in  the  nucleus  following  cisplatin  or  IR  and  this  is  induced  by  the 
treatments  and not  by  a transient  over-expression of the wtEGFR and EGFRvIII 
expressing  plasmids.  Interestingly,  not  only  does  DNAPKcs  co-localise  in  the 
nucleus with wtEGFR and EGFRvIII but the impaired nuclear localisation shown by 
the  remaining  mutants  seems  to  indirectly  determine  DNAPKcs  cytosolic 
accumulation. Moreover, in L858R expressing cells DNAPKcs seems to be capable 
of localising within the nucleus despite the lack of L858R nuclear localisation. This 
explains why L858R cells showed intermediate repair following IR and cisplatin. In 
addition, this suggests that the NLS123 mutation may further, sterically, obstruct the 
receptor direct or indirect mediation of DNAPKcs nuclear localisation. EGFR may 
indirectly  signal  for  DNAPKcs  cellular  distribution  by  activation  of  a  secondary 
messenger or by physical interaction with another protein. The NLS123 mutation 
within the wtEGFR (NLS123) and the L858R (LNLS123) may interfere with this 
mechanism supporting the evidence that targeting the NLS inhibits DNAPKcs-EGFR 
binding and its function in repair (Dittmann et al)  
 
5.3.5 EGFR–DNAPKcs interaction takes place both in the nucleus and in 
the cytoplasm 
It was clearly demonstrated that EGFR binds to DNAPKcs and that they both co-
localise within the same cellular compartments following  cisplatin and  IR. Since 
EGFR-DNAPKcs association has been reported this binding has only been shown by 
co-immunoprecipitating  these  two  proteins  from  nuclear  extracts.  Although  this 
answer the question relative to modulation in DNA repair, it does not characterise  
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this association with regards to whether these two proteins come into contact before 
entering the nucleus, whether this association is exclusively nuclear and therefore 
dependent of EGFR nuclear translocation.  This is central to fully understand how 
molecular  intervention  can  effectively  target  this  interaction  and  modulate  repair 
response and kinetics. The precise distance between two proteins sufficient to allow a 
physical  interaction  has  not  yet  been  defined.  The  proximity  ligation  assay 
determines whether the physical space between two proteins is smaller than 40 nm, 
which is acknowledged to be sufficient to allow protein-protein interaction. Fig 5.7 
confirms the result of the immunoprecipitation by showing that only in wtEGFR and 
EGFRvIII expressing cells EGFR and DNAPKcs are in the proximity sufficient to 
interact. Moreover, it also shows that this interaction takes place both in the nucleus 
and  in  the  cytoplasm  suggesting  that  DNAPKcs  recruitment  by  EGFR  is  most 
probably a cytosolic event that precedes the nuclear translocation.  The time course 
immunoprecipitation  discussed  in  the  previous  chapter  showed  that  the  binding 
between these two proteins increases over time and peaks at 18 following cisplatin 
treatment.  The  time  course  experiment  also  shows  interaction  already  at  1  hour 
following  cisplatin  treatment,  suggesting  a  recruitment  that  anticipates  the  DNA 
damage  response.  The  possibility  that  EGFR-DNAPKcs  complex  forms  in  the 
cytosol  and  then  migrates  to  the  nucleus  cannot  be  excluded.  Similarly,  the 
possibility that the cytosolic portion of this complex may have another secondary 
function still involved in response to therapy cannot be excluded. 
 
5.3.6 EGFR modulates DNAPKcs kinase activity 
 EGFR modulation of DNAPK kinase activity has been shown in several reports. 
Cetuximab-induced reduction in DNA-PK kinase has been correlated not only with 
inhibited EGFR kinase activation but also with EGFR nuclear localisation (Dittmann 
et  al,  2005b;  Li  et  al,  2008;  Perez-Torres  et  al,  2006).  This  has  supported  the 
experimental  evidence  that  IR  induces  EGFR-DNAPKcs  association  leading  to 
enhanced kinase activity of the NHEJ DNA-PK complex (Chen & Nirodi, 2007).  
This study showed that expression of EGFR modulates DNAPK kinase activity only 
in cells expressing wtEGFR or EGFRvIII. This did not occur in cells expressing 
EGFR constructs deficient in EGFR nuclear translocation and DNAPKcs binding. 
These data show that EGFR modulation of DNA repair is mediated via DNAPK 
pathways  and  requires  EGFR-DNAPKcs  binding  and  EGFR  nuclear  localisation.  
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The  decrease  of  DNAPK  activity  in  NLS123  expressing  cells  confirms  the 
previously  published  data  where  EGFR  inhibition  by  cetuximab  or  via  Src 
knockdown also induced inhibition of DNAPK kinase activity (Andersen et al, 2009; 
Dittmann et al, 2008a; Dittmann et al, 2009; Gueven et al, 1998; Wheeler et al, 
2009). Interestingly these down-regulations were highly statistically significant when 
compared to cells not expressing EGFR. The possibility that the NLS123 mutant 
indirectly inhibits the activation of signalling pathway involved in DNAPK kinase 
activity cannot be excluded. Future experiments utilising EGFR inhibitors and/or a 
kinase dead mutant will address this issue. There was no change in the kinase activity 
of cells expressing L858R or LNLS123 expressing cells. This suggests that, although 
nuclear  translocation  and  the  binding  are  determining  the  increment  of  DNAPK 
kinase activity, receptor kinase activation may also influence, indirectly, DNAPK. It 
has been shown that activation of AKT may lead to DNAPKcs activation as AKT 
has been shown to act as a kinase of DNAPKcs (Bozulic et al, 2008; Shi et al, 2009; 
Toulany et al, 2008b). The role of EGFR as a direct kinase activator of DNAPKcs 
via their physical interaction or as an indirect activator needs to be elucidated. It is 
arguable  that  EGFR  recruits  cytosolic  DNAPKcs  inducing  DNAPKcs  nuclear 
accumulation.  This  would  then  enhance  the  DNAPKcs-DNA  interaction  and 
therefore the kinase activity of the DNAPK complex.  In EGFRvIII expressing cells 
both the binding and/or the nuclear translocation and the possible activation of a 
putative AKT back-up activation pathway may trigger the enhanced DNAPK kinase 
activity significantly higher than in wtEGFR expressing cells allowing a faster rate of 
DNA SB repair following IR. 
 
5.3.7 Cisplatin toxicity 
Cisplatin is one of the most widely used anticancer drugs. Although it is generally 
accepted that the binding of cisplatin to genomic DNA is the main event responsible 
for  its  anti-tumor  property,  nearly  90%  of  platinum  is  bound  to  plasma  proteins 
(Turchi et al, 1999; Wang & Lippard, 2005; Wernyj & Morin, 2004). This leads to 
the activation of many signalling pathways which many line of evidence have shown 
to either confer sensitivity or resistance to the treatment. The activation of DNA 
repair mechanisms in response to cisplatin treatment has already been reviewed both 
in  the  introduction  and  in  result  chapter  2.  Therefore  the  transduction  of  DNA 
damage  signals  on  cellular  signalling  and  survival  will  be  briefly  reviewed  with  
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regards  to  the  cisplatin  induction  of  cell  death  and  the  involvement  of  AKT, 
MAPK/JNK/ERK in the response to cisplatin and how EGFR has been shown to 
modulate these pathways.  
 
5.3.7.1 Cisplatin-induced cell death 
Several lines of evidence have shown that cisplatin induces two different modes of 
cellular  death:  necrosis  and  apoptosis.  A  cytosolic  swelling  and  loss  of  plasma 
membrane  integrity  characterize  necrosis.  It  is  initialized  by  the  DNA  damage-
induced activation of PARP-1 that cleaves the glycolytic coenzyme NAD
+.  Loss of 
NAD
+  inhibits  the  glycolytic  production  of  ATP  with  subsequent  depletion  of 
cellular  ATP  leading  to  cell  death  via  necrosis.  In  contrast,  cells  undergoing 
apoptosis  show  shrinkage,  chromatin  condensation  and  DNA  fragmentation. 
Apoptotic death results from the activation of the caspases (aspartate specific family 
of  proteases).  The  activation  of  the  upstream  CASP8  or  CASP9  leads  to  the 
activation of downstream caspases such as CASP3 and CASP7. This induces the 
cleavage and subsequent degradation of many cellular proteins leading to apoptosis.  
Although in resistant cell lines cisplatin seems to produce characteristic features of 
necrosis  there  is  evidence  suggesting  that  within  the  same  population  of  cells, 
platinum can induce both necrosis and apoptosis. Moreover the cooperation of these 
two pathways has been shown by the caspase activation and induction of apoptosis in 
presence of PARP1 induced NAD
+ cleavage inhibition (Fishel et al, 2005; Lee et al, 
2005; Wernyj & Morin, 2004). 
 
5.3.7.2 Pro-survival AKT signalling  
AKT  promotes  cell  survival  via  the  down  regulation  of  apoptotic  pathways.  It 
phosphorylates  the  X-linked  inhibitor  of  apoptosis  XIAP  and  inhibits  the  auto-
ubiquitylation  of  this  protein  and  the  cisplatin  induced  ubiquitylation  activities. 
Increased levels  of XIAP have been shown to  correlate with  decreased levels  of 
CASP3 and down regulation of apoptosis(Fraser et al, 2003a; Fraser et al, 2003b). In 
addition AKT has been shown to induce activation of NFkB (Asselin et al, 2001; 
Dan et al, 2004). Increased activity of NFkB correlates with decreased apoptosis 
whereas its inhibition has been shown to augment cisplatin cytoxicity. It has been 
demonstrated that cisplatin-induced T308 phosphorylation of AKT in MDA-MB-468  
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is  dependent  on  Src  and  EGFR  with  EGFR  being  the  initiator  of  the  signal 
transduction that leads to the activation of this pro-survival signal (Yang et al, 2004). 
 
5.3.7.3 p38MAPK/MAPK/JNK role in cisplatin resistance  
There is a growing body of evidence suggesting that p38MAPK has a central role in 
the response to cisplatin treatment. Cisplatin activates p38MAPK for 8-12 hours in 
sensitive cells and for 1-3 hours in resistant cells suggesting that the different kinetics 
may explain the differential cytotoxicity (Mansouri et al, 2003).  There is instead 
conflicting evidence on the role of ERK in influencing cellular survival following 
cisplatin  treatment.  Some  studies  indicate  that  ERK  activation  is  associated  with 
enhanced survival (Hayakawa et al, 1999). However the use of the MEK1 inhibitor 
has been shown to be effective only in certain cell line suggesting a more complex 
and  cell  line  dependent  response  to  cisplatin  (Mandic  et  al,  2001).  In  addition 
elevated activation of RAS, an upstream component of the ERK signaling pathway 
has been shown to confer sensitivity to cisplatin (Wang & Lippard, 2005). 
Far  from  being  clear  is  also  the  JNK  mediated  response  to  cisplatin  treatment. 
Several studied have shown evidence that activation of the JNK pathway contributes 
to cisplatin induced apoptosis (Mansouri et al, 2003) whereas some other have shown 
a  protective  response  necessary  for  cell  survival  (Davis,  2000).  Interestingly  one 
study has shown that duration of the signalling pathway activation might be central 
for the decision between cellular proliferation or death (Chen et al, 1996). 
It has been shown that phosphorylation of the T669 by p38MAPK leads to cisplatin 
induced-EGFR internalization. This event seems to be mediated by ERK inducing 
the abrogation of EGFR signalling to JNK (Winograd-Katz & Levitzki, 2006). At the 
same time, this study has suggested that EGFR signalling to JNK is dependent on 
receptor internalization. Since internalization defective EGFR was shown to increase 
cell  proliferation  and  lead  to  ERK  down-  regulation  it  has  been  suggested  that 
internalized EGFR may form signalling complexes within the endosomes triggering 
a switch in signalling from proliferation to survival (Grandal & Madshus, 2008). 
 
5.3.7.4 EGFR is required for cisplatin resistance 
In line with these studies the MTT assay have shown that wtEGFR or EGFRvIII 
expression confers survival to cells following cisplatin treatment. Our analysis does 
not  verify  whether  the  cisplatin  induced  EGFR  activation  (wtEGFR)  or  the  
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constitutive kinase activation (EGFRvIII) may be responsible for induction of pro-
survival signalling. These data suggest that by 36 hours following cisplatin treatment, 
cells  expressing  wtEGFR  and  EGFRvIII  have  already  repaired  all  the  crosslinks 
induced by cisplatin treatment (Result Chapter 4) and also that by 18 hours both the 
wt receptor and the EGFRvIII mutant are expressed in the nucleus and associate with 
DNAPKcs  resulting  in  up-regulation  of  DNAPK  activity.  The  EGFR  kinase 
activation alone does not seem to be responsible for the survival response. Cells 
expressing the constitutive kinase active L858R mutant, which does not translocates 
to the nucleus, show less than 50% survival, suggesting that both EGFR nuclear 
expression and binding to DNAPKcs modulation of DNA repair could correlate with 
the  pro-survival  response.  This  is  confirmed  also  by  the  results  obtained  in  cell 
expressing NLS123 and LNLS123 where cisplatin toxicity is clearly compromising 
cellular viability.  Further experiments will show whether it is a direct effect of DNA 
repair inhibition or whether this is the result of signalling events in response to DNA 
damage or both. 
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CHAPTER 6: CONCLUSION 
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EGFR is commonly expressed in human tumours and has been an important target 
for therapy. Although several small molecules inhibitors and antibodies are currently 
utilised in the clinic in combination with chemotherapy and IR, the successfulness of 
these treatments has been limited. EGFR nuclear expression has been a source of 
important insights in the biology of this oncogene. This study investigated the role of 
nuclear EGFR in the modulation of DNA repair following treatment with cisplatin 
and IR. 
Chapter 3 focused on the construction of two NLS mutants, one in the background 
of wtEGFR and the other one in the background of the somatic mutation L858R 
often found in lung cancer. Then nuclear expression of EGFR following IR treatment 
and  EGF  induction  was  confirmed.  Evidence  was  provided  showing  that  the 
mutation  of  all  arginine  residues  of  EGFR  NLS  sequence  induced  inhibition  of 
nuclear translocation in the NLS123 and LNLS123 mutant. In line with published 
data, also L858R showed impaired nuclear translocation. The characterisation of the 
constructs  within  the  NIH3T3  murine  fibroblast  (negative  for  the  expression  of 
EGFR) showed that the NLS123 mutation impairs EGFR kinase activity.  Recent 
studies have shown the importance of the NLS sequence in EGFR activation and 
binding  to  the  importin  machinery.  This  suggested  that  the  inhibition  of  nuclear 
translocation was due to the lack of an allosteric change required by EGFR to adopt 
an  active  conformation.  Only  EGFR  molecules  undergoing  this  conformational 
change expose the NLS sequence for recognition. Interestingly LNLS123 expressing 
cells  showed  EGFR  constitutive  activation  suggesting  that  the  impaired  EGFR 
nuclear translocation observed in L858R is due to the receptor conformation. The 
kinase mutation at position 858 induces a modification within the active loop that 
allows constitutive kinase activation without requiring kinase domain juxtaposition. 
This  explains  why  the  single  amino  acid  mutation  is  sufficient  to  impair  EGFR 
nuclear translocation in L858R and LNLS123 expressing cells. Chapter 4 showed 
EGFR  modulation  of  DNA  repair  kinetics  following  cisplatin  and  IR  using  the 
alkaline single-cell gel  electrophoresis (comet assay). Constructs expressing point 
mutation within the NLS sequence, a deletion of the NLS sequence, an EGFR kinase 
death mutant and the somatic EGFRvIII were utilised to compare and contrast the 
different  modulation  of  the  unhooking  of  cisplatin  interstrand  crosslinks  and  the 
repair  of  DNA  strand  breaks.  Three  different  repair  behaviours  were  observed. 
Whilst  wtEGFR  and  EGFRvIII  showed  complete  repair  by  36  hours  following  
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cisplatin  and  4  hour  following  IR  treatment,  intermediate  levels  of  repair  were 
observed in cells expressing L858R, KMT and  NLS. Complete inhibition of repair 
was observed in cell expressing NLS123 and LNLS123. The result obtained by the 
comet assays suggested that EGFR kinase activity is not central to the modulation of 
repair  and  that  the  inhibition  of  nuclear  translocation  via  the  NLS  mutation  was 
central to the repair inhibition. The impaired receptor dimerisation and the lack of an 
active conformation seem to be critical for this mechanism. The confocal analysis on 
the transient transfectants showed that the impaired nuclear localisation of EGFR and 
DNAPKcs  (NLS123  and  LNLS123  expressing  cells)  correlated  with  complete 
inhibition of repair. Interestingly, while low levels of EGFR nuclear accumulation 
(M1  and  M12)  corresponded  to  DNA  repair,  low  levels  of  DNAPKcs  nuclear 
accumulation but complete inhibition of EGFR nuclear expression (L858R, KMT 
and  NLS  expressing  cells)  resulted  only  in  intermediate  levels  of  repair.  The 
difference in modulation shown with the comet assay and the nuclear expression of 
the different constructs shown in the confocal analysis confirms that the repair is 
mediated by EGFR and that is modulated by EGFR nuclear translocation. 
Chapter 5 investigated the mechanism involved in the EGFR mediated modulation 
of DNA repair. The association between EGFR and DNAPKcs, induced by IR and 
cisplatin, correlated with DNA repair. EGFR interaction with DNAPKcs was shown 
only  in  wtEGFR  and  EGFRvIII  expressing  cells.  Although  EGFR  nuclear 
translocation per se was not sufficient to mediate binding with DNAPKcs, nuclear 
expression was required for repair. The confocal analysis showed that the nls123 
mutation  not  only  inhibited  EGFR  nuclear  translocation  (NLS123  and  LNLS123 
expressing cells) but also binding to DNAPKcs and, indirectly, DNAPKcs nuclear 
accumulation. The formation of this complex was shown to take place both in the 
nucleus  and  in  the  cytoplasm  and  seemed  to  require  EGFR  allosteric  active 
conformational change. The association between EGFR and DNAPKcs is central to 
repair as shown by the DNAPK kinase assay. While, in cells expressing wtEGFR and 
EGFRvIII there was  a  clear upregulation  in  DNAPK kinase activity,  L858R and 
LNLS123 expressing cells showed no upregulation. In line with previous study that 
showed  that  Gefitinib-induced  EGFR  inhibition  resulted  in  down  regulation  of 
DNAPK kinase activity and also in DNAPKcs cytosolic accumulation, the impaired 
binding to  DNAPKcs  and impaired kinase  activity shown in  NLS123  expressing 
cells correlated with a significant downregulation in DNAPK kinase activity. These  
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data suggest that EGFR inhibition by targeting EGFR NLS sequence inhibits EGFR 
nuclear accumulation and EGFR kinase activity via the impairment of its allosteric 
activation. As a consequence, the binding to DNAPKcs and DNAPK kinase activity 
are significantly impaired leading to inhibition of DNA repair following cisplatin and 
IR.  Our data have also shown that the impairment of EGFR nuclear translocation 
and the consequent modulation of DNA repair via the inhibition of DNAPK kinase 
activity  correlate  with  cellular  survival  following  cisplatin.  The  mechanism  of 
nuclear  translocation,  following  treatment  with  cisplatin  or  IR  can  therefore  be 
accounted as a cellular response that cells employ to overcome DNA damage and 
survive treatment toxicity. 
 
6.1 EGFR and DNAPKcs physical interaction 
This  study  validates  the  importance  of  EGFR-DNAPKcs  interaction  following 
treatment with cisplatin and IR. Deletion constructs expressing either protein can be 
generated and used to determine the domain involved in this interaction. This could 
have potential implication in the design of novel drugs with relevance to the EGFR-
DNAPKcs association. Our initial work on the construction of deletion mutants has 
led to the conclusion that EGFR subcellular distribution and allosteric conformation 
are  determinant  to  the  binding.  Although,  deletion  mutants  would  be  ideal  to 
underpin the exact stretch of amino acid responsible for EGFR-DNAPKcs binding, 
the impaired association observed in the NLS mutants suggests that other regions 
within EGFR may indirectly impair this association. DNAPKcs deletion mutants are 
therefore the only viable option. 
Despite the in vitro success of many EGFR inhibitors clinical outcomes are still poor. 
This  study  points  out  that  dimerisation  and  conformational  change,  being  events 
upstream of kinase activation, may be better targets for EGFR directed therapy. The 
validation of EGFR allosteric conformational change as an absolute requirement for 
DNAPKcs binding can be evaluated by analysing EGFR dimer formations following 
treatment  in  wtEGFR  or  EGFR  mutants  expressing  cells.  This  together  with  a 
pharmacological inhibition of EGFR dimer formation will shed some light on other 
modalities  to  inhibit  EGFR  and  DNAPKcs  that  may  result  in  better  therapeutic 
outcome. 
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6.2 Novel partners involved in EGFR modulation of repair 
The  repair  of  SBs  shown  by  the  comet  assay  suggest  that  the  most  significant 
difference in repair kinetics among all the mutants is within the first 30 minutes 
following IR. Many studies have discussed the type of breaks detected by the comet 
assay and although it primarily detects singles strand breaks, double strand breaks are 
not  to  be  excluded.  Despite  being  difficult  to  detect  via  the  comet  assay,  the 
clustering  formation  of  DNA  damage  following  IR  implies  that  statistically  the 
formation of DSBs is inevitable. Considering their complexity as opposed to SSBs, 
DSBs  are  regarded  as  being  the  subject  of  „late  repair‟.  While  the  early  and 
immediate repair shows the kinetics of SSBs, the difference in kinetics of the late 
repair highlights the repair inhibition of DSBs.  DNAPKcs is the central component 
of NHEJ the pathway involved in the repair DSBs, therefore the observed differences 
in the early repair kinetics may be the result of EGFR interaction with other DNA 
repair proteins involved in SSB repair.   Our preliminary data on the gliomas model 
MO59J and M059K suggest that in absence of DNAPKcs, Gefitinib-induced EGFR 
inhibition results in slower repair kinetic following IR treatment. This suggests a role 
for EGFR in repair independent of DNAPKcs. The study of alternative interactions 
by  immunoprecipitation  and  confocal  imaging  in  cells  expressing  wtEGFR  and 
EGFR  mutants  in  the  NLS  sequence  may  reveal  novel  mechanisms  of  EGFR 
modulation of DNA repair. 
 
6.3 EGFR mediated transcription 
EGFR  nuclear  expression  following  ligand  activation  has  been  shown  to  induce 
iNOS, cyclin D1, Aurora A, and RNA helicase A expression. Binding with the STAT 
family  of  transcription  factors  is  central  to  the  modulation  of  gene  expression. 
Although here and in previous studies cisplatin and IR treatments have been shown 
to induce EGFR nuclear translocation, little is known about the modulation of gene 
expression mediated by EGFR following these treatments. Further studies should be 
designed to address this point and to determine a read out of all the genes whose 
expression is mediated by EGFR. The Hsp90 binding to wtEGFR following cisplatin 
treatment (chapter 5) is indicative of a stress response mechanism that may involve 
transcriptional  regulation.  The  system  validated  in  this  study  will  allow  the 
investigation of the EGFR characteristics involved in transcriptional activation and 
unveil novel mechanisms involved in resistance to cisplatin and IR.  
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6.4 Conclusion 
These results highlight the importance of understanding the events that lead to EGFR 
subcellular distribution and its involvement in mediating DNA response following 
cisplatin  and  IR.  The  molecular  mechanisms  of  EGFR  nuclear  translocation  and 
binding with DNAPKcs will form the design of future molecular targeted therapy 
and  point  the  way  for  further  studies  to  investigate  the  role  of  EGFR  in  cancer 
therapy. 
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